CN103142576A - Application of salvianolic acid A freeze-dried powder to preparation of drug for protecting cerebral vascular endothelial cells - Google Patents
Application of salvianolic acid A freeze-dried powder to preparation of drug for protecting cerebral vascular endothelial cells Download PDFInfo
- Publication number
- CN103142576A CN103142576A CN2012104871750A CN201210487175A CN103142576A CN 103142576 A CN103142576 A CN 103142576A CN 2012104871750 A CN2012104871750 A CN 2012104871750A CN 201210487175 A CN201210487175 A CN 201210487175A CN 103142576 A CN103142576 A CN 103142576A
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- freeze
- dried powder
- group
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 title claims abstract description 658
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 title claims abstract description 655
- 239000000843 powder Substances 0.000 title claims abstract description 295
- 230000002490 cerebral effect Effects 0.000 title claims abstract description 203
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 210000003556 vascular endothelial cell Anatomy 0.000 title abstract description 9
- 229940079593 drug Drugs 0.000 title abstract description 6
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims abstract description 97
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims abstract description 95
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims abstract description 95
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims abstract description 54
- GCJWPRRNLSHTRY-UHFFFAOYSA-N Salvianolic acid C Natural products C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)=CC=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-UHFFFAOYSA-N 0.000 claims abstract description 28
- GCJWPRRNLSHTRY-VURDRKPISA-N Salvianolic acid C Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2C=C(OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-VURDRKPISA-N 0.000 claims abstract description 28
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims abstract description 27
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims abstract description 27
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 19
- 239000000945 filler Substances 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 302
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 100
- 239000002994 raw material Substances 0.000 claims description 99
- 239000000243 solution Substances 0.000 claims description 96
- 239000000284 extract Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 55
- 230000006378 damage Effects 0.000 claims description 54
- 238000003756 stirring Methods 0.000 claims description 54
- 229920005989 resin Polymers 0.000 claims description 51
- 239000011347 resin Substances 0.000 claims description 51
- 238000010828 elution Methods 0.000 claims description 50
- 239000007864 aqueous solution Substances 0.000 claims description 48
- 238000006243 chemical reaction Methods 0.000 claims description 48
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 47
- 238000000605 extraction Methods 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 46
- 239000000741 silica gel Substances 0.000 claims description 45
- 229910002027 silica gel Inorganic materials 0.000 claims description 45
- 229960001866 silicon dioxide Drugs 0.000 claims description 45
- 229910052799 carbon Inorganic materials 0.000 claims description 42
- 238000001291 vacuum drying Methods 0.000 claims description 42
- 239000002253 acid Substances 0.000 claims description 36
- 208000027418 Wounds and injury Diseases 0.000 claims description 34
- 230000006837 decompression Effects 0.000 claims description 34
- 238000004064 recycling Methods 0.000 claims description 34
- 208000014674 injury Diseases 0.000 claims description 33
- 239000012535 impurity Substances 0.000 claims description 32
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 30
- 230000001476 alcoholic effect Effects 0.000 claims description 30
- 238000007710 freezing Methods 0.000 claims description 28
- 230000008014 freezing Effects 0.000 claims description 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
- 239000003054 catalyst Substances 0.000 claims description 26
- 206010030113 Oedema Diseases 0.000 claims description 25
- 239000000796 flavoring agent Substances 0.000 claims description 25
- 235000019634 flavors Nutrition 0.000 claims description 25
- 230000002829 reductive effect Effects 0.000 claims description 25
- 239000004952 Polyamide Substances 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 24
- 229920002647 polyamide Polymers 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 23
- 241000521257 Hydrops Species 0.000 claims description 20
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 20
- 241001072909 Salvia Species 0.000 claims description 19
- 235000017276 Salvia Nutrition 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 19
- 238000004108 freeze drying Methods 0.000 claims description 19
- 238000011084 recovery Methods 0.000 claims description 18
- 210000002889 endothelial cell Anatomy 0.000 claims description 14
- 206010013786 Dry skin Diseases 0.000 claims description 13
- 238000004440 column chromatography Methods 0.000 claims description 13
- 238000010792 warming Methods 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 12
- 239000003463 adsorbent Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 238000004587 chromatography analysis Methods 0.000 claims description 10
- 239000012044 organic layer Substances 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 4
- 210000004925 microvascular endothelial cell Anatomy 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- UJZQBMQZMKFSRV-RGKBJLTCSA-N (2s,3s)-4-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 UJZQBMQZMKFSRV-RGKBJLTCSA-N 0.000 abstract description 2
- UJZQBMQZMKFSRV-PHQFMFTGSA-N Lithospermic acid Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1c2[C@@H](C(=O)O)[C@H](c3cc(O)c(O)cc3)Oc2c(O)cc1 UJZQBMQZMKFSRV-PHQFMFTGSA-N 0.000 abstract description 2
- NFOCYHUCMXEHDG-UHFFFAOYSA-N Monomethyl lithospermate Natural products COC(=O)C1C(C=2C=C(O)C(O)=CC=2)OC(C(=CC=2)O)=C1C=2C=CC(=O)OC(C(O)=O)CC1=CC=C(O)C(O)=C1 NFOCYHUCMXEHDG-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002075 main ingredient Substances 0.000 abstract 3
- 241000700159 Rattus Species 0.000 description 236
- 210000001519 tissue Anatomy 0.000 description 178
- 208000028867 ischemia Diseases 0.000 description 120
- 230000000694 effects Effects 0.000 description 108
- 150000001875 compounds Chemical class 0.000 description 103
- 206010008118 cerebral infarction Diseases 0.000 description 97
- 210000004556 brain Anatomy 0.000 description 87
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 81
- 201000006474 Brain Ischemia Diseases 0.000 description 78
- 206010008120 Cerebral ischaemia Diseases 0.000 description 77
- 230000000302 ischemic effect Effects 0.000 description 59
- 206010021143 Hypoxia Diseases 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000000523 sample Substances 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 229960000715 nimodipine Drugs 0.000 description 42
- 206010008132 Cerebral thrombosis Diseases 0.000 description 37
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 37
- 230000010410 reperfusion Effects 0.000 description 37
- 239000007924 injection Substances 0.000 description 32
- 238000002347 injection Methods 0.000 description 32
- 230000007954 hypoxia Effects 0.000 description 31
- 239000013558 reference substance Substances 0.000 description 31
- 230000006907 apoptotic process Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- 239000011575 calcium Substances 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 28
- 210000002569 neuron Anatomy 0.000 description 26
- 208000007536 Thrombosis Diseases 0.000 description 25
- 206010063837 Reperfusion injury Diseases 0.000 description 23
- 210000004204 blood vessel Anatomy 0.000 description 23
- 210000005013 brain tissue Anatomy 0.000 description 23
- 206010061216 Infarction Diseases 0.000 description 22
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 22
- 230000006870 function Effects 0.000 description 22
- 230000007574 infarction Effects 0.000 description 22
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 21
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 21
- 230000004083 survival effect Effects 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 230000002879 macerating effect Effects 0.000 description 18
- 206010002660 Anoxia Diseases 0.000 description 17
- 241000976983 Anoxia Species 0.000 description 17
- 208000005189 Embolism Diseases 0.000 description 17
- 108010025020 Nerve Growth Factor Proteins 0.000 description 17
- 230000007953 anoxia Effects 0.000 description 17
- 239000002858 neurotransmitter agent Substances 0.000 description 17
- 230000002980 postoperative effect Effects 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 210000003462 vein Anatomy 0.000 description 17
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 16
- 230000009471 action Effects 0.000 description 16
- 230000008499 blood brain barrier function Effects 0.000 description 16
- 210000001218 blood-brain barrier Anatomy 0.000 description 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 15
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 14
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 14
- 208000026106 cerebrovascular disease Diseases 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 210000003657 middle cerebral artery Anatomy 0.000 description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 13
- 230000006735 deficit Effects 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- -1 solvent extraction Substances 0.000 description 13
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 12
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 102000015336 Nerve Growth Factor Human genes 0.000 description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 12
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 229930195725 Mannitol Natural products 0.000 description 11
- 208000001435 Thromboembolism Diseases 0.000 description 11
- 229920005549 butyl rubber Polymers 0.000 description 11
- 230000037149 energy metabolism Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000000594 mannitol Substances 0.000 description 11
- 235000010355 mannitol Nutrition 0.000 description 11
- 230000009223 neuronal apoptosis Effects 0.000 description 11
- 239000012188 paraffin wax Substances 0.000 description 11
- 230000010412 perfusion Effects 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000001964 calcium overload Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 230000000630 rising effect Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 9
- 102100029268 Neurotrophin-3 Human genes 0.000 description 9
- 229930040373 Paraformaldehyde Natural products 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 230000003511 endothelial effect Effects 0.000 description 9
- 230000002461 excitatory amino acid Effects 0.000 description 9
- 239000003257 excitatory amino acid Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 229940053128 nerve growth factor Drugs 0.000 description 9
- 229920002866 paraformaldehyde Polymers 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- 206010028851 Necrosis Diseases 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000000269 carotid artery external Anatomy 0.000 description 8
- 229960003638 dopamine Drugs 0.000 description 8
- 238000004043 dyeing Methods 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 210000004088 microvessel Anatomy 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 210000000653 nervous system Anatomy 0.000 description 8
- 230000003188 neurobehavioral effect Effects 0.000 description 8
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 8
- 229960002748 norepinephrine Drugs 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 102000007072 Nerve Growth Factors Human genes 0.000 description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 7
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 7
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 7
- 210000003710 cerebral cortex Anatomy 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 230000016273 neuron death Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 229960005356 urokinase Drugs 0.000 description 7
- 238000003809 water extraction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- 206010069729 Collateral circulation Diseases 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 108050009340 Endothelin Proteins 0.000 description 6
- 102000002045 Endothelin Human genes 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 6
- 230000036770 blood supply Effects 0.000 description 6
- 210000004958 brain cell Anatomy 0.000 description 6
- 208000029028 brain injury Diseases 0.000 description 6
- 210000001168 carotid artery common Anatomy 0.000 description 6
- 230000003727 cerebral blood flow Effects 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 208000037906 ischaemic injury Diseases 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 230000000324 neuroprotective effect Effects 0.000 description 6
- 239000003900 neurotrophic factor Substances 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 206010048962 Brain oedema Diseases 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 208000006752 brain edema Diseases 0.000 description 5
- 201000008247 brain infarction Diseases 0.000 description 5
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 210000003194 forelimb Anatomy 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 5
- 229940096397 interleukin-8 Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 150000002978 peroxides Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 201000003099 Renovascular Hypertension Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000003282 amino acid receptor affecting agent Substances 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 4
- 210000003725 endotheliocyte Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000002964 excitative effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000019581 neuron apoptotic process Effects 0.000 description 4
- 230000006576 neuronal survival Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000001202 rhombencephalon Anatomy 0.000 description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000001117 sulphuric acid Substances 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 210000001627 cerebral artery Anatomy 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960003699 evans blue Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 235000019353 potassium silicate Nutrition 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 229930183842 salvianolic acid Natural products 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 208000037823 Cerebral ischemia/reperfusion injury Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 108091006088 activator proteins Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000028600 axonogenesis Effects 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000008344 brain blood flow Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 2
- 229950004794 dizocilpine Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229950002798 enlimomab Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- IJAGKEKOJGWANE-KCBWXHRDSA-N (3r,4r,5r)-5-[(2s,3r)-4-[(e)-2-carboxyethenyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carbonyl]oxy-3,4-dihydroxycyclohexene-1-carboxylic acid Chemical compound O[C@@H]1[C@H](O)C=C(C(O)=O)C[C@H]1OC(=O)[C@@H]1C(C(\C=C\C(O)=O)=CC=C2O)=C2O[C@@H]1C1=CC=C(O)C(O)=C1 IJAGKEKOJGWANE-KCBWXHRDSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 241000272165 Charadriidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 206010051078 Lacunar infarction Diseases 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000003818 area postrema Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical group O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- OZFSWVOEXHGDES-INIZCTEOSA-N lubeluzole Chemical compound C([C@@H](O)CN1CCC(CC1)N(C)C=1SC2=CC=CC=C2N=1)OC1=CC=C(F)C(F)=C1 OZFSWVOEXHGDES-INIZCTEOSA-N 0.000 description 1
- 229950009851 lubeluzole Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000003977 optic chiasm Anatomy 0.000 description 1
- 230000004413 optic chiasma Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000002061 vacuum sublimation Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000008886 xiangdan Substances 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to application of a salvianolic acid A freeze-dried powder to preparation of a drug for protecting cerebral vascular endothelial cells. The salvianolic acid A freeze-dried powder contains a salvianolic acid A main ingredient, a filler and an antioxidant in the following weight proportion: 20g-60g of the salvianolic acid A main ingredient, 20g-60g of the filler and the antioxidant accounting for 0.02%-0.1% of the total amount. The salvianolic acid A main ingredient comprises 94%-97% of salvianolic acid A, 0.2%-1.5% of lithospermic acid, 0.2%-1.5% of rosmarinic acid, 0.2%-1.5% of salvianolic acid B and 0.4%-2% of salvianolic acid C.
Description
Technical field
The present invention relates to the purposes of a kind of salvianolic acid A freeze-dried powder for the preparation of protection cerebrovascular endothelial cell medicine.
Technical background
Cerebrovascular claims again apoplexy, is to make to supply a kind of nervous system disease due to the blood vessel generation pathological changes of brain blood by the various causes of disease.Its Etiological be the reasons such as cerebral arteries system disease damage (as cerebral arteriosclerosis) the cerebral arteries luminal stenosis, vasospasm, the obturation that cause or break, Oligemia or total blockage, brain blood circulation and dysfunction, the impaired and series of symptoms that occurs of cerebral tissue.Mainly comprise ischemic and hemorrhagic apoplexy.Wherein (ICVD claims again Ischemic Stroke) account for 80% left and right.
Ischemic cerebrovascular refers to that local brain tissue comprises the afunction of degeneration, necrosis or a property crossed that neurocyte, glial cell and contact fiber occur due to blood supply disorder.The cerebral arteries emphraxis that Intravascular Thrombus formation, thromboembolism, angiostenosis cause is the main cause of cerebral infarction.Ischemia cause cranial nerve cell damage and dead mechanism of action various, complicated, after cerebral infarction (being cerebral ischemia), supply due to brain shortage blood and oxygen, cause large brain energy metabolism unbalance, produce a series of pathologic damage, as oxidative stress, toxicity of excitatory amino acid, calcium overload, inflammatory reaction etc., thereby cause neuronic mortality.It is commonly encountered diseases, frequently-occurring disease clinically, and mortality rate and disability rate are very high, existing one of the three universally acknowledged large lethal diseases that become.Treatment is mainly the recovery of function of nervous system after thrombolytic, the neuron of being at death's door of saving ischemic area (half blanking bar) and promotion damage clinically.The control ischemic cerebrovascular is current mankind difficult medical problem in the urgent need to address.At present U.S. FDA has only been ratified tissue plasmin activation factor (tPA) for the thromboembolism treatment after apoplexy, but its therapeutic time window is very narrow, only in apoplexy, uses just effectively in 4.5 hours; But also exist hemorrhage and Ischemia Reperfusion to increase the weight of the danger of brain injury.And at present for the neuroprotective drug of ischemic stroke treatment comprise calcium channel blocker as nimodipine, glutamate receptor antagonists as dizocilpine (DizocilPine), antioxidant or free radical scavenger as Edaravone, NO signal transduction pathway regulator lu pei Shandong mile (Lubeluzole) and inflammation inhibitor enlimomab (Enlimomab) etc.But the therapeutical effect had in them is imprecise or specificity is not strong, some toxic and side effects than large, toleration is little, have also in clinical before or the clinical research stage, being difficult to actively affects in the performance of control cerebral infarction.Thereby, develop quick control brain ischemia medicament effective, safety and stability extremely urgent.Brought into play very important positive role at this field Chinese medicine.
Salvianolic acid A (Salvianolic acid A), have another name called Salvianolic acid A, it is a kind of water-soluble phenolic compounds contained in the dry root and rhizome of labiate Radix Salviae Miltiorrhizae Salviamiltiorrhiza Bunge, salvianolic acid A has obvious pharmacological action to the cerebral microvascular thromboembolism, and the effect be better than salvianolic acid B (Zhang Hengai. impact and the Mechanism Study [D] of salvianolic acid A on cerebral microvascular thromboembolism rat. Beijing: Beijing Union Medical College graduate school, 2011), salvianolic acid A is to be formed by danshensu and caffeic acid condensation, contain a plurality of phenolic hydroxyl groups, hydroxyl, the reactive groups such as ester bond, it is unstable to light and heat, exposure air easily is oxidized to salvianolic acid C and different salvianolic acid C etc., above-mentioned physicochemical property due to salvianolic acid A, make the salvianolic acid A injection agent, its stability becomes the key technology of making injection.But particularly injection Research Literature data is few for relevant salvianolic acid A preparation, and the instable problem of ubiquity injection, can't guarantee the salvianolic acid A pharmacological action.
Summary of the invention
The above-mentioned defect existed for overcoming prior art, the invention provides the purposes of a kind of salvianolic acid A freeze-dried powder for the preparation of protection cerebrovascular endothelial cell medicine, and wherein, described salvianolic acid A freeze-dried powder comprises containing salvianolic acid A master part raw material, filler and antioxidant; Each composition of wherein said freeze-dried powder is pressed column weight amount proportioning and is made: containing salvianolic acid A master part raw material 20g~60g, filler 20g~60g, antioxidant is to make 0.02%~0.1% of total amount, wherein said containing in salvianolic acid A master part raw material: salvianolic acid A 94%~97%, alkannic acid 0.2%~1.5%, rosmarinic acid 0.2%~1.5%, salvianolic acid B 0.2%~1.5%, salvianolic acid C 0.4%~2.0%;
Described salvianolic acid A freeze-dried powder adopts the method that is prepared as follows to obtain:
Get red rooted salvia, be cut into decoction pieces or be ground into diameter 1mm~5mm granule, add 3~15 times of amounts, 45~95 ℃ of water temperature lixiviates are got at every turn, with 10~50 rev/mins of speed, stir simultaneously, or add 3~15 times of water gagings decoction extractions, and extract altogether 1~3 time, extract 1~4 hour at every turn; Extracting solution is evaporated to relative density 1.0~1.25 (60 ℃), adds ethanol to make to measure 50%~85% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, obtains Radix Salviae Miltiorrhizae extract; Perhaps
Get red rooted salvia, be cut into decoction pieces or be ground into diameter 1mm~5mm granule, add 3~15 times of amount 30%~60% alcohol reflux at every turn, extract 1~4 hour at every turn, extract altogether 1~3 time; Decompression recycling ethanol also is concentrated into without the alcohol flavor, obtains Radix Salviae Miltiorrhizae extract;
Above-mentioned Radix Salviae Miltiorrhizae extract was diluted with water to every 1ml containing salvianolic acid B 1~30mg, and adjusting PH with base to 3.5 for aqueous solution~6.5 add with salvianolic acid B molar percentage 0.1~3% zinc chloride as catalyst, 100~140 ℃ of temperature thermal conversions 1~6 hour;
Conversional solution adjust pH to 2.5~4.5, standing, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 1~10mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 35~1: 70 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 4~1: 30, use respectively 1~8 times of cylinder hydrops, 1~10 times of column volume 10%~40% ethanol elution, remove impurity, use again 2~10 times of column volume 20%~60% ethanol elutions, HPLC detects, 20%~60% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor,
Aqueous solution is concentrated into the solution of every 1ml containing the 1-10mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 5~1: 25 with the polyamide ratio, the resin column blade diameter length ratio is 1: 4~1: 25, use respectively 1~10 times of cylinder hydrops, 5~20 times of column volume 20%~60% alcoholic solution eluting remove impurity, use again 4~15 times of column volumes, 40%~90% alcoholic solution eluting, 40%~90% alcoholic solution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without alcohol flavor aqueous solution;
Aqueous solution is concentrated, acid adjustment pH to 2.0~4.0, the t-butyl methyl ether of doubly measuring with aqueous solution 1-8, minute 2~6 extractions, separate organic layer, the reclaim under reduced pressure t-butyl methyl ether, make the extract of every 1ml containing salvianolic acid A 1g~10g, add 1~3 times of amount silica gel, stir, volatilize;
Stirring sample silica gel, be added on 5~20 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 4~1: 25, take pentane-t-butyl methyl ether as eluant, gradient elution, use respectively 6~30 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 6~30 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 5~20 times of water gagings and dissolves, microwave vacuum drying, obtain described containing salvianolic acid A master part raw material
Get containing salvianolic acid A master part raw material 10g~80g and inject water 1500~2800ml and be stirred to dissolve, by adjusting PH with base value 4.0~5.0, add again described filler to make its dissolving, add again described antioxidant, be stirred to dissolve and mix, then add active carbon 0.5~2g stirring and adsorbing, active carbon is removed in filtration, inject the water fill and become bottle, send into freeze dryer and carry out again lyophilization
Wherein said lyophilization comprises the steps:
A, freezing: be cooled to-40 ℃~-45 ℃ with 20 ℃~30 ℃/h speed, be incubated freezing 10~16 hours;
B, distillation: be evacuated to below 0.3mbar, in 10~14 hours, the salvianolic acid A salvianolic acid A formulation temperature freezed risen to-23 ℃~-27 ℃, maintain-23 ℃~-27 ℃ vacuum dryings 6~8 hours;
C, drying: continue to heat up, with 0.5 ℃~1.0 ℃/min, evenly be warming up to 40 ℃~45 ℃, maintain 40 ℃~45 ℃ dryings after 2~5 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Preferably, also comprise the purposes for the protection of Injury of Cerebral Microvascular Endothelial Cells.
Preferably, wherein said filler loading is 20mg~40mg/2ml~3ml.
Preferably, microwave vacuum drying temperature: 20-100 ℃, return difference temperature 1-5 ℃, more than vacuum-0.07Mpa, microwave power 1-100KW, dry 10-200 minute.
Preferably, microwave vacuum drying temperature: 50-85 ℃, return difference temperature 2-4 ℃, more than vacuum-0.07Mpa, microwave power 10-80KW, dry 100-150 minute.
Preferably, microwave vacuum drying temperature: 55-80 ℃, return difference temperature 2-3 ℃, more than vacuum-0.07Mpa, microwave power 25-60KW, dry 120-140 minute.
Salvianolic acid A freeze-dried powder principal agent provided by the invention is salvianolic acid A master part raw material, the present invention is by the extraction to Radix Salviae Miltiorrhizae, transform, purification, drying process, obtained take salvianolic acid A as main part of main raw material: through screening and the optimization of system, at first relatively extraction solvent and the extracting method of initiation material salvianolic acid B have been determined, because the salvianolic acid B water solublity is better, employing water extraction or low concentration alcohol extraction have been determined, again because the salvianolic acid B heat stability is poor, determined that employing hot water warm macerating extracts and adds the stirring extracting method, or use the low-concentration ethanol reflux, extract, make to extract solubility lower than 100 ℃, keep salvianolic acid B not to be destroyed, optimum solvent consumption and extraction time have been determined by orthogonal experiment, obtained adapting to the salvianolic acid B optimum extraction process of suitability for industrialized production.
The present invention is compared with the prior art and shows: the direct extraction of the red rooted salvia conversion that can be fed intake for initiation material, do not need salvianolic acid B is carried out being transformed after purification again, be in catalytic conversion reaction of the present invention, the reaction raw materials salvianolic acid B does not need high-purity, does not for example need the purity of salvianolic acid B >=50%.It is generally acknowledged that reaction raw materials is more pure better, yet, in catalytic conversion reaction of the present invention, the purity of salvianolic acid B height is on the not impact of conversion reaction effect.On the contrary, not only produce a large amount of impurity during salvianolic acid B purity>50%, and do not improve conversion ratio, therefore, the present invention has obtained unforeseeable technique effect.
Moreover the present invention by experiment repeatedly relatively, has at first determined that factor that salvianolic acid A master part raw material productive rate is produced to material impact is as the concentration that transforms front pressure differential self, pH value, temperature, time etc.On this basis, by paying concentration and other correlated conditions that a large amount of time, material and energy tests repeatedly to temperature, pH value, time, salvianolic acid B, be studied again, and these factors how synergism exerts an influence to salvianolic acid A master part raw material productive rate jointly each other, thereby determined that salvianolic acid B transforms the optimum temperature of the needs control of salvianolic acid A, pH value, time etc., and the salvianolic acid B initial concentration is controlled to 1mg/ml~30mg/ml, thereby make salvianolic acid A conversion ratio of the present invention more obviously be better than other conversion conditions.In chemical reaction, the purity of reactant usually affects the effect of reacting with concentration.Generally reactant is had to concentration requirement, and think that the high specific concentration of concentration hangs down.In catalytic conversion reaction of the present invention, the concentration of salvianolic acid B height is on the not impact of conversion reaction effect.On the contrary, may be due to pyrolytic conversion, salvianolic acid B purity height not only produces a large amount of impurity, and does not improve conversion ratio.And not more high better containing the concentration of salvianolic acid B in the salvianolic acid B aqueous solution, the above concentration conversion ratio of 30mg/ml is low on the contrary, and effect is poorer.Therefore, the present invention, aspect cost-saving and production cycle, has obtained unforeseeable technique effect, creative.In the situation that prior art does not provide any technology enlightenment, if only deduction theoretically of those skilled in the art is impossible show that the sour B of pellet being changed into to salvianolic acid A master part raw material under above-mentioned each conditional parameter has the conclusion of better changing effect.
What is more important, the present invention passes through performing creative labour, find that zinc chloride can significantly improve as catalyst the conversion ratio that salvianolic acid B transforms salvianolic acid A master part raw material, reaching that conversion ratio is highly stable approaches 60%, most cases can surpass 60%, this is all impossible in any one prior art in the past, therefore, has obtained unforeseeable technique effect.
Because salvianolic acid A content is lower, the large raising of salvianolic acid A content after transforming, but also containing a large amount of impurity, therefore, selected respectively low pole and nonpolar macroporous adsorption resin to carry out crude separation, select again polyamide, solvent extraction, silica gel to separate, and various flows part is measured, after removing the impurity part, salvianolic acid A content in salvianolic acid A master part raw material is brought up to 80% from 10% left and right, to 90%, to 93%, to 96%.
Further, when significantly improving conversion ratio, the present invention is by being suitable for the purification step of actual industry application, especially by after the steps such as a series of separation, eluting processing, do not adopt traditional constant pressure and dry, and from vacuum drying, spray drying, microwave vacuum drying method preferred microwave vacuum drying, thereby thoroughly overcome, baking temperature was too high in the past, drying time long and to the destruction of salvianolic acid A large defect; And sublimation drying is long, the high and extract lyophilization gained of cost can't be removed the dissolvent residual problem fully.
In addition, the present invention can also mix low concentration with the salvianolic acid B of high concentration, only need be made into suitable initial conversion concentration and get final product, and can reach equally the purpose that changes into salvianolic acid A master part raw material.Therefore, the preparation technology of this conversion raw material is very simple, and production cost also is very suitable for the application in actual industry when reducing.
Salvianolic acid A master part raw material, except containing the main component salvianolic acid A, also contains a small amount of salvianolic acid B, alkannic acid, rosmarinic acid, salvianolic acid C; Salvianolic acid A is by removing free radical, alleviates mobility and the permeability that the membrane lipid peroxidating causes and changes, and stops the spilling of abnormal penetrating and enzyme of ion, thereby reduced cerebral ischemia re-pouring and the damage that causes, and cerebral ischemia is had to protective effect.But salvianolic acid A dose dependent ground suppresses the platelet aggregation that adenosine diphosphate (ADP), thrombin, arachidonic acid, collagen or U46619 induce, reduce cAMP level in platelet, and the expression and the Fibrinogen combination that reduce the P-selectin that ADP causes, thereby the platelet leukocyte recruitment that stops ADP to cause, be formed with preventive and therapeutic effect to atherosclerosis and thromboembolism; Salvianolic acid A improves middle cerebral artery occlusion model in rats rat function of nervous system defect state, dwindles infarct size, alleviates cerebral edema, reduces the related brain areas neure damage degree, cerebral ischemia is had to protective effect, to the protective effect of learning memory injury.
Salvianolic acid B in salvianolic acid A master part raw material is the main effective ingredient of Radix Salviae Miltiorrhizae and preparation Radix Salviae Miltiorrhizae Injection thereof, XIANGDAN ZHUSHEYE, and the same with salvianolic acid A have protective effect to cerebral ischemia, and atherosclerosis and thromboembolism are formed with to preventive and therapeutic effect; Cerebral ischemia is had to protective effect; alkannic acid, rosmarinic acid, salvianolic acid C effect and salvianolic acid A are roughly the same; stronger antioxidation is all arranged; can remove oxygen-derived free radicals; suppress lipid peroxidation; its action intensity is higher than vitamin C, vitamin E; it is one of natural product that at present known antioxidation is the strongest; the aggreation that obviously suppresses ADP, arachidonic acid, collagen-induced Rabbit Blood Platelets; and suppress thrombotic effect, and can extend the time-to-live of animal under anoxia condition.Can obviously improve function of nervous system's defect of cerebral reperfusion injury rat, improve behavior disorder, obviously dwindle brain infarction area, obviously improve FeCl
3due to the animal nerve function damage that causes of rat cerebral ischemia, make the improvement of its obstacle, and can dwindle brain infarction area; Rosmarinic acid also contributes to prevent that the cell that free radical causes is impaired, has therefore reduced cancer and arteriosclerotic risk.
Alkannic acid in salvianolic acid A master part raw material suppresses propagation and the migration of vascular smooth muscle cell in addition, and prevention of arterial is atherosis, angiostenosis and vascellum endometrial hyperplasia, has vasodilative effect.Can suppress uric acid and cross the formation of ultra-oxygen anion free radical, the generation of inhibition peroxide, the effect of antiinflammatory and uric acid resisting is arranged.The external effect that can suppress metakentrin release.
Thereby the salvianolic acid C in salvianolic acid A master part raw material is also apoptosis-induced by suppressing the retardance of tubulin polymerization inducing cell mitosis, has anti-tumour cell proliferative activity.
There is common cerebrovascular is had protective effect, atherosclerosis and thromboembolism are formed with preventive and therapeutic effect, cerebral ischemia is had to protective effect after salvianolic acid A in salvianolic acid A master part raw material, salvianolic acid B, alkannic acid, rosmarinic acid, salvianolic acid C combination; use effect is stronger separately than salvianolic acid A monomeric compound to make it, have in addition simultaneously antiinflammatory and uric acid resisting effect, reduced cancer and arteriosclerotic risk.
Salvianolic acid A freeze-dried powder provided by the invention, to prepare on salvianolic acid A master part raw material process basis above-mentioned, chemistry and physical characteristic according to salvianolic acid A, from affecting the stable additives of medicine, dosage form, container, extraneous as air, light, moisture, the generation chemical reactions such as impurity cause the decomposition of medicament to carry out creationary experimental analysis on the contrary.By the screening preparation prescription, repetition test, selected mannitol, glucose, lactose etc., made freeze-dried powder, the molding of powder pin is good, block is loose, hole, color and luster are even, and stability is very high, by adding a small amount of antioxidant, solved due to air, light, moisture, the medicine that the generation chemical reactions such as impurity cause decomposes.Salvianolic acid A is made to suitable preparation, solved salvianolic acid A and made the injection stability problem, by selecting suitable adjuvant and dosage form, guaranteed the salvianolic acid A pharmacological action, for clinical, provide safe and effective salvianolic acid A injection formulation.
We by selecting suitable dosage form, have screened different adjuvants according to the physicochemical property of salvianolic acid A, and preferred different preparation technology and technological parameters, prepared stable, safe, effective, quality controllable salvianolic acid A freeze-dried powder.
The present invention is compared with the prior art and shows: the present invention passes through performing creative labour, finally determined lyophilizing speed cooling rate and cooling time, programming rate and temperature during distillation, determine the vacuum sublimation time, clear and definite dry programming rate and temperature, and drying time; The creationary complex relationship of clearly having determined between frozen cooling speed and temperature, distillation programming rate and the dry programming rate of temperature and temperature and time, and suitable numerical range is definite etc., thus just finally obtained stable lyophilized injectable powder.
Importantly, the salvianolic acid A freeze-dried powder that adopts preparation method of the present invention to make can not change the original chemical attribute of salvianolic acid A fully; The salvianolic acid A freeze-dried powder compositions of making is compared the characteristics such as have good water solubility, heat stability is high, solubility is good with salvianolic acid A.
What is more important, crude drug salvianolic acid A in the present invention is adjusted to applicable scope by alkali liquor by pH value, again by adding mannitol etc., make it be easier to lyophilization, and do not affect the property of medicine, and make the content of principal agent salvianolic acid A after freeze-dried powder and increase, and the content of salvianolic acid B decreases, can not make the preparation effect reduce, can make on the contrary the preparation effect strengthen, play beyond thought effect.
On the other hand, the present invention also provides it for prevention and or the purposes for the treatment of ischemic cerebrovascular aspect.
Known through the experimental data contrast, the easily postoperative recovery from anesthesia scoring of apoplectic type renovascular hypertension in rats middle cerebral artery occlusion (MCAO), model group revive after (12h in) neural behavior scoring (symmetry of spontaneous activity, quadruped locomotion, forelimb stretch the action of creeping symmetry, climb the cage wall, push away the trunk reaction, antenna is to the reaction that stimulates etc.) significantly lower than sham operated rats, illustrate that after the cerebral thrombosis ischemia, easily apoplectic type renovascular hypertension in rats (RHRSP) function of nervous system is impaired serious, and, in lasting 72h, neural behavior scoring continues to be starkly lower than sham operated rats; The nimodipine group is compared with model group with salvianolic acid A monomeric compound group and each dosage group of salvianolic acid A freeze-dried powder, neurobehavioral after rat revives has rising in various degree, the most obvious with the middle and high dosage group of salvianolic acid A freeze-dried powder, and after its ischemia, the neurobehavioral of 24h approaches the sham operated rats level substantially; Recovered normally to each dosage group rat neurobehavioral of 72h salvianolic acid A freeze-dried powder after ischemia, and recovered soon than salvianolic acid A monomeric compound group and slightly good with the integrality of dosage salvianolic acid A freeze-dried powder group rat, neurobehavioral has more excellent trend.Prompting salvianolic acid A freeze-dried powder can improve neurobehavioral after RHRSP cerebral thrombosis ischemia, the effect of nervous symptoms after thering is protection and improving cerebral ischemia, and effect is better than nimodipine, and the trend that is better than same dosage salvianolic acid A monomeric compound is arranged.
Known through histopathology checking experiment Data Comparison, sham operated rats cerebral tissue Bilateral Symmetry, have no pathological changes, and the model group Intravascular Thrombus adheres to seriously.With model group relatively, the contraction in length of each dosage group rat ischemia side middle cerebral artery (MCA) local thrombus of Microscopic observation salvianolic acid A freeze-dried powder, reduce at the arterial wall bond area, with high, middle dosage group is the most obvious.The TTC visible infarcted cerebral constitution that dyes is white in color, and is dyed to white cerebral tissue scope in each dosage group of salvianolic acid A freeze-dried powder and dwindles than model control group is remarkable.HE dyes in visible model group ischemia side cortex MCA blood supply district (centered by the cortex of volume top) infarct has obvious cerebral tissue softening, necrocytosis, the phenomenons such as the local necrosis tissue comes off, salvianolic acid A freeze-dried powder high dose group rat has no Telatrophy's obscission herein; The HE dyeing of each dosage group of salvianolic acid A freeze-dried powder and model control group shows in kitchen range, kitchen range Zhou Jun has little blood vessel hyperplasia, but the little number of blood vessel of each dosage group of salvianolic acid A freeze-dried powder and model group comparison hypertrophy significantly increases; In addition, the kitchen range shape that HE dyeing display model matched group differs in size as seen is hemorrhage, and high, the middle dosage group of salvianolic acid A freeze-dried powder there is no and finds that there is kitchen range shape bleeding.Result shows that the salvianolic acid A freeze-dried powder can obviously improve RHRSP cerebral thrombosis Neurons Against Cerebral Ischemia histopathology state; reduce the thrombosis bond area, reduce infarct size; thereby increasing the little blood vessel number, the necrosis of minimizing cerebral hemorrhage phenomenon protection cerebral tissue that reach surrouding brain tissue in infarcted region comes off; there is protection cerebral thrombosis ischemia and cause the effect of brain tissue impairment, and be better than the salvianolic acid A monomeric compound.
Known through the experimental data contrast, cerebral thrombosis tissues following MCAO in rats blood-brain barrier disruption, permeability increases, and azovan blue (EB) albumin-binding can enter cerebral tissue by open blood brain barrier (BBB).After the administration of salvianolic acid A freeze-dried powder; under each dosage group rat cerebral tissue microscope, EB hot spot number and cerebral tissue EB detect content and obviously reduce; and the salvianolic acid A monomeric compound group that is less than same dosage; with model group, more all there were significant differences; illustrate that the salvianolic acid A freeze-dried powder increases inhibited to brain tissue impairment hyperamization brain Barrier Permeability; can protect blood brain barrier, and the further damaged of protection cerebral tissue, action effect is better than the salvianolic acid A monomeric compound.
Known through the experimental data contrast, by RHRSP cerebral thrombosis rat model group is compared, sham operated rats has no infarcted cerebral constitution; Each dosage group cerebral tissue Infarction volume of salvianolic acid A freeze-dried powder and brain water content are significantly less than model control group, and dosage is larger, and Infarction volume is less, and brain water content is fewer.Salvianolic acid A freeze-dried powder basic, normal, high dosage group Infarction volume and brain water content are all lower than the nimodipine group; And than low with the salvianolic acid A monomeric compound group of dosage.Illustrate that the salvianolic acid A freeze-dried powder can accelerate the reparation of focus, reduce ischemic tissue of brain infarction size after the RHRSP cerebral thrombosis, alleviate the cerebral tissue edema, have and repair and the effect of protection Neurons Against Cerebral Ischemia tissue injury, be better than salvianolic acid A monomeric compound and nimodipine.
Known through the experimental data contrast, with RHRSP cerebral thrombosis ischemia model group, compare, after the ischemia treatment, each dosage group cerebral tissue ischemia penumbra MVD of salvianolic acid A freeze-dried powder and blood vessel scene are long-pending significantly to be increased to some extent, than nimodipine and more obvious with dosage salvianolic acid A monomeric compound, and more stable in 7d.Show that the salvianolic acid A freeze-dried powder can increase MVD and the blood vessel field Area Ratio of cerebral tissue ischemia half blanking bar, prompting salvianolic acid A freeze-dried powder has the effect that promotes that ischemic tissue of brain Angiogenesis and collateral circulation are set up, and effect is better than salvianolic acid A monomeric compound and nimodipine.
Known through the experimental data contrast; RHRSP cerebral thrombosis ischemia model group VEGF Messenger RNA (VEGFmRNA) expression is increased significantly than sham operated rats; illustrate after the cerebral tissue hypoxic-ischemic can Stimulation of The Brain tissue in the expression increase of VEGF; after the prompting cerebral infarction, body self there will be a kind of protective response that resists ischemia injury; the expression of VEGF is increased, self " compensatory revascularization " occur after ischemia.Each dosage group of salvianolic acid A freeze-dried powder and model group group are relatively; the VEGFmRNA expression significantly raises; show that the salvianolic acid A freeze-dried powder can significantly promote the ischemic tissue of brain angiogenesis; promote the foundation of collateral circulation compensation; save ischemia half blanking bar; the brain tissue impairment that the protection ischemia causes, and have certain dose-effect relationship, the trend that is better than same dosage salvianolic acid A monomeric compound is arranged.
Known through the experimental data contrast; RHRSP cerebral thrombosis ischemia model group rat cerebral tissue's basic fibroblast growth factor (bFGF) protein expression is increased significantly than sham operated rats; but the prolongation with Ischemia Time; have a declining tendency; after prompting cerebral tissue hypoxic-ischemic; body self produces of short duration protection stress, but Stimulation of The Brain organizes the bFGF protein expression to increase.Relatively, the bFGF protein expression of each time period significantly increases for each dosage group of salvianolic acid A freeze-dried powder and model group; Each time period of each dosage group self relatively shows, the bFGF protein expression is continual and steady; Prompting salvianolic acid A freeze-dried powder can increase former of ischemic tissue of brain and secondary bFGF protein expression; effect with good neurocyte protection effect and promotion angiogenesis; contribute to the foundation of collateral circulation; save ischemia half blanking bar, and action effect is better than salvianolic acid A monomeric compound and nimodipine.
Known through the experimental data contrast, the salvianolic acid A freeze-dried powder can alleviate cerebral ischemia-reperfusion injury in rats neurologic impairment symptom, be conducive to its neurobehavioral recovery, the salvianolic acid A freeze-dried powder has the effect that improves function of nervous system after brain tissue impairment, and action effect is more obvious than salvianolic acid A monomeric compound.
Known through the experimental data contrast, each dosage group of salvianolic acid A freeze-dried powder is compared with the Ischemia-Reperfusion Injury Model group: cerebral infarction volume is than significantly reducing, cerebral index and brain water content all obviously reduce, show that the salvianolic acid A freeze-dried powder can reduce rats after cerebral ischemic reperfusion cerebral tissue infarction size, can alleviate the cerebral tissue edema degree after cerebral ischemia reperfusion injury, effect is better than salvianolic acid A monomeric compound and nimodipine.
Known through the experimental data contrast, Level In Rats With Focal Cerebral Ischemia, give various dose salvianolic acid A freeze-dried powder 10min and begin, each medicine group than self administration before ischemia half blanking bar regional cerebral blood flow (rCBF) obvious rising is arranged, and particularly remarkable with high, the middle dosage group of salvianolic acid A freeze-dried powder; Each dosage group of salvianolic acid A freeze-dried powder is compared, and good dose-effect relationship is arranged; In the salvianolic acid A freeze-dried powder, the rCBF of dosage group day part is suitable with the nimodipine group.Hence one can see that, and the salvianolic acid A freeze-dried powder has the effect that increases rats with cerebral ischemia cerebral tissue ischemia half blanking bar rCBF, is conducive to save the cerebral tissue that ischemia half blanking bar is at death's door, the effect of performance treatment cerebral ischemia, and the trend that is better than the salvianolic acid A monomeric compound is arranged.
Known through the experimental data contrast, after rat continuous ischemia 2h recovers to fill with again, each organizes rat ischemia half blanking bar rCBF all increase in various degree.But focal cerebral ischemia is filled with the model group rat ischemia again, to fill with in 3h blood perfusion extremely unstable again, recovering to fill with again in 1~1.5h, ischemia half blanking bar rCBF rises to top level, but still before ischemia below 50%, cerebral tissue still is low perfusion state, and it is front below 40% after this sharply to drop to again ischemia, cerebral tissue because of fill with again aggravate impaired.And, after filling with, nimodipine, the high, medium and low dosage group of salvianolic acid A freeze-dried powder rat rCBF obviously increase again, each time period rCBF has compared utmost point significant difference with model group.1h after filling with again, salvianolic acid A freeze-dried powder high dose group rCBF returns to and approaches 75% of former rCBF, in nimodipine group and salvianolic acid A freeze-dried powder, the dosage group returns to and is about 69% of former rCBF, 10mg/kg salvianolic acid A monomeric compound group returns to 65% left and right of former rCBF, salvianolic acid A freeze-dried powder low dose group returns to and is about 61% of former rCBF, and, to pouring in 3h, each medicine group rCBF maintains in metastable scope again.Result shows that the salvianolic acid A freeze-dried powder can obviously improve the cerebral blood flow of ischemia half blanking bar cerebral tissue after Ischemia and Reperfusion in vivo in Rats, recovering brain cell blood supplies, thereby save ischemia half blanking bar, further damage is even dead to prevent cerebral tissue, and effect is better than the salvianolic acid A monomeric compound, ischemic cerebrovascular is had to good therapeutical effect.
Known through the experimental data contrast, can the raise content of ischemic tissue of brain adenosine triphosphate (ATP), adenosine diphosphate (ADP) (ADP), (AMP) AMP, phosphagen (PC) of salvianolic acid A freeze-dried powder, reduce cerebral tissue lactic acid (LA) content, can significantly improve the energy metabolism of rat cerebral ischemia and ischemia-reperfusion.The salvianolic acid A freeze-dried powder can be by improving the energy metabolism of Neurons Against Cerebral Ischemia tissue, increase the supply of cerebral tissue energy matter, strengthen the survival ability of brain cell, the brain cell that ischemia half blanking bar after the redemption cerebral ischemia is at death's door, further damage is even dead to prevent cerebral tissue, and action effect is obvious than salvianolic acid A monomeric compound and nimodipine, can perform well in treating ischemic cerebrovascular.
Known through the experimental data contrast, after rat cerebral ischemia 2h fills with 24h again, neuronal apoptosis is serious; And, after nimodipine, salvianolic acid A monomeric compound and the intervention of various dose salvianolic acid A freeze-dried powder, with model group, compare, in rat cerebral tissue, neuronal apoptosis significantly reduces (P<0.001 or P<0.01); And the apoptosis rate with high, the middle dosage group of salvianolic acid A freeze-dried powder is minimum; Show that the salvianolic acid A freeze-dried powder has the effect that suppresses cerebral ischemia rat cerebral tissue neuronal death, suppresses neuronal apoptosis, effect is better than salvianolic acid A monomeric compound and nimodipine.
The neurotrophic factor histone matter molecule essential with survival that be neure growth, play supporting function to the integrity of neure growth, growth and function.Nerve growth factor (NGF), Brain Derived Neurotrophic Factor (BDNF), neurotrophic factor-3 (NT-3) are the parts of neurotrophic factor family, can maintain neuronal survival and promote the neurocyte differentiation and induce axon growth; Energy neuroprotective unit, promotion neuron reparation and inhibition delayed neuronal death, thereby to anti-cerebral ischemia, protection cerebral ischemia.After Cerebral Ischemia-reperfusion, in rat cerebral tissue, than sham operated rats, increase to some extent, after the prompting cerebral reperfusion injury, in cerebral tissue, NGF, BDNF express stress protectiveness increase; But in the Neurons Against Cerebral Ischemia tissue, NT-3 content obviously reduces.Known through the experimental data contrast, with model control group, compare, each dosage group of salvianolic acid A freeze-dried powder NGF, BDNF, NT-3 protein expression all obviously strengthen, and the trend that is better than same dosage salvianolic acid A monomeric compound and nimodipine is arranged.Prompting salvianolic acid A freeze-dried powder can strengthen the expression of ischemic injuries cerebral tissue endogenous neurotrophic factor NGF, BDNF, NT-3, for neuronal survival provides condition, and reaches the effect of neuro-protective.
After cerebral ischemic reperfusion in rats, in cerebral tissue, inflammatory cytokine interleukin-1 ' beta ' (IL-1 β), interleukin-6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor-alpha (TNF-α), intercellular adhesion molecule-1 (ICAM-1) content all extremely significantly increase; Known through the experimental data contrast, each inflammatory cytokine content of rat cerebral tissue that gives each dosage group of salvianolic acid A freeze-dried powder obviously reduces than model group, and salvianolic acid A monomeric compound group and the nimodipine group with dosage is remarkable.Prompting salvianolic acid A freeze-dried powder can suppress the expression of ischemic injuries brain tissue inflammation cytokine, suppress the generation of brain tissue inflammation's reaction, suppress neuron and the cerebral tissue cascade damage of inflammatory reaction mediation, effect is better than salvianolic acid A monomeric compound and nimodipine.
Ca in cell
2+overload is one of encephaloclastic important mechanism of mediation Secondary cases in During Ischemia, is the last common pathway that ischemia, anoxia produce irreversible neuronal damage.Ca
2+overload can be by exciting activator protein enzyme as the second message,second messenger, activate phospholipase, activate a series of enzyme reactions such as endonuclease produces infringement to cell, and cell death inducing, cause acute cell death and Delayed onset neuronal necrosis.K
+, Mg
2+be Ca
2+antagonist.K
+as the requisite cation of neurocyte polarized state, can suppress calcium ion in flow to and alleviate calcium overload; Mg
2+can activate plurality of enzymes system in body, participate in the multiple important metabolic activity of cell in cerebral tissue, conduction, ion transport, the synthetic all many-sides of energy metabolism that reach of albumen affect the nerves, the spasm of energy alleviating vascular smooth muscle, improve microcirculation, improve hypoxic-ischemic after brain injury, calcium overload in retardance after craniocerebral injury neurocyte.Known through the experimental data contrast, cerebral ischemia re-pouring model group and sham operated rats be cerebral tissue Ca relatively
2+content extremely significantly increases, K
+, Mg
2+content significantly reduces; With model group, compare, each dosage group of nimodipine group, salvianolic acid A monomeric compound group and salvianolic acid A freeze-dried powder can significantly reduce Ca in cerebral tissue
2+content, rising K
+, Mg
2+content, and the most remarkable with salvianolic acid A freeze-dried powder effect.Illustrate that the salvianolic acid A freeze-dried powder can suppress Ca
2+interior stream alleviates calcium overload, thereby can suppress Ca
2+the neuronal cell apoptosis that overload is induced.
Known through the experimental data contrast; the salvianolic acid A freeze-dried powder can obviously improve the content of the cerebral cortex of cerebral ischemia-reperfusion injury in rats and striatum monoamine transmitters 5-hydroxy tryptamine (5-HT), norepinephrine (NE), dopamine (DA), γ-aminobutyric acid (GABA), taurine (Tau) content, the content that significantly reduces cerebral tissue Glutamic Acid (Glu), aspartic acid (Asp), glycine (Gly) and aminoacid exitotoxicity index in rising cerebral ischemia/reperfusion injury of rats cerebral tissue.And dosage increases, effect strengthens.The salvianolic acid A freeze-dried powder shown in conjunction with the histopathology pathological examination can obviously alleviate cerebral edema, improves the result of neuronal cell form, shows that the salvianolic acid A freeze-dried powder can suppress monoamine neurotransmitter and excessively discharge, and improves the monoamine neurotransmitter disorder; Suppress the accumulation of excitatory amino acid in cerebral ischemia re-pouring, stablize the balance of excitatory amino acid-inhibitory aminoacid mediator, alleviate toxicity of excitatory amino acid; Thereby suppress the neuronal cell apoptosis that monoamine neurotransmitter is disorderly and toxicity of excitatory amino acid is induced, and effect has more advantage with dosage salvianolic acid A monomeric compound and nimodipine.
Known through experimental data contrast, each dosage group of salvianolic acid A freeze-dried powder is compared with the ischemia-reperfusion injury model group, and lipid peroxide in rat cerebral tissue (LPO) content significantly reduces, and lower than the salvianolic acid A monomeric compound group of same dosage; Superoxide dismutase (SOD) and glutathion peroxidase (GSH-Px) activity significantly raise, and the trend higher than same dosage salvianolic acid A monomeric compound group is arranged, and effect is also more obvious than the nimodipine group; Illustrate that the salvianolic acid A freeze-dried powder can increase the generation of the activity of peroxide scavenger enzyme in the ischemical reperfusion injury cerebral tissue, inhibition peroxide, thereby the damage to antioxidant radical to neuronal cell and cerebral tissue, its antioxidation has the trend of the salvianolic acid A monomeric compound that is better than same dosage.
Known through experimental data contrast, the cerebrovascular endothelial cell apoptosis number of cerebral thrombosis ischemia model each time period of group is significantly higher than sham operated rats, 6h after the cerebral tissue ischemia, and endothelial cell apoptosis is showed increased just, to ischemia, within 24 hours, reaches peak.With model group, compare, the apoptosis digital display work of each time period of each dosage group of salvianolic acid A freeze-dried powder reduces, and is less than salvianolic acid A monomeric compound and the nimodipine group of same dosage.Illustrate that the salvianolic acid A freeze-dried powder can suppress cerebral ischemia hindbrain apoptosis of vascular endothelial cell, improve the cerebrovascular endothelial cell survival rate, thereby guarantee the normal of cerebrovascular endothelial cell function, maintain the complete of ischemic injuries hindbrain blood vessel structure and function and strengthen the ability to anti-cerebral ischemia damnification, the effect of performance treatment ischemic cerebrovascular.
Known through the experimental data contrast, after salvianolic acid A freeze-dried powder and nimodipine effect, anoxia and Hypoxia/Reoxygenation Injury Brain Microvascular Endothelial survival rate significantly raise, and salvianolic acid A freeze-dried powder group survival rate is significantly higher than the nimodipine group, and also higher than the cell survival rate of the salvianolic acid A monomeric compound group with dosage.Prompting salvianolic acid A freeze-dried powder can be protected microvascular endothelial cells oxygen and Hypoxia/Reoxygenation Injury; strengthen its hypoxia-bearing capability; improve the brain microvessel endothelial cells in vitro survival rate of anoxia-induced apoptosis and Hypoxia/Reoxygenation Injury, be better than nimodipine and salvianolic acid A monomeric compound.
Known through the experimental data contrast, Hypoxia/Reoxygenation Injury, can cause each phase apoptosis rate of Brain Microvascular Endothelial significantly to increase.With model group relatively, each dosage group of salvianolic acid A freeze-dried powder, salvianolic acid A monomeric compound group and nimodipine group all can significantly lower cell early, late period and total apoptosis rate; Be certain dose-effect relationship between each dosage group of salvianolic acid A freeze-dried powder.And salvianolic acid A freeze-dried powder 10 μ mol/L dosage groups are suitable with nimodipine 40 μ mol/L dosage group effects, with the salvianolic acid A freeze-dried powder of dosage, be better than the salvianolic acid A monomeric compound.Prompting salvianolic acid A freeze-dried powder has the effect of the Brain Microvascular Endothelial apoptosis that good anti-hypoxia-reoxygenation injury causes.
After various dose salvianolic acid A freeze-dried powder, salvianolic acid A monomeric compound and nimodipine effect, the Brain Microvascular Endothelial secretory tissue fiber proenzyme activator (t-PA) of Hypoxia/Reoxygenation Injury and the secretory volume of nitric oxide (NO) significantly raise (P<0.01 or P<0.001) than model group, and wherein the middle and high dosage group of salvianolic acid A freeze-dried powder rises to the Normal group level that approaches; Each administration group t-PA/PAI and NO/ET ratio also significantly improve than model group.Experimental result prompting salvianolic acid A freeze-dried powder can improve the secretory function of brain microvessel endothelial cells in vitro after Hypoxia/Reoxygenation Injury, and action effect significantly is better than nimodipine, and the trend that is better than same dosage salvianolic acid A monomeric compound is arranged.
After Hypoxia/Reoxygenation Injury, Ca in BMVEC born of the same parents
2+concentration significantly increases.Known through the experimental data contrast, compare each medicine group Ca with model group
2+concentration extremely significantly reduces, the most remarkable with the middle and high dosage group of salvianolic acid A freeze-dried powder effect, and intracellular calcium concentration is significantly lower than nimodipine 40 μ mol/L dosage groups, and is better than the salvianolic acid A monomeric compound of same dosage.Prompting salvianolic acid A freeze-dried powder has the Hypoxia/Reoxygenation Injury of inhibition and causes Ca in BMVEC born of the same parents
2+the effect of concentration.
Known through the experimental data contrast, the salvianolic acid A freeze-dried powder compares impact and the normal saline matched group of rat artery thrombus formation time, the thrombus formation time significant prolongation of the high, medium and low dosage group of salvianolic acid A freeze-dried powder; Low dose group (0.5mg/kg) thrombus formation time is suitable with 20mg/kg aspirin group; Middle dosage group extends than the salvianolic acid A monomeric compound group thrombus formation time with dosage; Show that the salvianolic acid A freeze-dried powder can extend thrombus formation time, the formation of prevention of arterial thrombosis, pre-preventing thrombosis and the ischemic cerebrovascular that causes.
Known through the experimental data contrast, relatively, the high, medium and low dosage group of salvianolic acid A freeze-dried powder rat suppository is wet, dry weight all significantly alleviates for the impact that the salvianolic acid A freeze-dried powder forms rat suppository and normal saline group.And low dose group is suitable with 20mg/kg aspirin group effect.Illustrate that the salvianolic acid A freeze-dried powder has the thrombotic effect of good inhibition, can be for prevention or treatment the ischemic cerebrovascular due to thrombosis, and than salvianolic acid A monomeric compound successful.
Known through the experimental data contrast, the salvianolic acid A freeze-dried powder compares impact and the normal saline group of rat vein thromboembolism, the high, medium and low dosage group of salvianolic acid A freeze-dried powder rat vein thrombosis is wet, dry weight significantly alleviates, low dose group (0.5mg/kg) and 20mg/kg aspirin group effect suitable (P>0.05); Middle dosage group is with the salvianolic acid A monomeric compound successful of dosage.Show that the salvianolic acid A freeze-dried powder has the effect that suppresses venous thrombosis, can be used for the venous thromboembolism after the prophylaxis of acute ischemic cerebrovascular occurs.
Known through the experimental data contrast, the salvianolic acid A freeze-dried powder compares rats in vitro thrombosis and normal saline group, the thrombotic length of the high, medium and low dosage group of salvianolic acid A freeze-dried powder rats in vitro significantly shortens, thrombosis is wet, dry weight significantly alleviates, and low dose group (0.5mg/kg) is suitable with 20mg/kg aspirin group effect; Show that the salvianolic acid A freeze-dried powder forms and has inhibitory action preferably external thrombus, and the trend that is better than same dosage salvianolic acid A monomeric compound is arranged.。
Known through the experimental data contrast, the salvianolic acid A freeze-dried powder compares impact and the normal saline group of established thrombosis in body, and the normal saline group all continues thromboembolism, and without logical phenomenon occurring again; The number of animals that each medicine group continues thromboembolism is few, with the normal saline group, compares utmost point significant difference is all arranged; Dosage group in the salvianolic acid A freeze-dried powder, its vessel open degree is similar to salvianolic acid A monomeric compound group and the 2000U/kg urokinase group of same dosage, its recanalization rate is suitable, but its vessel open state has more stable trend than salvianolic acid A monomeric compound and urokinase group; The lasting recanalization rate of salvianolic acid A freeze-dried powder high dose group and recanalization rate are all higher than the urokinase group, and the bolt rate is starkly lower than the urokinase group again; Though salvianolic acid A freeze-dried powder low dose group recanalization rate is lower than the urokinase group, bolt rate is suitable with the urokinase group again for it, and has lower than the urokinase trend of bolt rate again.Illustrate the salvianolic acid A freeze-dried powder thrombolytic is arranged preferably and prevents thrombolytic after the effect of thromboembolism again, and effect is more stable.
After cerebral thrombosis, rat whole blood viscosity, plasma viscosity significantly increase, and packed cell volume also significantly raises, known through the experimental data contrast, relatively, its whole blood viscosity and plasma viscosity and packed cell volume all obviously reduce for each dosage group of salvianolic acid A freeze-dried powder and model group; Results suggest salvianolic acid A freeze-dried powder can be accelerated micro-blood flow velocity, reduces blood viscosity, improves hemorheology and the effect that effectively resists cerebral thrombosis, and, than nimodipine group more remarkable effect, the trend that is better than same dosage salvianolic acid A monomeric compound is also arranged.
In sum, salvianolic acid A freeze-dried powder of the present invention has obvious therapeutic effect to ischemic cerebrovascular, and ischemic cerebrovascular described in the present invention comprises that the pathological changes that affects cerebral circulation that the various causes of disease form and the damaged of neuronal death and function of nervous system of take caused thereof are main ischemic rat brain infringement.Mainly comprise any one or more: (1) cerebral thrombosis: by the embolus from heart, as artificial valve, atrial fibrillation, ventricle thrombosis, DCM (dilated cardiomyopathy), moving/vein blood vessel inflammation etc. form embolus and flow into cerebral vessels with blood, cause forming the front circulation of whole brain blood circulation and any position and/or the multiple location thrombosis of metacyclic blood vessels at different levels.(2) cerebral ischemia reperfusion injury (3) cerebral embolism.(4) atherosis or narrow (5) lacunar infarction of cranium arteria carotis externa and brain basilar artery.(6) Transient ischemic attacks (7) vascular dementia.
Medical science and study of pharmacy personnel can't, in advance under the prerequisite of not doing related experiment, learn that the salvianolic acid A freeze-dried powder has above-mentioned good purposes in advance.
The accompanying drawing explanation
Fig. 1. salvianolic acid A hydrogen nuclear magnetic resonance spectrogram;
Fig. 2. salvianolic acid A carbon-13 nmr spectra figure;
Fig. 3. alkannic acid hydrogen nuclear magnetic resonance spectrogram;
Fig. 4. alkannic acid carbon-13 nmr spectra figure;
Fig. 5. rosmarinic acid hydrogen nuclear magnetic resonance spectrogram;
Fig. 6. rosmarinic acid carbon-13 nmr spectra figure;
Fig. 7. salvianolic acid B hydrogen nuclear magnetic resonance spectrogram;
Fig. 8. salvianolic acid B carbon-13 nmr spectra figure;
Fig. 9. salvianolic acid C hydrogen nuclear magnetic resonance spectrogram;
Figure 10. salvianolic acid C carbon-13 nmr spectra figure;
Figure 11. mix reference substance solution HPLC figure;
Figure 12. alkannic acid reference substance solution HPLC figure;
Figure 13. rosmarinic acid reference substance solution HPLC figure;
Figure 14. salvianolic acid B reference substance solution HPLC figure;
Figure 15. salvianolic acid A reference substance solution HPLC figure;
Figure 16. salvianolic acid C reference substance solution HPLC figure;
Figure 17. salvianolic acid A compositions HPLC figure;
Figure 18. injection salvianolic acid A freeze-drying curve figure;
Figure 19. injection salvianolic acid A lyophilizing vacuum curve figure.
The specific embodiment
Get red rooted salvia, be ground into 6 order granules, add 92 ℃ of water of 7 times of amounts at every turn, warm macerating extracts 3 times, with 25 rev/mins of speed, stirs simultaneously, and each warm macerating extracts 3 hours, extracting solution is evaporated to relative density 1.20 (60 ℃), adds ethanol to make to measure 70% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 20mg, aqueous solution is adjusted pH to 4.0 with 10% sodium hydroxide, adds 0.5%ZnCl
2as catalyst, 120 ℃ of temperature thermal conversions 4 hours, 20% phosphoric acid adjust pH to 2.5 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 3mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 50 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 10, uses respectively 3 times of cylinder hydrops, 5 times of column volume 25% ethanol elutions, removes impurity, use again 4 times of column volume 40% ethanol elutions, HPLC detects, and collects the 40% ethanol elution part that contains salvianolic acid A, and decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 5mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 10 with the polyamide ratio, the resin column blade diameter length ratio is 1: 8, use respectively 3 times of cylinder hydrops, 12 times of column volume 40% alcoholic solution eluting remove impurity, use 8 times of column volumes, 60% alcoholic solution eluting again, collect the 60% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 15mg aqueous solution, aqueous solution is adjusted pH to 2.5 with 20% phosphoric acid, and by the t-butyl methyl ether of 3 times of amounts of aqueous solution, minute 3 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.5g, adds 1~3 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 15 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 10, take pentane-t-butyl methyl ether as eluant, gradient elution, use respectively pentane: 10 times of column volumes of t-butyl methyl ether (4: 6) eluting, pentane: 10 times of column volumes of t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 12 times of water gagings and dissolves, with microwave vacuum drying (50 ℃ of baking temperatures, 4 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 60KW) 130 minutes, obtain salvianolic acid A master part raw material.
After measured, described is 94.57% containing salvianolic acid A content in salvianolic acid A master part raw material, alkannic acid content 0.663%; Rosmarinic acid contents 1.16%; Content of danshinolic acid B 1.24%; Salvianolic acid C content 1.48%.
Get red rooted salvia, be ground into diameter 2mm granule, add 90 ℃ of water of 7 times of amounts at every turn, warm macerating extracts 3 times, with 25 rev/mins of speed, stirs simultaneously, and each warm macerating extracts 3 hours, extracting solution is evaporated to relative density 1.16 (60 ℃), adds ethanol to make to measure 70% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 20mg, aqueous solution is adjusted pH to 3.5 with 10% sodium hydroxide, adds 0.5%ZnCl
2as catalyst, 120 ℃ of temperature thermal conversions 4 hours, 20% phosphoric acid adjust pH to 2.5 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 3mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 50 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 10, uses respectively 3 times of cylinder hydrops, 5 times of column volume 25% ethanol elutions, removes impurity, use again 4 times of column volume 40% ethanol elutions, HPLC detects, and collects the 40% ethanol elution part that contains salvianolic acid A, and decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 5mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 10 with the polyamide ratio, the resin column blade diameter length ratio is 1: 8, use respectively 3 times of cylinder hydrops, 12 times of column volume 40% alcoholic solution eluting remove impurity, use 8 times of column volumes, 60% alcoholic solution eluting again, collect the 60% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 15mg aqueous solution, aqueous solution is adjusted pH to 2.5 with 20% phosphoric acid, and by the t-butyl methyl ether of 3 times of amounts of aqueous solution, minute 3 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.5g, adds 1~3 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 15 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 10, take pentane-t-butyl methyl ether as eluant, gradient elution, use respectively 10 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 10 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 10 times of water gagings and dissolves, with microwave vacuum drying (50 ℃ of baking temperatures, 2 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 20KW) 120 minutes, must contain salvianolic acid A master part raw material.
After measured, described is 95.23% containing salvianolic acid A content in salvianolic acid A master part raw material, alkannic acid content 0.70%; Rosmarinic acid contents 1.08%; Content of danshinolic acid B 1.21%; Salvianolic acid C content 1.48%.
Embodiment 3
Get red rooted salvia, be cut into decoction pieces, add 85 ℃ of water temperature lixiviates of 8 times of amounts at every turn and get 3 times, stir with 20 rev/mins of speed simultaneously, each warm macerating extracts 2.5 hours, extracting solution is evaporated to relative density 1.20 (60 ℃), adds ethanol to make to measure 75% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 15mg, aqueous solution is adjusted pH to 5.0 with 10% potassium hydroxide, adds 0.6%ZnCl
2as catalyst, 120 ℃ of temperature thermal conversions 3.5 hours, 15% hydrochloric acid adjust pH to 2.5 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 45 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 8, use respectively 3.5 times of cylinder hydrops, 4 times of column volume 25% ethanol elutions, remove impurity, use again 5 times of column volume 45% ethanol elutions, HPLC detects, the 45% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 5mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 9 with the polyamide ratio, the resin column blade diameter length ratio is 1: 7, use respectively 4 times of cylinder hydrops, 10 times of column volume 40% alcoholic solution eluting remove impurity, use 8 times of column volumes, 65% alcoholic solution eluting again, collect the 65% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 12mg aqueous solution, aqueous solution is adjusted pH to 2.6 with 15% hydrochloric acid, and by the t-butyl methyl ether of 4 times of amounts, minute 4 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.8g, adds 2~3 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 13 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 8, take the pentane t-butyl methyl ether as eluant, gradient elution, use respectively 8 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 8 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 8 times of water gagings and dissolves, with microwave vacuum drying (60 ℃ of baking temperatures, 2.5 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 10KW) 130 minutes, must contain salvianolic acid A master part raw material.
After measured, described is 96.03% containing salvianolic acid A content in salvianolic acid A master part raw material, alkannic acid content 0.60%; Rosmarinic acid contents 1.01%; Content of danshinolic acid B 1.08%; Salvianolic acid C content 1.27%.
Get red rooted salvia, be ground into diameter 2mm granule, add 85 ℃ of water temperature lixiviates of 9 times of amounts at every turn and get 2 times, stir with 30 rev/mins of speed simultaneously, each warm macerating extracts 3.5 hours; Extracting solution is evaporated to relative density 1.18 (60 ℃), adds ethanol to make to measure 75% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor; Be diluted with water to every 1ml containing salvianolic acid B 18mg, aqueous solution is adjusted pH to 5.2 with 10% sodium carbonate, adds 0.6%ZnCl
2as catalyst, 123 ℃ of temperature thermal conversions 4.5 hours, 15% nitric acid adjust pH to 2.8 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 6mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 40 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 7, uses respectively 4 times of cylinder hydrops, 4 times of column volume 25% ethanol elutions, removes impurity, use again 5 times of column volume 40% ethanol elutions, HPLC detects, and collects the 40% ethanol elution part that contains salvianolic acid A, and decompression recycling ethanol also is concentrated into without the alcohol flavor; Aqueous solution is concentrated into the solution of every ml containing the 6mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 8 with the polyamide ratio, the resin column blade diameter length ratio is 1: 8, use respectively 4 times of cylinder hydrops, 9 times of column volume 40% alcoholic solution eluting remove impurity, use 7 times of column volumes, 65% alcoholic solution eluting again, collect the 65% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 10mg aqueous solution; Aqueous solution is adjusted pH to 2.6 with 15% nitric acid, and by the t-butyl methyl ether of 4 times of amounts, minute 4 extractions, separate organic layer, and the reclaim under reduced pressure methyl acetate is made the extract of every 1ml containing salvianolic acid A 0.7g, adds 3 times of amount silica gel, stirs, and volatilizes; Stirring sample silica gel, be added on 10 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 7, take pentane-t-butyl methyl ether as eluant, gradient elution, use respectively 8 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 9 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 8 times of water gagings and dissolves, with microwave vacuum drying (60 ℃ of baking temperatures, 3 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 5KW) 100 minutes, must contain salvianolic acid A master part raw material.
After measured, described is 94.72% containing salvianolic acid A content in salvianolic acid A master part raw material, alkannic acid content 0.76%; Rosmarinic acid contents 1.13%; Content of danshinolic acid B 1.26%; Salvianolic acid C content 1.46%.
Get red rooted salvia, be cut into decoction pieces, add 80 ℃ of water temperature lixiviates of 10 times of amounts at every turn and get 3 times, stir with 15 rev/mins of speed simultaneously, each warm macerating extracts 3 hours; Extracting solution is evaporated to relative density 1.12 (60 ℃), adds ethanol to make to measure 70% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor; Be diluted with water to every 1ml containing salvianolic acid B 20mg, aqueous solution is adjusted pH to 4.4 with 10% sodium bicarbonate, adds 0.8%ZnCl
2as catalyst, 128 ℃ of temperature thermal conversions 4.0 hours, 20% sulphuric acid adjust pH to 2.6 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 40 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 7, uses respectively 4 times of cylinder hydrops, 4 times of column volume 25% ethanol elutions, removes impurity, use again 5 times of column volume 40% ethanol elutions, HPLC detects, and collects the 40% ethanol elution part that contains salvianolic acid A, and decompression recycling ethanol also is concentrated into without the alcohol flavor; Aqueous solution is concentrated into the solution of every ml containing the 6mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 10 with the polyamide ratio, the resin column blade diameter length ratio is 1: 15, use respectively 4 times of cylinder hydrops, 7 times of column volume 35% alcoholic solution eluting remove impurity, use 6 times of column volumes, 60% alcoholic solution eluting again, collect the 60% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 12mg aqueous solution; Aqueous solution is adjusted pH to 2.8 with 20% sulphuric acid, and by the t-butyl methyl ether of 4 times of amounts, minute 4 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.5g, adds 2.5 times of amount silica gel, stirs, and volatilizes; Stirring sample silica gel, be added on 9 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 8, take pentane: t-butyl methyl ether is eluant, gradient elution, use respectively 8 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 8 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 10 times of water gagings and dissolves, with microwave vacuum drying (65 ℃ of baking temperatures, 4 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 12KW) 110 minutes, must contain salvianolic acid A master part raw material.
After measured, described is 95.23% containing salvianolic acid A content in salvianolic acid A master part raw material, alkannic acid content 0.69%; Rosmarinic acid contents 1.17%; Content of danshinolic acid B 1.25%; Salvianolic acid C content 1.47%.
Embodiment 6
Get red rooted salvia, be ground into diameter 2mm granule, add 85 ℃ of water temperature lixiviates of 9 times of amounts at every turn and get 3 times, stir with 20 rev/mins of speed simultaneously, each warm macerating extracts 2.5 hours, extracting solution is evaporated to relative density 1.1 (60 ℃), adds ethanol to make to measure 70% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 10mg, aqueous solution is adjusted pH to 5.5 with 20% sodium citrate, adds 0.4%ZnCl
2as catalyst, 132 ℃ of temperature thermal conversions 3.5 hours, 20% acetic acid adjust pH to 2.6 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 35 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 8, use respectively 3 times of cylinder hydrops, 4.5 column volume 25% ethanol elution doubly, remove impurity, use again 6 times of column volume 40% ethanol elutions, HPLC detects, the 40% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 8mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 12 with the polyamide ratio, the resin column blade diameter length ratio is 1: 18, use respectively 4 times of cylinder hydrops, 8 times of column volume 30% alcoholic solution eluting remove impurity, use 5 times of column volumes, 65% alcoholic solution eluting again, collect the 65% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 15mg aqueous solution, aqueous solution is adjusted pH to 2.7 with 20% acetic acid, and by the t-butyl methyl ether of 5 times of amounts, minute 5 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.5g, adds 2 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 10 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 10, with pentane, t-butyl methyl ether is eluant, gradient elution, use respectively 8 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 8 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 12 times of water gagings and dissolves, with microwave vacuum drying (65 ℃ of baking temperatures, 5 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 15KW) 90 minutes, must contain salvianolic acid A master part raw material.
After measured, described is 95.24% containing salvianolic acid A content in salvianolic acid A master part raw material, alkannic acid content 0.69%; Rosmarinic acid contents 1.07%; Content of danshinolic acid B 1.21%; Salvianolic acid C content 1.46%.
Get red rooted salvia, be ground into diameter 2mm granule, add 88 ℃ of water temperature lixiviates of 9 times of amounts at every turn and get 3 times, stir with 22 rev/mins of speed simultaneously, each warm macerating extracts 3.5 hours, extracting solution is evaporated to relative density 1.24 (60 ℃), adds ethanol to make to measure 75% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 13mg, aqueous solution is adjusted pH to 3.6 with 10% sodium hydroxide, adds 0.5%ZnCl
2as catalyst, 133 ℃ of temperature thermal conversions 4.5 hours, 10% hydrochloric acid adjust pH to 2.7 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 40 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 9, uses respectively 4 times of cylinder hydrops, 4 times of column volume 22% ethanol elutions, removes impurity, use again 6 times of column volume 43% ethanol elutions, HPLC detects, and collects the 43% ethanol elution part that contains salvianolic acid A, and decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 10mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 15 with the polyamide ratio, the resin column blade diameter length ratio is 1: 20, use respectively 4 times of cylinder hydrops, 8 times of column volume 30% alcoholic solution eluting remove impurity, use 5 times of column volumes, 60% alcoholic solution eluting again, collect the 60% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 12mg aqueous solution, aqueous solution is adjusted pH to 2.8 with 10% hydrochloric acid, and by the t-butyl methyl ether of 5 times of amounts, minute 5 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.5g, adds 3 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 12 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 10, with pentane, t-butyl methyl ether is eluant, gradient elution, use respectively 6 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 7 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 10 times of water gagings and dissolves, with microwave vacuum drying (50 ℃ of baking temperatures, 1 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 3KW) 150 minutes, must contain salvianolic acid A master part raw material.
After measured, described is 95.02% containing salvianolic acid A content in salvianolic acid A master part raw material, alkannic acid content 0.75%; Rosmarinic acid contents 1.12%; Content of danshinolic acid B 1.26%; Salvianolic acid C content 1.46%.
Get red rooted salvia, be cut into decoction pieces, add 90 ℃ of water temperature lixiviates of 9 times of amounts at every turn and get 3 times, stir with 25 rev/mins of speed simultaneously, each warm macerating extracts 3 hours; Extracting solution is evaporated to relative density 1.13 (60 ℃), adds ethanol to make to measure 75% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor; Be diluted with water to every 1ml containing salvianolic acid B 20mg, aqueous solution is adjusted pH to 3.5 with 10% sodium carbonate, adds 1.0%ZnCl
2as catalyst, 135 ℃ of temperature thermal conversions 4.5 hours, 15% sulphuric acid adjust pH to 3.0 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 36 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 9, uses respectively 3 times of cylinder hydrops, 4 times of column volume 25% ethanol elutions, removes impurity, use again 5 times of column volume 45% ethanol elutions, HPLC detects, and collects the 45% ethanol elution part that contains salvianolic acid A, and decompression recycling ethanol also is concentrated into without the alcohol flavor; Aqueous solution is concentrated into the solution of every 1ml containing the 6mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 10 with the polyamide ratio, the resin column blade diameter length ratio is 1: 10, use respectively 4 times of cylinder hydrops, 8 times of column volume 45% alcoholic solution eluting remove impurity, use 8 times of column volumes, 65% alcoholic solution eluting again, collect the 65% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 10mg aqueous solution; Aqueous solution is adjusted pH to 2.7 with 15% sulphuric acid, and by the t-butyl methyl ether of 4 times of amounts, minute 4 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.6g, adds 3 times of amount silica gel, stirs, and volatilizes; Stirring sample silica gel, be added on 10 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 8, take pentane, t-butyl methyl ether is eluant, gradient elution, use respectively 8 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 8 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 8 times of water gagings and dissolves, with microwave vacuum drying (80 ℃ of baking temperatures, 4 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 60KW) 120 minutes, must contain salvianolic acid A master part raw material.
After measured, described is 95.34% containing salvianolic acid A content in salvianolic acid A master part raw material, alkannic acid content 0.62%; Rosmarinic acid contents 1.10%; Content of danshinolic acid B 1.23%; Salvianolic acid C content 1.47%.
Embodiment 9
Get that embodiment 3 makes containing salvianolic acid A master part raw material 80g, inject water 2800ml and be stirred to dissolve, with 10% sodium hydroxide adjust pH 4.5, add mannitol 60g to make dissolving, add again vitamin C 0.5g, be stirred to dissolve, mix, add active carbon 2g stirring and adsorbing, filter, remove active carbon; Inject water to 3000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 20 ℃/h speed, be cooled to-40 ℃, be incubated freezing 16 hours; Be evacuated to below 0.3mbar, in 10 hours, the salvianolic acid A formulation temperature freezed risen to-25 ℃, maintain-25 ℃ of vacuum dryings 8 hours; Continue to heat up, with 0.5 ℃/min, evenly be warming up to 41 ℃, maintain 41 ℃ of dryings after 3 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Get that embodiment 4 makes containing salvianolic acid A master part raw material 20g, inject water 1800ml and be stirred to dissolve, with 10% sodium hydroxide adjust pH 4.6, add mannitol 40g to make dissolving, add again vitamin C 0.3g, be stirred to dissolve, mix, add active carbon 1g stirring and adsorbing, filter, remove active carbon; Inject water to 2000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 30 ℃/h speed, be cooled to-45 ℃, be incubated freezing 10 hours; Be evacuated to below 0.3mbar, in 14 hours, the salvianolic acid A formulation temperature freezed risen to-27 ℃, maintain-27 ℃ of vacuum dryings 6 hours; Continue to heat up, with 1.0 ℃/min, evenly be warming up to 45 ℃, maintain 45 ℃ of dryings after 2 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Embodiment 11
Get that embodiment 5 makes containing salvianolic acid A master part raw material 10g, injecting water 1500ml is stirred to dissolve, with 10% sodium hydroxide adjust pH 4.6, add mannitol 20g to make to dissolve, then add vitamin C 0.8g, be stirred to dissolve, mix, add active carbon 1.2g stirring and adsorbing, filter, remove active carbon; Inject water to 2000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 25 ℃/h speed, be cooled to-42 ℃, be incubated freezing 12 hours; Be evacuated to below 0.3mbar, in 13 hours, the salvianolic acid A formulation temperature freezed risen to-23 ℃, maintain-23 ℃ of vacuum dryings 7 hours; Continue to heat up, with 0.8 ℃/min, evenly be warming up to 42 ℃, maintain 42 ℃ of dryings after 4 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Embodiment 12
Get that embodiment 6 makes containing salvianolic acid A master part raw material 30g, injecting water 2000ml is stirred to dissolve, with 20% sodium carbonate adjust pH 4.6, add mannitol 20g, lactose 10g to make to dissolve, then add thiourea 0.5g, be stirred to dissolve, mix, add active carbon 1.0g stirring and adsorbing, filter, remove active carbon; Inject water to 2000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 29 ℃/h speed, be cooled to-44 ℃, be incubated freezing 14 hours; Be evacuated to below 0.3mbar, in 11 hours, the salvianolic acid A formulation temperature freezed risen to-26 ℃, maintain-26 ℃ of vacuum dryings 6.5 hours; Continue to heat up, with 0.6 ℃/min, evenly be warming up to 43 ℃, maintain 43 ℃ of dryings after 3.5 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Get that embodiment 7 makes containing salvianolic acid A master part raw material 35g, injecting water 2500ml is stirred to dissolve, with 10% potassium hydroxide adjust pH 4.6, add glucose 30g to make to dissolve, then add sodium sulfite 3g, be stirred to dissolve, mix, add active carbon 1.5g stirring and adsorbing, filter, remove active carbon; Inject water to 3000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 27 ℃/h speed, be cooled to-43 ℃, be incubated freezing 11 hours; Be evacuated to below 0.3mbar, in 12.5 hours, the salvianolic acid A formulation temperature freezed risen to-24 ℃, maintain-24 ℃ of vacuum dryings 7.5 hours; Continue to heat up, with 0.7 ℃/min, evenly be warming up to 40 ℃, maintain 40 ℃ of dryings after 5 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Get that embodiment 8 makes containing salvianolic acid A master part raw material 40g, injecting water 2700ml is stirred to dissolve, with 10% sodium hydroxide adjust pH 4.6, add glucose 20g, lactose 20g to make to dissolve, then add sodium pyrosulfite 4g, be stirred to dissolve, mix, add active carbon 1.5g stirring and adsorbing, filter, remove active carbon; Inject water to 3000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 28 ℃/h speed, be cooled to-41 ℃, be incubated freezing 13 hours; Be evacuated to below 0.3mbar, in 13.5 hours, the salvianolic acid A formulation temperature freezed risen to-25.5 ℃, maintain-25.5 ℃ of vacuum dryings 6.5 hours; Continue to heat up, with 0.9 ℃/min, evenly be warming up to 44 ℃, maintain 44 ℃ of dryings after 3.5 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Embodiment 15
Get that embodiment 1 makes containing salvianolic acid A master part raw material 60g, inject water 2700ml and be stirred to dissolve, with 10% sodium hydroxide adjust pH 4.6, add mannitol 40g to make dissolving, add again Catergen g, be stirred to dissolve, mix, add active carbon 2g stirring and adsorbing, filter, remove active carbon; Inject water to 3000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 24.5 ℃/h speed, be cooled to-42.5 ℃, be incubated freezing 11.5 hours; Be evacuated to below 0.3mbar, in 13.5 hours, the salvianolic acid A formulation temperature freezed risen to-24.5 ℃, maintain-24.5 ℃ of vacuum dryings 6.5 hours; Continue to heat up, with 0.55 ℃/min, evenly be warming up to 42.5 ℃, maintain 42.5 ℃ of dryings after 2.5 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Get that embodiment 2 makes containing salvianolic acid A master part raw material 70g, inject water 2800ml and be stirred to dissolve, with 10% sodium hydroxide adjust pH 4.6, add mannitol 40g to make dissolving, add again Catergen g, be stirred to dissolve, mix, add active carbon 2g stirring and adsorbing, filter, remove active carbon; Inject water to 3000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 28.5 ℃/h speed, be cooled to-44.5 ℃, be incubated freezing 11.5 hours; Be evacuated to below 0.3mbar, in 13.5 hours, the salvianolic acid A formulation temperature freezed risen to-24.5 ℃, maintain-24.5 ℃ of vacuum dryings 6.5 hours; Continue to heat up, with 0.75 ℃/min, evenly be warming up to 43.5 ℃, maintain 43.5 ℃ of dryings after 3 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Embodiment 17
Get commercially available salvianolic acid A monomeric compound raw material (salvianolic acid A content 99.62%) 40g, injecting water 2700ml is stirred to dissolve, with 10% sodium hydroxide adjust pH 4.6, add glucose 20g, lactose 20g to make to dissolve, then add sodium pyrosulfite 4g, be stirred to dissolve, mix, add active carbon 1.5g stirring and adsorbing, filter, remove active carbon; Inject water to 3000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 28 ℃/h speed, be cooled to-41 ℃, be incubated freezing 13 hours; Be evacuated to below 0.3mbar, in 13.5 hours, the salvianolic acid A formulation temperature freezed risen to-25.5 ℃, maintain-25.5 ℃ of vacuum dryings 6.5 hours; Continue to heat up, with 0.9 ℃/min, evenly be warming up to 44 ℃, maintain 44 ℃ of dryings after 3.5 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
Experimental example 1: salvianolic acid A master part raw material analysis method and separation, Structural Identification research
One, salvianolic acid A master part raw material analysis method research
1. instrument and reagent
Instrument: Waters e2695 high performance liquid chromatograph, Empower2 chromatographic work station, 2998 diode array detector; Sartorius cp225D 100,000/electronic balance.
Chromatographic column: YMCC
18chromatographic column (250 * 4.6mm, 5 μ m);
Reagent: methanol is chromatographically pure, and water is ultra-pure water prepared by Millipore, and other reagent are analytical pure.
Rosmarinic acid reference substance, salvianolic acid B reference substance are all purchased from Nat'l Pharmaceutical & Biological Products Control Institute, for assay; Alkannic acid reference substance, salvianolic acid C reference substance are all purchased from the bright bio tech ltd in sea, Shanghai, and the salvianolic acid A reference substance, for self-control, is 99.52% through purity mark content.
2. the preparation of reference substance solution and need testing solution
2.1 the preparation of reference substance solution: precision takes the about 10.00mg of alkannic acid reference substance respectively, the about 10.00mg of rosmarinic acid reference substance, the about 10.00mg of salvianolic acid B reference substance, the about 10.00mg of salvianolic acid C reference substance, the about 10.00mg of salvianolic acid A reference substance, put in different 100ml measuring bottles, add respectively dissolve with methanol and be diluted to scale, shake up, precision is drawn the alkannic acid reference substance respectively, the rosmarinic acid reference substance, the salvianolic acid B reference substance, each 10ml of salvianolic acid C reference substance, put in different 100ml measuring bottles, add respectively dissolve with methanol and be diluted to scale, shake up, product stock solution in contrast.Accurate each 10ml of above-mentioned stock solution that draws, put in same 100ml measuring bottle, adds methanol and be diluted to scale, shakes up, as mixing reference substance solution.
2.3 the preparation precision of need testing solution takes the about 10.00mg of embodiment 1 sample, puts in the 50ml measuring bottle, adds dissolve with methanol and is diluted to scale, the accurate absorption in 10ml to 100ml measuring bottle, add methanol and be diluted to scale, shakes up, and obtains.
3. chromatographic condition and system suitability
Take octadecylsilane chemically bonded silica as filler; Flow velocity 1.0ml/min; Detect wavelength: 286nm; 30 ℃ of column temperatures; Number of theoretical plate calculates and should be not less than 10000 by the salvianolic acid A peak.
In the time of 0~10 minute, the ratio of methanol is down to 60% by 30% ratio that rises to 40%, 0.1~0.5% phosphate aqueous solution by 70%; In the time of 10~30 minutes, the ratio of methanol is down to 45% by 40% ratio that rises to 55%, 0.1~0.5% phosphate aqueous solution by 50%; In the time of 30~60 minutes, the ratio of methanol is down to 20% by 55% ratio that rises to 80%, 0.1~0.5% phosphate aqueous solution by 45%.
Under these conditions, the chromatographic peak retention time of 5 reference substances is shown in Figure 11~17 in Table 1, HPLC collection of illustrative plates.
The chromatographic peak retention time result of each reference substance of table 1.
4. the investigation of linear relationship
Accurate above-mentioned mixing reference substance solution 0.1ml, 0.2ml, 0.5ml, 1ml, 2ml, the 5ml of drawing, put respectively in the 10ml measuring bottle, adds methanol and be diluted to series standard solution.Accurate each the 10 μ l injection liquid chromatographies of above-mentioned standard solution of drawing, calculate peak area by " 3. chromatographic condition and system suitability " lower chromatographic condition, take the peak area integrated value respectively as vertical coordinate, and each concentration reference substance sample size is abscissa, the drawing standard curve.Result shows to mix reference substance solution and become good linear relationship in following scope, in Table 2.
Table 2. mixes reference substance solution linear relationship result
5. precision test
Get the mixing reference substance solution, measure according to " 3. chromatographic condition and system suitability " lower chromatographic condition, repeat sample introduction 6 times.Result shows that the precision of the method is good, in Table 3.
Table 3 Precision test result
6. stability test
Get need testing solution, according to " 3. chromatographic condition and system suitability " lower chromatographic condition, measure, at regular intervals sample introduction once, as a result in need testing solution each composition in 24 hours peak area without significant change, show having good stability of need testing solution, in Table 4.
Table 4 stability test result
7. replica test
Get this salvianolic acid A compositions, add methanol and make 6 parts of need testing solutions, measure according to " 3. chromatographic condition and system suitability " lower chromatographic condition.Result shows that the method repeatability is good, in Table 5.
Table 5. replica test result
8. recovery test
Adopt the application of sample recovery test, get the salvianolic acid A compositions 10mg of known content, accurately weighed, parallel 6 parts, add corresponding reference substance solution by each constituent content equal proportion respectively, by 2.3 below legal system available test sample solutions, measure and calculate average recovery and the RSD of each composition.Result shows that the accuracy of the method is good, in Table 6.
Table 6. recovery test result
Two, salvianolic acid A master part raw material separation, Structural Identification research
Salvianolic acid A, molecular formula: C
26h
222o
10, molecular weight: 494.45, structure is as follows:
Salvianolic acid A physicochemical property and spectral data, be shown in Fig. 1,2.
Salvianolic acid A (Salvianolic acid A), pale yellow powder, easily easy methanol, water.ESIMSm/z:493[M-H]
-, 518[M+Na]
+, molecular formula: C
26h
22o
10, molecular weight: 494.45;
1h (600MHz, CD
3oD) and
13c NMR (150MHz, CD
3oD) data are as follows:
1NMR(CD
3OD,600MHz)δ:2.96(1H,dd,J=14.4,8.4Hz,H-7``),3.06(1H,dd,J=14.4,4.2Hz,H-7``),5.17(1H,dd,J=9.0,4.2Hz,H-8``),6.27(1H,d,J=16.2Hz,H-8`),6.54(1H,dd,J=7.8,1.8Hz,H-6``),6.63(1H,d,J=7.8Hz,H-5``),6.65(1H,d,J=16.2,Hz,H-7),6.72(1H,d,J=8.4Hz,H-4`),6.74(1H,d,J=8.4Hz,H-5),6.76(1H,d,J=1.8Hz,H-2``),6.88(1H,dd,J=8.4,1.8Hz,H-6),7.05(1H,d,J=1.8Hz,H-2),7.11(1H,d,J=8.4Hz,H-5`),7.14(1H,d,J=16.2Hz,H-8);8.06(1H,d,J=16.2Hz,H-7`).
13CNMR(CD
3OD,150MHz)δ:36.6(C-7``),73.3(C-8``),112.6(C-2),113.4(C-5),114.2(C-8`),114.9(C-4`),115.1(C-5``),116.0(C-2``),118.7(C-5`),119.6(C-6),119.3(C-8),120.6(C-6``),124.7(C-6`),127.0(C-1),127.9(C-1``),130.0(C-1`),136.5(C-7),
143.1(C-3),143.9(C-3``),144.8(C-4``),145.1(C-2`),145.4(C-4),146.0(C-7`),146.9(C-3`),167.3(C-9`),172.1(C-9``).
Alkannic acid, its molecular formula: C
27h
22o
12, molecular weight: 538.46, structure is as follows:
Alkannic acid physicochemical property and spectral data, be shown in Fig. 3,4.
Alkannic acid (lithospermic acid), pale yellow powder, easily easy methanol, water.ESIMSm/z:539[M+H]
+, 537[M-1]
-, 560[M+Na]
-, 492[M-COOH]
-; Molecular formula: C
27h
22o
12, molecular weight 538.45;
1h (600MHz, CD
3oD) and
13c NMR (150MHz, CD
3oD) data are as follows:
1NMR(CD
3OD,600MHz)δ:3.02(1H,dd,J=14.4,9.6Hz,H-7``),3.06(1H,dd,J=14.4,3.0Hz,H-7``),4.25(1H,dd,J=5.4Hz,H-8`),4.97(1H,dd,J=9.6,3.0Hz,H-8``),5.88(1H,d,J=5.4Hz,H-7`),6.31(1H,d,J=16.0Hz,H-8),6.59(1H,dd,J=8.0,1.8Hz,H-6``),6.65(1H,d,J=8.0Hz,H-5``),6.73(1H,dd,J=8.4,2.0Hz,H-6`),6.74(1H,d,J=1.8Hz,H-2``),6.74(1H,d,J=8.4Hz,H-5`),6.83(1H,d,J=8.4Hz,2.4Hz,H-5),6.97(1H,d,J=2.0Hz,Hz,H-2`),7.13(1H,d,J=8.4Hz,H-6);7.93(1H,d,J=16.0Hz,H-7).
13CNMR(CD
3OD,150MHz)δ:37.3(C-7``),59.9(C-8`),76.7(C-8``),88.9(C-7`),112.4(C-2``),114.6(C-5``),114.9(C-5`),115.7(C-8),116.1(C-2`),117.2(C-6``),119.5(C-6),119.9(C-6`),123.5(C-1),129.3(C-2),129.8(C-1``),133.4(C-1`),142.4(C-7),143.3(C-4),143.4(C-3``),144.7(C-4``),145.1(C-3`),145.1(C-4`),147.4(C-3),167.8(C-9),176.5(C-9``),178.5(C-9`).
Rosmarinic acid, the molecular formula of rosmarinic acid: C
18h
16o
8, molecular weight: 360.31, structure is as follows:
Rosmarinic acid physicochemical property and spectral data, be shown in Fig. 5,6.
Rosmarinic acid (Rosmarinic acid), white powder, easily easy methanol, water.ESIMSm/z:359[M-H]
-, 383[M+Na]
+; Molecular formula: C
18h
16o
8, molecular weight 360.31;
1h (600MHz, CD
3oD) and
13c NMR (150MHz, CD
3oD) data are as follows:
1NMR(CD
3OD,600MHz)δ:3.01(1H,dd,J=14.4,8.4Hz,H-7`),3.10(1H,dd,J=14.4,4.2Hz,H-7`),5.18(1H,dd,J=8.4,4.2Hz,H-8`),6.27(1H,d,J=16.0Hz,H-8),6.61(1H,dd,J=7.8,1.8Hz,H-6`),6.70(1H,d,J=7.8Hz,H-5`),6.75(1H,d,J=1.8Hz,H-2`),6.78(1H,d,J=8.4Hz,H-5),6.95(1H,dd,J=8.4,2.4Hz,H-6),7.04(1H,d,J=1.8Hz,H-2),7.55(1H,d,J=16.0Hz,H-7);
13CNMR(CD
3OD,150MHz)δ:36.6(C-7`),73.2(C-8`),113.1(C-8),113.9(C-2),114.9(C-5),115.1(C-5`),116.2(C-2`),120.4(C-6),121.8(C-6`),126.3(C-1),127.9(C-1`),143.9(C-3),144.8(C-4),145.5(C-3`),146.4(C-4`),148.4(C-7),167.1(C-9),172.1(C-9`).
Salvianolic acid B, its molecular formula: C
36h
30o
16, molecular weight: 718.61, structure is as follows:
Salvianolic acid B physicochemical property and spectral data, be shown in Fig. 7,8.
Salvianolic acid B (Salvianolic acid B), pale yellow powder, easily easy methanol, water.ESIMSm/z:717[M-H]
-, 741[M+Na]
+; Molecular formula: C
36h
30o
16, molecular weight 718.62;
1h (600MHz, CD
3oD) and
13c NMR (150MHz, CD
3oD) data are as follows:
1NMR(CD
3OD,600MHz)δ:2.80-3.10(2H,m,H-7``),2.80-3.10(2H,m,H-7```),4.35(1H,d,J=4.8Hz,H-8``),5.15-5.19(1H,m,H-8`),5.15-5.19(1H,m,H-8```),5.85(1H,d,J=4.8Hz,H-7``),6.20(1H,d,J=16.2Hz,H-8),6.31(1H,dd,J=8.1,2.1Hz,H-6`),6.52(1H,d,J=2.4Hz,H-2```),6.54(1H,d,J=7.8Hz,H-5``),6.62(1H,d,J=2.1Hz,H-2`),6.66(1H,dd,J=8.1,2.4Hz,H-6```),6.70(1H,d,J=7.8Hz,H-5`),6.74(1H,d,J=8.1Hz,H-5```),6.75(1H,dd,J=7.8,2.4Hz,H-6``),6.76(1H,d,J=2.4Hz,H-2``),6.83(1H,d,J=8.4Hz,H-5),7.16(1H,d,J=8.4Hz,H-6),7.52(1H,d,J=16.2Hz,H-7);
13CNMR(CD
3OD,150MHz)δ:36.111(C-7```),36.51(C-7`),56.58(C-8``),73.28(C-8),74.19(C-8```),86.93(C-7``),111.99(C-2``),115.01(C-5``),115.04(C-5`),115.13(C-2`),115.18(C-2```),115.95(C-8),116.20(C-6``),116.97(C-5```),117.04(C-5),120.37(C-6),120.89(C-6```),123.28(C-1),125.04(C-2),127.55(C-1`),127.85(C-1```),132.27(C-1``),142.20(C-7),143.70(C-3```),143.72(C-4```),143.88(C-4``),144.57(C-3``),144.73(C-4`),145.23(C-3`),145.39(C-3),147.71(C-4),166.66(C-9),170.92(C-9```),171.17(C-9``),172.29(C-9`).
Salvianolic acid C, its molecular formula: C
26h
20o
10, molecular weight: 492.43, structure is as follows:
Salvianolic acid C physicochemical property and spectral data, be shown in Fig. 9,10.
Salvianolic acid C (Salvianolic acid C), pale yellow powder, easily easy methanol, water.ESIMSm/z:491[M-H]
-, 515[M+Na]
+; Molecular formula: C
26h
20o
10, molecular weight 492.43;
1h (600MHz, CD
3oD) and
13c NMR (150MHz, CD
3oD) data are as follows:
1NMR(CD
3OD,600MHz)δ:3.07(1H,dd,J=13.8,8.4Hz,H-7``),3.15(1H,dd,J=13.8,4.2Hz,H-7``),5.25(1H,dd,J=8.4,4.2Hz,H-8``),6.46(1H,d,J=15.9Hz,H-8),6.46(1H,dd,J=8.1,2.1Hz,H-2``),6.72(1H,d,J=8.1Hz,H-3``),3.74(1H,d,J=8.4Hz,H-5),6.80(1H,d,J=2.4Hz,H-6``),6.88(1H,d,J=7.8Hz,H-5`),7.20(1H,s,,H-8`),7.36(1H,d,J=7.8Hz,H-6),7.37(1H,dd,J=7.8Hz,2.4Hz,H-6`),7.40(1H,d,J=2.4Hz,2.1Hz,H-2`),7.94(1H,d,J=15.9Hz,H-7);
13CNMR(CD
3OD,150MHz)δ:36.2(C-7``),73.3(C-8``),97.9(C-8`),110.4(C-5),112.0(C-2`),113.5(C-8),114.9(C-5``),115.4(C-5`),116.3(C-2``),117.4(C-6`),118.2(C-1),120.5(C-6``),122.0(C-1`),125.0(C-6),128.0(C-1``),131.3(C-2),143.0(C-3),
143.8(C-7),144.0(C-3``),144.6(C-4),144.8(C-4``),145.3(C-2`),146.7(C-4`),158.0(C-7`),167.3(C-9),172.4(C-9``).
Experimental example 2: the extraction of salvianolic acid B
1.1 extract the confirmation of solvent and extracting method
Take red rooted salvia 400g, the method under Chinese Pharmacopoeia Radix Salviae Miltiorrhizae item of pressing is measured content of danshinolic acid B, is divided into 4 parts, by following testing program, is tested:
Experiment 1: get red rooted salvia 100g, add 8 times of water gagings at every turn and extract 1.5 hours at 80 ℃ of warm macerating, warm macerating extracts three times altogether, and merge extractive liquid, is measured salvianolic acid B and calculates extraction ratio, and result is as table 7.
Experiment 2: get red rooted salvia 100g, add 8 times of water gagings at every turn and extract 1.5 hours at 80 ℃ of warm macerating, stir with 10~50 rev/mins of speed simultaneously, warm macerating stirs and extracts three times altogether, and merge extractive liquid, is measured salvianolic acid B and calculates extraction ratio, and result is as table 7.
Experiment 3: get red rooted salvia 100g, add 8 times of water gagings at every turn and decoct 1.5 hours, decoct altogether three times, merge extractive liquid,, measure salvianolic acid B and calculate extraction ratio, and result is as table 7.
Experiment 4: get red rooted salvia 100g, add 8 times of amount 50% alcohol reflux 1.5 hours at every turn, extract altogether three times, merge extractive liquid,, measure salvianolic acid B and calculate extraction ratio, and result is as table 7.
Table 7. extracts solvent and extracting method experimental result
Above-mentioned experimental result shows, adopt 50% ethanol to make the extraction solvent influential to the salvianolic acid B extraction ratio, 50% ethanol extraction is better than water extraction, but soak and add that stir to extract difference little with water temperature, two kinds of extracting modes that stir in the water extraction process and do not stir are influential to the extraction ratio of salvianolic acid B, decocting extraction may be because temperature is higher, to salvianolic acid B, extracts influential.
1.2 the preferred extraction process of orthogonal experiment
1.2.1 the optimization of water extraction process research: according to above result of the test, water extraction process is usingd extraction time (A), extraction time (B), quantity of solvent (C), extract four of temperature (D) as the investigation factor, each factor is established three levels, presses L9 (3
4) orthogonal table carries out Orthogonal Experiment and Design (table 8, table 9), the extraction ratio that to investigate index be salvianolic acid B.
Table 8. extraction factor water-glass
Table 9. extraction process orthogonal experiments table
Table 10. the results of analysis of variance
F
0.05(2,2)=19.00F
0.01(2,2)=99.00
The water extraction the results of analysis of variance shows, each experimental factor is to the extraction rate of transform of salvianolic acid B there are no significant difference, therefore the water extraction condition of salvianolic acid B of the present invention is for adding 3~15 times of water gagings, extracting 1~3 time at 45~95 ℃ of lower warm macerating, with 10~50 rev/mins of speed, stir simultaneously, extract 1~4 hour at every turn or add 3~15 times of amounts at every turn and decoct extraction, the each extraction 1~4 hour, extract 1~3 time altogether.
1.2.2 the optimization of alcohol extraction technique research: according to above result of the test, alcohol extraction technique is usingd extraction time (A), four of extraction times (B), quantity of solvent (C), concentration of alcohol (D) be as the investigation factor, each factor is established three levels, presses L9 (3
4) orthogonal table carries out Orthogonal Experiment and Design (table 11, table 12), the extraction ratio that to investigate index be salvianolic acid B.
Table 11. extraction factor water-glass
Table 12. extraction process orthogonal experiments
Table 13. the results of analysis of variance
F
0.05(2,2)=19.00F
0.01(2,2)=99.00
Alcohol reflux extracts the results of analysis of variance and shows, each experimental factor, to the extraction rate of transform of salvianolic acid B there are no significant difference, therefore the extraction conditions of this salvianolic acid B is measured 30%~60% alcohol reflux 1~3 time for adding 3~15 times, extracts 1~4 hour at every turn.
1.3 salvianolic acid B raw material preparation
According to above-mentioned orthogonal experiment Optimization Technology, get red rooted salvia 10kg, add 8 times of water gagings at every turn and extract 1.5 hours at 80 ℃ of warm macerating, with 10~50 rev/mins of speed, stir simultaneously, warm macerating stirs and extracts 3 times altogether, filters merging filtrate, extracting solution is evaporated to relative density 1.10~1.25 (60 ℃), add ethanol to make to measure 60% containing alcohol, filter, decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, vacuum drying, salvianolic acid extract 4.15kg, recording content of danshinolic acid B is 10.25%.
Experimental example 3: salvianolic acid B transforms salvianolic acid A master part raw material process relatively
Experiment 1: get the about 30g of salvianolic acid B raw material of preparation under 1.3, be mixed with 200ml solution, add 10% sodium hydroxide solution adjust pH to 4.5;
Experiment 2: get the about 30g of salvianolic acid B raw material of preparation under 1.3, be mixed with 200ml solution, add 10% sodium hydroxide solution adjust pH to 4.5, add 1.0%ZnCl
2;
Experiment 3: get containing the about 6g of salvianolic acid B (content 51.54%) raw material, adding purified water, to be diluted to salvianolic acid B concentration be 15mg/ml solution, adds carbamide, and making it with the mol ratio of salvianolic acid B is 0.5;
Above-mentioned each experimental group is placed in same autoclave, and under 120 ℃, reaction is 4.0 hours, cooling, calculates the salvianolic acid A productive rate.
Table 14. salvianolic acid B transforms salvianolic acid A master part raw material experimental result
The demonstration of table 14 result, the salvianolic acid B high-purity, on transforming not impact, does not need to be purified to more than 50% to be transformed, and salvianolic acid B is converted in salvianolic acid A master part raw material process, regulates pH value, adds 1.0%ZnCl
2, can greatly improve the productive rate of salvianolic acid A master part raw material.
Experimental example 4: salvianolic acid B transforms salvianolic acid A master part raw material process and optimizes
Above-mentioned experimentation proves, salvianolic acid B purity is not to affect the factor that salvianolic acid B transforms salvianolic acid A master part raw material, but adds certain catalysts influence salvianolic acid B to transform salvianolic acid A master part raw material, and therefore, we all add 1%ZnCl to each experimental group
2as catalyst, be converted into other factors of salvianolic acid A master part raw material to affecting salvianolic acid B: salvianolic acid B concentration (A), pH (B), temperature (C), time (D) are carried out orthogonal test, and each factor is established three levels, presses L9 (3
4) orthogonal table carries out EXPERIMENTAL DESIGN (table 15, table 16), the productive rate that to investigate index be salvianolic acid A master part raw material.
Table 17. the results of analysis of variance table
*F
0.05(2,2)=19.00ΔF
0o1(2,2)=99.00
The results of analysis of variance demonstration, the optimum condition that this orthogonal test is optimized according to intuitive analysis is A
3b
2c
2d
2factor A (salvianolic acid B concentration) has certain influence to salvianolic acid A master part raw material productive rate, from the K value, analyze, concentration is converted into the not impact of effect of salvianolic acid A on improving salvianolic acid B higher than 30mg/ml, and the impurity formed is more, therefore, transform front salvianolic acid B concentration and should select 1~30mg/ml; Factor B (pH), factor C (temperature) have utmost point significant difference to salvianolic acid A master part raw material productive rate, should strictly control pH and temperature in prompting salvianolic acid B conversion process, can success realize the salvianolic acid B higher yields to salvianolic acid A master part feedstock conversion.
Experimental example 5: catalyst Z nCl
2the impact of consumption on transforming
Transform salvianolic acid A master part raw material process optimal conditions by above-mentioned salvianolic acid B, get the salvianolic acid B raw material, add purified water 200ml, make the solution that salvianolic acid B concentration is 15mg/ml, regulating pH is 4.5, and conversion temperature is 120 ℃, and transformation time is 4 hours, by with the salvianolic acid B molar percentage, add respectively not commensurability catalyst Z nCl
2, the results are shown in Table 18.
Table 18. catalyst Z nCl
2consumption affects experimental result to transforming
Catalyst Z nCl
2consumption affects experimental result to conversion and shows, catalyst amount>=0.02% can produce 55.65% conversion ratio, preferred catalyst consumption 0.1%~3.0%, and more preferably, after 0.5%~2.0%. catalyst amount>3%, conversion ratio no longer is significantly improved.
Experimental example 6: catalyst transforms the catalytic action of salvianolic acid A master part raw material to salvianolic acid B
Transform salvianolic acid A master part raw material process optimal conditions by above-mentioned salvianolic acid B, get the salvianolic acid B raw material, add purified water 200ml, make the solution that salvianolic acid B concentration is 15mg/ml, regulating pH is 4.5, and conversion temperature is 120 ℃, and transformation time is 4 hours, add respectively the catalyst of different cultivars and various dose to be transformed, the results are shown in Table 19.
Table 19. different catalysts transforms the impact of red A master's part raw material on red B
Table 19 result shows, above 4 kinds of catalyst all can be used as the catalyst in the salvianolic acid B conversion reaction, and each catalyst amount and salvianolic acid B molar percentage be 0.5%~3.0%, the productive rate of salvianolic acid A master part raw material >=40%.Conversion ratio surpasses 60%, but Comprehensive Assessment adopts ZnCl
2optimum.
Experimental example 7: the purification with macroreticular resin of salvianolic acid A master part raw material
Get 13 parts of salvianolic acid A master part feedstock conversion solution, put in each model macroporous resin 100g that pretreatment is good, after shaking table dynamic adsorption 8 hours, the dress post, wash successively 3 column volumes of eluting, 5 column volumes of 20% ethanol elution, 5 column volumes of 70% ethanol elution with water, collect 70% ethanol containing salvianolic acid A master part raw material eluent part, carry out the salvianolic acid A assay, the eluent evaporate to dryness calculates dry cream amount, the results are shown in Table 20.
The confirmation of table 20. macroporous resin model
Result shows: above 13 kinds of macroporous resins are good to the adsorption effect of salvianolic acid A master part raw material, and can well remove impurity with the ethanol gradient elution of variable concentrations, obtain salvianolic acid A master part raw material eluent that content is greater than 75%, with the HPD-100 amount of getting dry extract maximum, main part of material content is high, and the resin absorption amount is large.
Experimental example 8: the polyamide column chromatography purification of salvianolic acid A master part raw material
Get 3 parts of salvianolic acid A master part material solutions after purification with macroreticular resin, put in each model resin 100g that pretreatment is good, after shaking table dynamic adsorption 8 hours, the dress post, wash successively 3 column volumes of eluting, 5 column volumes of 20% ethanol elution, 5 column volumes of 70% ethanol elution with water, collect 70% ethanol elution and carry out the salvianolic acid A assay, part eluent evaporate to dryness calculates dry cream amount, the results are shown in Table 21.
The confirmation of table 21. resin model
Result shows: above 3 kinds of resins are good to the adsorption effect of salvianolic acid A, and can well remove impurity with the ethanol gradient elution of variable concentrations, obtain content and are about salvianolic acid A master part raw material eluent of 90%; Maximum with the polyamide amount of getting dry extract, the content high adsorption capacity is large.
Experimental example 9: the abstraction purification of salvianolic acid A master part raw material
By 70% ethanol elution decompression recycling ethanol after the polyamide column chromatography purification, adjust pH 2.0~4.0, use again n-butyl alcohol, t-butyl methyl ether, methyl acetate, ethyl acetate, butyl acetate, Ethyl formate, ethanol extraction 5 times, the Separation of Organic phase, reclaim solvent, drying, obtain salvianolic acid A master part raw material, measure salvianolic acid A content, the results are shown in Table 22.
The confirmation of organic solvent for table 22. extraction
Table 22 result shows: n-butyl alcohol is because polarity is large, salvianolic acid A master part material quantity is maximum, but its salvianolic acid A content is not improved significantly, ether is because polarity is less than normal, water-solubility impurity is few, and salvianolic acid A content is high, but the salvianolic acid A master part material quantity obtained is few, salvianolic acid A master part material quantity that other extraction solvent t-butyl methyl ether, methyl acetate, ethyl acetate, butyl acetate, Ethyl formate obtain is larger, and salvianolic acid A content all is improved; Obtain with t-butyl methyl ether that extract is many, salvianolic acid A content is high.
Experimental example 10: the purification by silica gel column chromatography of salvianolic acid A master part raw material
Get 12 parts of salvianolic acid A master part raw material abstraction liquid after abstraction purification, every part containing salvianolic acid A 10g, adds the silica gel of 20g, stirs, and volatilizes; Stirring sample silica gel, be added on the dry silicagel column of the 100g installed, the two-phase solvent that petroleum ether, pentane, normal heptane, ethyl acetate, methyl acetate, Ethyl formate, t-butyl methyl ether form of take respectively is eluant, HPLC or thin layer chromatography detect, collect salvianolic acid A master part raw material eluent, the eluent evaporate to dryness, get dry extract, measure salvianolic acid A content, the results are shown in Table 23.
The confirmation of table 23. eluant
Result shows: when salvianolic acid A master part raw material is used normal phase silica gel column chromatography, the two-phase solvent that adopts pentane-t-butyl methyl ether to form is eluant, and gradient elution, can well remove impurity, obtains highly purified salvianolic acid A master part raw material eluent.
Experimental example 11: salvianolic acid A master part raw material drying method research
Get 4 parts of eluents after the silica gel purification eluting, every part containing salvianolic acid A 100g, be concentrated into without the thick paste shape, adding after 10 times of water gagings dissolve adopts respectively vacuum drying, lyophilisation, spray drying, microwave vacuum drying to obtain salvianolic acid A master part raw material, this salvianolic acid A master part raw material is detected, be the results are shown in Table 24.
Table 24. salvianolic acid A master part raw material drying method testing result
Result shows: adopt the lyophilisation overlong time, and high cost, and organic solvent residual is serious; The vacuum drying time is slightly long, and Drying Time of Vertical Spray Dryer is short but instantaneous temperature is higher; The microwave vacuum drying baking temperature is low, and the time is short, and gained salvianolic acid A master part raw material indices is good.
Through further experiment is definite, the microwave vacuum drying optimum range is chosen as temperature: 20-100 ℃, and return difference temperature 1-5 ℃, more than vacuum-0.07Mpa, microwave power 1-100KW, dry 10-200 minute.
Experimental example 12: the Preliminary screening of salvianolic acid A freeze-dried powder adjuvant
Freeze-dried powder generally need add appropriate amount of auxiliary materials, adjuvant mainly comprises filler and antioxidant, be mainly used in following purpose: the dissolubility that increases composition in injection, during the molding of powder pin, need add adjuvant as supporter, improve mouldability, regulate the powder pin admittedly containing thing weight, regulate osmotic pressure, the antioxidant Main Function is to keep preparation stabilization.
We get salvianolic acid A master part raw material and make freeze-dried powder from different filleies and vitamin C.
Table 25. prescription filler screening table
Get salvianolic acid A master part raw material by table 25 formula, add the water for injection of making total amount 90% and be stirred to dissolve, with 10% sodium hydroxide adjust pH 4.5, add adjuvant to make to dissolve, mix, add active carbon 2g stirring and adsorbing, filter, remove active carbon; Inject water to 3000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 28 ℃/h speed, be cooled to-42 ℃, be incubated freezing 12 hours; Be evacuated to below 0.3mbar, in 11 hours, the salvianolic acid A formulation temperature freezed risen to-25 ℃, maintain-25 ℃ of vacuum dryings 6.5 hours; Continue to heat up, with 0.8 ℃/min, evenly be warming up to 40 ℃, maintain 40 ℃ of dryings after 5 hours, sample temperature is down to room temperature, add a cover, observe mouldability, in Table 26.
The different filleies of table 26. affect result to mouldability
From table 26 experimental result, add not commensurability filler, larger on the impact of mouldability, mannitol, glucose, lactose are better to the lyophilized formulations effect, the lyophilized powder sedimentation is good, porous nickel, therefore as selecting adjuvant, general lower than 20mg mouldability and solubility.
Experimental example 13: different filleies and the antioxidant impact on the lyophilized formulations type
According to the filler experimental result, select respectively mannitol, glucose, lactose to carry out confirmatory study, and antioxidant is compared to research, select respectively vitamin C, thiourea, sodium sulfite, sodium pyrosulfite as antioxidant, experimental program is in Table 27, and compare with not adding the antioxidant prescription, experimental result is in Table 28.
The different filleies of table 27 and antioxidant Preliminary screening
Get salvianolic acid A master part raw material by table 27 formula, add the water for injection of making total amount 90% and be stirred to dissolve, with 10% sodium hydroxide adjust pH 4.5, add adjuvant to make to dissolve, mix, add active carbon 2g stirring and adsorbing, filter, remove active carbon; Inject water to 3000ml, detect intermediate content, pH value, detect qualified rear use 0.22 μ m microporous filter membrane and filter, the filtrate fill is in aseptic cillin bottle, and part is butyl rubber bung beyond the Great Wall, make altogether 1000 bottles, sabot, after fill completes, send into freeze dryer, close chamber door, open freeze dryer, with 25 ℃/h speed, be cooled to-42 ℃, be incubated freezing 14 hours; Be evacuated to below 0.3mbar, in 10~14 hours, the salvianolic acid A formulation temperature freezed risen to-25 ℃, maintain-23 ℃ of vacuum dryings 7 hours; Continue to heat up, with 0.6 ℃/min, evenly be warming up to 44 ℃, maintain 44 ℃ of dryings after 2 hours, sample temperature is down to room temperature, add a cover, observe mouldability, in Table 28.
The different filleies of table 28. and the antioxidant result that affects on mouldability and the quality of the pharmaceutical preparations
Table 28 experimental result shows, adds not commensurability filler mannitol, glucose, lactose better to preparations shaping, and the lyophilized powder sedimentation is good, porous nickel, consumption select 20mg~40mg/2ml~3ml mouldability and solubility all better.Add water-soluble vitamin c, thiourea, sodium sulfite, sodium pyrosulfite, to salvianolic acid A content and other compositions of main constituent, certain influence is all arranged, salvianolic acid content slightly raises, and red sour B content descends to some extent, and the preparation effect is more excellent.
Experimental example 14: lyophilisation condition research
3.1 lyophilisation condition is preferred: mainly contain two factors in freezing conditions: on the impact of mouldability: the temperature of freezing body before freezing speed, vacuum drying; Impact on freeze drying rate: heating curve during vacuum freeze-drying.
Preferably following on freeze dryer:
A, the medicinal liquid chilling rate with 20-30 ℃/h in freeze dryer is cooled to-40 ℃~-45 ℃, be incubated freezing 10~16 hours, be evacuated to below 0.3mbar, in 10~14 hours, the salvianolic acid A formulation temperature freezed is risen to-23 ℃~-27 ℃, maintain-23 ℃~-27 ℃ vacuum dryings 6~8 hours;
B, the medicinal liquid first chilling rate with 20-30 ℃/h in freeze dryer is cooled to-25 ℃, be incubated freezing 5~8 hours, be refrigerated to again-40 ℃~-45 ℃, be incubated freezing 5~8 hours, be evacuated to below 0.3mbar, in 10~14 hours, the salvianolic acid A formulation temperature freezed is risen to-23 ℃~-27 ℃, maintain-23 ℃~-27 ℃ vacuum dryings 6~8 hours;
C, the medicinal liquid chilling rate with 20-30 ℃/h in freeze dryer is cooled to-15 ℃, be incubated freezing 5~8 hours, be refrigerated to again-40 ℃~-45 ℃, be incubated freezing 5~8 hours, be evacuated to below 0.3mbar, in 10~14 hours, the salvianolic acid A formulation temperature freezed is risen to-23 ℃~-27 ℃, maintain-23 ℃~-27 ℃ vacuum dryings 6~8 hours;
Above three kinds of result of the tests: 1, medicinal liquid directly is refrigerated to-40 ℃~-45 ℃ with 20-30 ℃/h, and powder body is more even, and without crack, drying time is short.2, powder body is inhomogeneous, and crack is arranged, and 3, freeze-drying time is long, powder body is inhomogeneous, has crack therefore, while selecting medicinal liquid freezing, with the chilling rate of 20-30 ℃/h, directly is down to-40 ℃~-45 ℃, and powder body is more even, without crack, can save freeze-drying time.
3.2 pilot scale freeze-drying curve
Freeze-drying curve refers to the relation curve of product temperature in freeze-drying process or shelf temperature time to time change.The many factors such as the number of the shape of freeze-drying curve and the performance of product, loading amount, the kind of separation container and appointed condition are relevant.The freeze dryer that we select when middle trial production is 4000 bottles of scales, substantially meets large production requirement.Cooled the temperature to-40 ℃~-45 ℃ at 1~4 hour, at this temperature, keep 10~16 hours, at 10~14 hours, temperature is risen to again to-23 ℃~-27 ℃ and keep 6~8 hours, then at 6~9 hours, temperature is risen to 40 ℃~45 ℃ and keep 2~5 hours, freeze-drying curve is as shown in Figure 18 and Figure 19.
Experimental example 15: preparation stabilization Journal of Sex Research
Get embodiment 10,11,12 samples, by the requirement of stability of drug products experimentation relevant technologies, by above three lot number samples at ambient temperature, by 0 month, 1 month, 2 months, 3 months, 6 months intervals, make regular check on the situation of change of sample property, solubility and clarity, pH value, salvianolic acid A content, total impurities, the results are shown in Table 29.
Table 29 stability experiment result
The demonstration of table 29 stability experiment observed result, lyophilized injectable powder salvianolic acid A at ambient temperature is stable, and other compositions are also without significant change, and the preparation appearance character is good, and the preparation solubility is good, and pH value is stable, the solution clarification.
Below experiment all gets with the salvianolic acid A freeze-dried powder sample that embodiment 14 preparation methoies obtain, and salvianolic acid A monomeric compound freeze-dried powder is got the sample that embodiment 17 preparation methoies obtain.
Experimental example 16: the impact of function of nervous system's symptom after salvianolic acid A freeze-dried powder commute apoplectic type renovascular hypertension in rats (RHRSP) cerebral thrombosis
1, experiment material:
Main agents and instrument: tiger red (rose bengal): the true Bioisystech Co., Ltd in Shanghai; TTC: U.S. Sigma company; SDP-1 type rat heart rate sphygomanometer: China-Japan Friendship Hospital's development; YAG laser device: Wuhan Chinese workers' laser engineering company limited; Japan Olympus BH-5 microscope; Image is processed: the JVCky-F3OB3-CCD coloured image is shot with video-corder the input instrument; Graphical analysis: German KONTRON IBAS2.0 Image analysis system.
Laboratory animal: 2~3 monthly ages, the male SD rat (Beijing Vital River Experimental Animals Technology Co., Ltd. provides) of body weight (100 ± 20) g.
2, experimental technique and result:
2.1 method
2.1.1 the preparation of animal model:
Get the male SD rat of 2~3 monthly ages, body weight (100 ± 20) g and set up the RHRSP model with two narrow renal artery of kidney double fastener method: rat abdominal cavity anesthesia, through the long otch of the about 5cm of xiphoid-process Ventral Midline stringer, cut skin, abdominal muscle, the blunt separation bilateral renal arteries, the annular silver brain clip that is 0.3mm with internal diameter is clamped respectively the bilateral renal arteries initial part.Before operation, measuring blood pressure once, is surveyed once weekly continuous 12 weeks after operation.Separately get 10 SD rats that body weight is suitable, survey its blood pressure as normal control.Reject: in operation and postoperative death, the 12 weeks after operation blood pressure is lower than the 160mmHg rat, and softening kitchen range that apoplexy symptom and sign, dissection be shown in that left basal ganglia region is little and the rat of subarachnoid hemorrhage are arranged.Blood pressure >=160mmHg and be successful model without the RHRSP of apoplexy symptom after 16 weeks.With photochemical method, cause middle cerebral artery occlusion (MCAO) model to cause middle cerebral artery (MCA) thrombosis the RHRSP be successfully prepared: after 2% pentobarbital sodium is pressed 40mg/kg body weight intraperitoneal injection of anesthesia, through left temporo side approach, at zygomatic arch and 1mm place, front lower place, aquamous part of temporal bone junction, bore by dental burr the bone window that a diameter is 5mm, through cerebral dura mater, can know and see left MCA trunk and branch thereof.Dosage injection 2.5% tiger of pressing the 40mg/kg body weight through femoral vein is red, green laser beam (the spot diameter 2mm of the 532hm occurred by the YAG laser device after 5min, intensity of illumination 0.37W) prolonged exposure MCA trunk 15min, visible this MCA far-end and each branch blood flow interrupt, and see that under operating microscope local white thrombus points out this MCA thrombosis, the success of MCAO model copy.In art, rat anus temperature remains on (37 ± 0.3) ℃.Local wound is rinsed with the penicillin diluent before sewing up, and postoperative conventional intramuscular injection penicillin 80,000 U/ only.Reject in art and postoperative 1d death and hemorrhage many or operating microscope under the not clear and definite blood supply rat of whether interrupting.
2.1.2 grouping and administration
First by animal, divide 7 groups at random: sham operated rats, model control group, the high, medium and low dosage group of salvianolic acid A freeze-dried powder, salvianolic acid A monomeric compound group, nimodipine group.The sham operated rats window that only opens seam, do not do laser irradiation; Model group, the high, medium and low dosage group of salvianolic acid A freeze-dried powder, salvianolic acid A monomeric compound group, nimodipine group prepare easy apoplectic type renovascular hypertension in rats MCAO model by the model preparation method.And by the 0.3ml/100g tail vein injection, be administered once respectively in the postoperative 30min of MCAO model, after this be administered once every day, continuous three days altogether.Sham operated rats, the postoperative tail vein injection saline of model control group; The postoperative tail vein injection salvianolic acid A respectively of the high, medium and low dosage group of salvianolic acid A freeze-dried powder freeze-dried powder 20mg/kg, 10mg/kg, 5mg/kg, the postoperative tail vein injection salvianolic acid A of salvianolic acid A monomeric compound group monomeric compound 10mg/kg, the postoperative tail vein injection nimodipine of nimodipine group 10mg/kg.
2.2 result
18 minutes point systems according to Garcia etc. are marked: the symmetry of spontaneous activity, quadruped locomotion, forelimb stretch the action of creeping symmetry, climb the cage wall, push away the trunk reaction, the reaction of antenna to stimulating.In first three items, without movable or reaction (extremity or suffering limb), be 0 minute, a little activity is 1 minute, and reaction calibration constant is 2 minutes, and activity is normally 3 minutes; Rear three reactionless be 1 minute, activity calibration constant is 2 minutes, activity is normally 3 minutes.Total points is the highest 18 minutes, minimum 3 minutes.After the postoperative rat anesthesia of MCAO is revived, scoring once, is respectively carried out a neuroethology scoring (at every turn all being marked after administration on the same day) at MCAO postoperative (after being ischemia) 24h, 48h, 72h to rat respectively afterwards.Each experimental group rat is carried out to blind state by 5 people that are unfamiliar with this experiment grouping simultaneously and observe scoring, finally average.And observe the rat body state simultaneously, measure body weight and blood pressure.
Table 30 salvianolic acid A freeze-dried powder on the RHRSP cerebral thrombosis after the impact (x ± s) of neuroethology scoring
Annotate: compare #P<0.01 with sham operated rats; Compare * P<0.01, ☆ P<0.05 with model group
Experimental result shows: after model group is revived, the neuroethology scoring of (in 12h) is significantly lower than sham operated rats (P<0.01), after the cerebral thrombosis ischemia is described, RHRSP function of nervous system is impaired serious, and, in lasting 72h, the neuroethology scoring continues to be starkly lower than sham operated rats (P<0.01); The nimodipine group is compared with model group with salvianolic acid A monomeric compound group and each dosage group of salvianolic acid A freeze-dried powder, neuroethology scoring after rat revives has rising (P<0.05 or P<0.01) in various degree, and after the middle and high dosage group of salvianolic acid A freeze-dried powder ischemia, the scoring of the neuroethology of 24h approaches the sham operated rats level substantially; Recovered normal to each dosage group rat neuroethology scoring of 72h salvianolic acid A freeze-dried powder after ischemia, compared difference with model group and still have statistical significance (P<0.01).10mg/kg salvianolic acid A freeze-dried powder group and 10mg/kg salvianolic acid A monomeric compound group relatively, although the neuroethology scoring does not have significant difference, also have slightly excellent trend; And, in the laboratory observation process, the integrality of the rat of salvianolic acid A freeze-dried powder group is recovered soon than salvianolic acid A monomeric compound group and is slightly good.Above results suggest; after the salvianolic acid A freeze-dried powder can improve RHRSP cerebral thrombosis ischemia, neuroethology is marked; the effect of nervous symptoms after prompting salvianolic acid A freeze-dried powder has protection and improves cerebral ischemia, and the trend that is better than same dosage salvianolic acid A monomeric compound is arranged.
Experimental example 17: the impact of salvianolic acid A freeze-dried powder on RHRSP cerebral thrombosis tissues following MCAO in rats pathological change
The preparation of RHRSP Cerebrovascular embolism model, grouping, medication are with experimental example 16.After the neuroethology scoring finishes the last time, the rat broken end is got brain, and observes MCA local thrombus situation under operating microscope.Put into afterwards smooth vessel be built in-20 ℃ freezing, the row crown section.The Mus brain section, every thick about 2mm.The brain sheet is put into rapidly to 2%TTC solution, hatch under 37 ℃, the every face of brain sheet is hatched 15min, and normal cerebral tissue peony, and the ischemic infarction cerebral tissue is white in color.Taking out the brain sheet observes and takes pictures.Then cerebral tissue is placed in to 4% paraformaldehyde PBS buffer (pH7.3) fixing, row dehydration afterwards, paraffin embedding, get cerebral tissue and do paraffin section and do conventional H E staining analysis, micro-Microscopic observation, takes pictures.The results are shown in Table 31.
The impact of table 31 salvianolic acid A freeze-dried powder on RHRSP cerebral thrombosis tissues following MCAO in rats pathological change
Experimental result shows: sham operated rats cerebral tissue Bilateral Symmetry, have no pathological changes, and the model group Intravascular Thrombus adheres to seriously.With model group relatively, the contraction in length of the left MCA local thrombus of each dosage group rat of Microscopic observation salvianolic acid A freeze-dried powder, reduce at the arterial wall bond area, with high, middle dosage group is the most obvious.The TTC visible infarcted cerebral constitution that dyes is white in color, and is dyed to white cerebral tissue scope in each dosage group of salvianolic acid A freeze-dried powder and dwindles than model control group is remarkable.HE dyes in visible model group left cortical MCA blood supply district (centered by the cortex of volume top) infarct has obvious cerebral tissue softening, necrocytosis, the phenomenons such as the local necrosis tissue comes off, salvianolic acid A freeze-dried powder high dose group rat has no Telatrophy's obscission herein, other each administration group necrocytosiss are less, the accidental obscission of organizing; The HE dyeing of each administration group and model control group shows in kitchen range, kitchen range Zhou Jun has little blood vessel hyperplasia, but the little number of blood vessel of each administration group and model group comparison hypertrophy significantly increases, and particularly remarkable with high, the middle dosage group of salvianolic acid A freeze-dried powder; In addition, the kitchen range shape that HE dyeing display model matched group differs in size as seen is hemorrhage, high, the middle dosage group of salvianolic acid A freeze-dried powder there is no and finds that there is kitchen range shape bleeding, salvianolic acid A freeze-dried powder low dose group and salvianolic acid A monomeric compound group and nimodipine group also only have indivedual animals to have the kitchen range shape hemorrhage, and hemorrhagic focus is less than model group.Result of the test shows that the salvianolic acid A freeze-dried powder can obviously improve RHRSP cerebral thrombosis Neurons Against Cerebral Ischemia histopathology state; reduce the thrombosis bond area, reduce infarct size; thereby increasing the little blood vessel number, the necrosis of minimizing cerebral hemorrhage phenomenon protection cerebral tissue that reach surrouding brain tissue in infarcted region comes off; there is protection cerebral thrombosis ischemia and cause the effect of brain tissue impairment, and action effect is better than the salvianolic acid A monomeric compound.
Experimental example 18: the salvianolic acid A freeze-dried powder on the RHRSP cerebral thrombosis after the impact of blood brain barrier (BBB) permeability
1 test method
Animal grouping and the preparation of RHRSP Cerebrovascular embolism model are with experimental example 16 methods.4.5h after the model surgery success, each group is tail vein injection salvianolic acid A freeze-dried powder 40mg/kg, 20mg/kg, 10mg/kg respectively, salvianolic acid A monomeric compound 10mg/kg, nimodipine 20mg/kg; Sham operated rats and model group tail vein injection are with the normal saline of volume.Each is organized rat and puts to death and get the cerebral tissue specimen in MCAO postoperative (after being the cerebral thrombosis ischemia) 6h, 12h, 24h in batches respectively, and before putting to death 1h tail vein injection 2% azovan blue (EvansBlue, EB) normal saline solution 2ml/kg body weight, after fully circulating, dark numb animal, cut open breast through heart perfusion normal saline flushing blood vessel inner dye, broken end is got brain.
Each group is randomly drawed the cerebral tissue of 3 rats, frozen section immediately, the crown section of the thick about 30um of row continuously, with 70% glycerol PBS buffer (pH8.5~9.0) mounting, observe the situation of oozing out of EB in cerebral tissue under Bio-Rad Radiance2100 laser scanning co-focusing microscope, observe BBB open area and degree.While observing, section is not put 4 ℃ of refrigerators and is kept in Dark Place.Each group is separately got the cerebral tissue of 5 rats at random, blots weighing cutaneous horn weight after surface moisture; Cerebral tissue is placed in to homogenizer, adds 50% trichloroacetic acid to make tissue homogenate, more than moving into test tube sealing and standing 60min; The centrifugal 10min of 3000rpm/min, get supernatant, and spectrofluorophotometer is surveyed fluorescent value: excitation wavelength 620nm, emission wavelength 680nm; Calculate EB content in supernatant by standard curve, then calculate every Borneo camphor and organize EB content, with this, react each rat BBB permeability.
2 experimental results
2.1 laser scanning co-focusing microscope observed result
EB is bright-coloured bright red fluorescence under the exciting light state.Observe each treated animal cerebral tissue WuBBBNao district (as pinus, area postrema and hypophysis cerebri) under laser microscope and present homogeneous, diffusivity EB dip-dye, sharpness of border, the line sample profile that meninges red color visible fluorescence is sketched the contours of.And the BBBNao district, other except sham operated rats are respectively organized the equal visible light spot of cerebral tissue, and mainly be distributed in thalamus, hypothalamus, cerebellum, Hippocampus etc. locate, spot size differs, fluorescence intensity weakens to periphery gradually from the center of hot spot, obscurity boundary.The hot spot number of each group and distribution are obviously different: the model group hot spot is maximum, and the hot spot of 120 left and right diameter 100~200um is approximately arranged, and intensive place in the form of sheets.Each salvianolic acid A freeze-dried powder injecta medicine group number of spots significantly reduces than model group, and the salvianolic acid A freeze-dried powder is fewer than the salvianolic acid A monomeric compound group hot spot of same dosage; Each dosage group of salvianolic acid A freeze-dried powder relatively, presents the remarkable dose-difference opposite sex; Wherein more with the low dose group hot spot, on same level, hot spot approximately has 50, but is fused into the less of lamellar; Middle dosage group hot spot is less, is dispersed in distribution; The high dose group hot spot seldom is dispersed in, and fluorescence is very weak.
2.2 the permeability result of the EB of rat cerebral tissue content detection blood brain barrier
Each is organized rat cerebral tissue's specimen and calculates EB content by the fluorescent value recorded, and data statistic analysis is in Table 32.
Table 32 salvianolic acid A freeze-dried powder on the RHRSP cerebral thrombosis after the impact of blood-brain barrier permeability
Annotate: compare #P<0.01 with sham operated rats; Compare * P<0.01 with model group
2.3 conclusion
EB is water-soluble dye, enter after blood can be absolutely rapidly and albumin bound, can not see through blood brain barrier under normal circumstances.From 2.1 and 2.2 results, sham operated rats BBBNao district, have no EB under the cerebral tissue microscope and ooze out hot spot; And under model group rat cerebral tissue microscope, have a large amount of EB to ooze out hot spot, and the cerebral tissue spectrofluorophotometer detects the EB of high-load, than sham operated rats, there were significant differences (P<0.01), show cerebral thrombosis tissues following MCAO in rats blood-brain barrier disruption, permeability increases, and the EB albumin-binding can enter cerebral tissue by open BBB.Experimental result shows under each dosage group rat cerebral tissue microscope of salvianolic acid A freeze-dried powder that EB hot spot number and cerebral tissue EB detect content and obviously reduce, with model group, more all there were significant differences (P<0.01), and will be less than the salvianolic acid A monomeric compound group of same dosage.Prompting salvianolic acid A freeze-dried powder increases inhibited to blood-brain barrier permeability following brain injury, can protect blood brain barrier, and the further damaged of protection cerebral tissue is done by effect and is better than the salvianolic acid A monomeric compound.
Experimental example 19: the impact of salvianolic acid A freeze-dried powder on RHRSP cerebral thrombosis cerebral infarction scope and brain water content
Method by experimental example 16 prepares RHRSP cerebral thrombosis rat model, grouping, administration; After last administration finishes, the rat broken end is got brain.Each group is got the brain tissue slice of 5 rats at random, through TTC dyeing, after taking pictures under the microscope centered by infarct, infarct is delimited, and processes and calculate the infarct size of every brain sheet by image analysis software.The addition of every all brain sheets of rat infarct size, be brain infarction area, is multiplied by the about 2mm of thickness of every brain sheet, is cerebral infarction volume; Get the in kind approximate calculation of all brain sheets of corresponding rat simultaneously and go out corresponding brain cumulative volume; The two ratio calculation cerebral infarction volume percentage ratio.Each group is separately got 5 rat cerebral tissues and is claimed immediately weight in wet base, puts afterwards in 105 ℃ of baking ovens and dries to constant weight, calculates brain water content.
The impact (x ± s) of table 33 salvianolic acid A freeze-dried powder on RHRSP cerebral thrombosis cerebral infarction scope and brain water content
Annotate: compare #P<0.01 with sham operated rats; Compare * P<0.01 with model group
Adopt the SPSS11.5 statistical package to carry out statistical procedures to data.Experimental result shows: sham operated rats has no infarcted cerebral constitution; Each dosage group cerebral tissue Infarction volume of salvianolic acid A freeze-dried powder and brain water content are significantly less than model control group (P<0.01), and dosage is larger, Infarction volume is less, and brain water content is fewer, and difference has statistical significance (P<0.01 or p<0.05).Salvianolic acid A freeze-dried powder basic, normal, high dosage group Infarction volume and brain water content are all lower than the nimodipine group.10mg/kg salvianolic acid A freeze-dried powder group rat cerebral infarction volume and brain water content are all low than the salvianolic acid A monomeric compound group of same dosage.Illustrate that the salvianolic acid A freeze-dried powder in the present invention can accelerate the reparation of focus, reduce ischemic tissue of brain infarction size after the RHRSP cerebral thrombosis, alleviate the cerebral tissue edema, have and repair and the effect of protection Neurons Against Cerebral Ischemia tissue injury.
Experimental example 20: the salvianolic acid A freeze-dried powder on RHRSP cerebral thrombosis ischemia after the microvascular impact of rat cerebral tissue
Animal grouping and the preparation of RHRSP Cerebrovascular embolism model are with experimental example 16 methods.4.5h tail intravenously administrable after the model surgery success, after this be administered once, until it is complete to draw materials every day.Each dosage group of salvianolic acid A freeze-dried powder is tail vein injection salvianolic acid A freeze-dried powder 20mg/kg, 10mg/kg, 5mg/kg respectively, salvianolic acid A monomeric compound group injection salvianolic acid A monomeric compound 10mg/kg, nimodipine group injection nimodipine 10mg/kg; Model group and sham operated rats injection are with the normal saline of volume.Each group is got rat broken end respectively at the postoperative 6h of MCAO, 1d, 3d, 7d in batches and is got brain, conventional fixing, the dehydration of the neutral PBS buffer of cerebral tissue 4% paraformaldehyde of ischemic focus half penumbra area or same area, paraffin embedding, section, every thick about 5um.SABC method CD31 immunohistochemical staining, by SABC test kit description operation; The DAB colour developing.With PBS, replace primary antibodie to make negative control.With the appearance of erythrocyte or tube chamber, whether do not count blood vessel.All single endotheliocytes of dying brown color or endotheliocyte are bunch all as a vascular counts, and all tube chambers are greater than 8 erythrocyte sizes, all do not count with the angiosomes blood vessel of thicker flesh layer.Vascular counts is undertaken by the Weidner method.First under low power (* 40) visual field, find high vessel density zone, then carry out Microvessel Count under high power (* 400) visual field, 10 high power fields are chosen in every section at random, finally get the microvessel density value (MVD) of its meansigma methods as this specimen.And adopt the full automatic colour image processing system to carry out graphical analysis, measure blood vessel field Area Ratio (Positive Objects area/Statistical Fields gross area).
Table 34 respectively organizes that rat cerebral tissue's blood vessel scene is long-pending, the immune positive microvessel density of CD31 (MVD) value (n=6)
Annotate: compare #P<0.01 with sham operated rats; Compare * P<0.01, ☆ P<0.05 with model group
Table 34 experimental data shows, with sham operated rats, compares, and model group ischemia penumbra MVD and blood vessel scene are amassed 1d after ischemia to be increased to some extent, but after ischemia, 3d, 7d continue significantly to reduce (P<0.01); With model group, compare, after the ischemia treatment, each dosage group of nimodipine group and salvianolic acid A freeze-dried powder and salvianolic acid monomeric compound group 6h, 1d, 3d, 7d cerebral tissue ischemia penumbra MVD and blood vessel scene after ischemia is long-pending significantly increases (P<0.05 or P<0.01) to some extent, and more stable in 7d.Three kinds of different pharmaceuticals relatively, the most remarkable with salvianolic acid A freeze-dried powder effect.Between three dosage groups of salvianolic acid A freeze-dried powder, relatively, difference has statistical significance (P<0.05).Result shows that the salvianolic acid A freeze-dried powder can increase MVD and the blood vessel field Area Ratio of cerebral tissue ischemia half blanking bar, prompting salvianolic acid A freeze-dried powder can promote the effect that Angiogenesis and collateral circulation are set up, and effect is better than salvianolic acid A monomeric compound and nimodipine.
Experimental example 21: the salvianolic acid A freeze-dried powder on RHRSP cerebral thrombosis ischemia after the impact of rat cerebral tissue vascular endothelial growth factor expression
Modeling and grouping administration are with experimental example 19.Respectively at the postoperative 2h of rat MCAO, 24h, 48h, each component is criticized and is got rat abdominal cavity anesthesia, opens breast and exposes heart, liquid-solid fixed containing 4% paraformaldehyde of 0.1%DEPC through the heart perfusion, gets rapidly brain, in forebrain optic chiasma place, does the crown section that about 2mm is thick.Be placed in 4% paraformaldehyde fixative and spend the night, conventional dehydration, paraffin embedding, be cut into the paraffin section that about 5um is thick continuously, and routine dewaxes to water, with hybridization in situ, detects the expression that VEGF impels ribonucleic acid (VEGFmRNA).Illustrate and operated by VEGF in situ hybridization test kit (Wuhan Boster Biological Technology Co., Ltd.), with microscopic image analysis software, carry out optical density (IOD) analysis.
The impact that table 35 salvianolic acid A freeze-dried powder is expressed RHRSP cerebral thrombosis Neurons Against Cerebral Ischemia tissue VEGF
Annotate: compare #P<0.05 with sham operated rats; Compare #P<0.01, ☆ P<0.05 with model group
VEGF (VEGF), be again the blood vessel opsonin, has the effect of short endothelial cell division, can promote the growth of blood vessel and the foundation of side Zhi Xunhuan.Experimental result shows; model group VEGFmRNA expression is increased significantly (P<0.05) than sham operated rats; illustrate after the cerebral tissue hypoxic-ischemic can Stimulation of The Brain tissue in the expression increase of VEGF; after the prompting cerebral infarction, body self there will be a kind of protective response that resists ischemia injury; the expression of VEGF is increased, self " compensatory revascularization " occur after ischemia.Relatively, the VEGFmRNA expression significantly raises (P<0.05 or P<0.01), and the trend that is better than same dosage salvianolic acid A monomeric compound group is arranged for each dosage group of salvianolic acid A freeze-dried powder and model group group.Prompting salvianolic acid A freeze-dried powder can significantly promote the ischemic tissue of brain angiogenesis, promotes the foundation of collateral circulation compensation, saves ischemia half blanking bar, the brain tissue impairment that the protection ischemia causes, and have certain dose-effect relationship.
Experimental example 22: the salvianolic acid A freeze-dried powder on RHRSP cerebral thrombosis ischemia after the impact of rat cerebral tissue basic fibroblast growth factor protein expression
With experimental example 20,2h, 24h, 48h after finishing respectively at the rat administration, each component criticizes that to get the rat heart perfusion liquid-solid fixed containing 4% paraformaldehyde of 0.1%DEPC, gets rapidly brain, the crown section of row, paraffin embedding, section.The ABC immunohistochemic al technique method detects the expression of cerebral tissue alkalescence fibroblast growth factor (bFGF) albumen.By bFGF protein immunization group detection kit (Wuhan Boster Biological Technology Co., Ltd.) description, operated, micro-Microscopic observation, counting is dyed the positive cell number of brown color, and all visuals field of 5 infarcts are selected in each section at random, average.Data are carried out statistical analysis.
Table 36 salvianolic acid A freeze-dried powder on RHRSP cerebral thrombosis ischemia after the bFGF of rat cerebral tissue protein expression impact (x ± s)
Annotate: compare #P<0.05 with sham operated rats; Compare * P<0.01 with model group
BFGF is the strong neurotrophic factor with various biological activity, can neuroprotective unit to multiple detrimental effects such as ischemia resisting, anoxia, toxicity of excitatory amino acid, calcium overload, free radical and NO are synthetic, slow down neuronal apoptosis and necrosis; And can work in coordination with the effect that VEGF promotes angiogenesis in infarcted region.
Experimental result shows; after ischemia occurs; the bFGF of model group rat cerebral tissue protein expression raises to some extent than sham operated rats; to ischemia 24h, significant difference (P<0.05) is arranged; but the prolongation with Ischemia Time, have a declining tendency, after prompting cerebral tissue hypoxic-ischemic; body self produces of short duration protection stress, but Stimulation of The Brain organizes the endogenous bFGF protein expression to increase.Relatively, the bFGF protein expression of each time period all significantly increases (P<0.01) for nimodipine group, each dosage group of salvianolic acid A freeze-dried powder and salvianolic acid A monomeric compound group and model group; With salvianolic acid A freeze-dried powder effect optimum.Between three dosage groups of salvianolic acid A freeze-dried powder, relatively, difference has statistical significance (P<0.05); Each time period of each dosage group self relatively shows, the bFGF protein expression is continual and steady; Prompting salvianolic acid A freeze-dried powder can increase former of ischemic tissue of brain and secondary bFGF protein expression; effect with good neurocyte protection effect and promotion angiogenesis; contribute to the foundation of collateral circulation; save ischemia half blanking bar, and action effect is better than salvianolic acid A monomeric compound and nimodipine.
Experimental example 23: the impact of salvianolic acid A freeze-dried powder on the rats after cerebral ischemic reperfusion nervous symptoms
Male SD rat (250 ± 20) g, be divided at random 7 groups: sham operated rats, ischemia-reperfusion injury model matched group, the high, medium and low dosage of salvianolic acid A freeze-dried powder (10mg/kg, 5mg/kg, 2.5mg/kg) group, salvianolic acid A monomeric compound group (10mg/kg), nimodipine matched group (10mg/kg).Adopt the standby rat brain focal cerebral ischemia-reperfusion injury model of improvement line bolt legal system: male SD rat, pentobarbital sodium intraperitoneal anesthesia.Expose and separate left carotid, external carotid artery, internal carotid artery and arteria pterygopalatina, ligation external carotid artery distal end, arteriole folder folder closes common carotid artery, the tie wings arteria palatina, cut a kerf in the nearly common carotid artery crotch of external carotid artery, head end is scribbled to the fishing line that smooth paraffin diameter is 0.3mm and through left side external carotid artery trunk otch, slowly to internal carotid artery, enter the propelling of cranium direction, take the common carotid artery crotch as labelling, while advancing 18~20mm to feel slight resistance, block middle cerebral artery and cause cerebral ischemia.Fishing line stays about 1cm in order to pouring into use, sterilization, skin suture outward again.After continuous ischemia 2h, extract the bolt line, realize ischemia-reperfusion injury model.Sham operated rats except plug wire not, the same model group of all the other operating process.Each group 30min and each is administered once through tail vein injection when perfusion starts again before ischemia, after this each injection every day once, continues to and draws materials.Sham operated rats and ischemia-reperfusion injury model matched group give the normal saline of same volume.
After cerebral ischemic reperfusion in rats, 3h, 24h, 48h, 72h respectively carry out neurological deficits score one time respectively, and scoring adopts the Bederson improved method: carry an approximately chi of Mus tail built on stilts, observe forelimb flexing situation, stretch to ground as two forelimb symmetries and count 0 minute; As the offside forelimb of performing the operation occurs that the flexing of wrist flexing meter 1 minute, elbow flexing meter 2 minutes, shoulder inward turning meter 3 minutes, existing wrist elbow has again shoulder inward turning meter 4 minutes.Rat is placed on level land, pushes away respectively both shoulders to side shifting, check resistance, as symmetrical as the bilateral resistance and strong, be designated as 0 minute; Resistance descender when promoted to the operation offside, according to decline degree difference be divided into gently, in, severe, count respectively 1,2,3 minute.Rat two forelimbs are placed on wire netting, observe the muscular tension of two forelimbs, bilateral muscular strength equity and strong person count 0 minute, operation offside muscular tension decline degree is divided into gently, in, severe, count respectively 1,2,3 minute.Rat does not stop, to a side person of turn-taking, to count 1 minute.According to above standards of grading, full marks are 11 minutes, and mark is higher, illustrate that the behavior disorder degree of rat is more serious, neurologic impairment is more serious.Concrete data are in Table 37.
The impact (x ± s, n=12) of table 37 salvianolic acid A freeze-dried powder on the rats after cerebral ischemic reperfusion neurological deficits score
Annotate: compare * * P<0.01, * P<0.05 with model group
Result of the test is known, ischemia-reperfusion injury model group function of nervous system serious defect, last till again fill with after 72h, although more again after perfusion behavioristics's obstacle of 3h, 24h significantly alleviate (P<0.05), neurologic impairment is serious (neurological deficits score still is greater than 5) still.Each dosage group of nimodipine group and salvianolic acid A freeze-dried powder is compared with model group, from pouring into again 3h, the neurologic impairment sx↓, neural row is learned damaged mark and is significantly reduced (P<0.05), to pouring into 72h again, the neurobehavioral of each medicine group rat recovers substantially.Between each dosage group of salvianolic acid A freeze-dried powder: low dose group and the scoring of middle and high dosage group relatively have statistical significance (P<0.05); Between high dose group and middle dosage group, scoring relatively has the trend of reduction, but difference does not have statistical significance (P>0.05).Each time period neurologic defect symptom of salvianolic acid A freeze-dried powder group rat will be lighter than the salvianolic acid A monomeric compound group of same dosage.
Experimental result shows that the salvianolic acid A freeze-dried powder can alleviate rats after cerebral ischemic reperfusion neurologic impairment symptom, be conducive to its neurobehavioral recovery, prompting salvianolic acid A freeze-dried powder has the effect that improves nervous symptoms after brain tissue impairment, and action effect is more obvious than salvianolic acid A monomeric compound.
Experimental example 24: the impact of salvianolic acid A freeze-dried powder on rats after cerebral ischemic reperfusion cerebral infarction scope, cerebral index and brain water content
Experimental example 23 is respectively organized rat the last time after neuroethology scoring, get 6 broken ends for every group and get brain, be placed in immediately-20 ℃ of refrigerator freezing 10min, after removing olfactory bulb, cerebellum and low brain stem, the cerebral tissue continuous coronal section of row 2mm thickness, immerse the brain sheet in 2%TTC solution, 37 ℃ of dyeing 10min, take out, be placed in fixedly 2h of 4% paraformaldehyde PBS buffer.Normal structure is dyed redness, and infarct is white in color.Fixing brain sheet is sequentially arranged by section, before and after the brain sheet of taking pictures under microscope, behind two sides, inputted computer, calculate the approximation of front brain volume and Infarction volume according to each slice thickness, show that Infarction volume accounts for the percentage ratio of front brain volume.
Each claims the cutaneous horn weight after organizing other 6 rats broken end and getting brain immediately, in 105 ℃ of baking ovens, dries to constant weight, calculates brain water content and cerebral index.
The impact (x ± s, n=6) of table 38 salvianolic acid A freeze-dried powder on rats after cerebral ischemic reperfusion cerebral infarction volume ratio, cerebral index, brain water content
Annotate: with model group, compare * p<0.05, * * p<0.01
The experimental data demonstration, each dosage group of salvianolic acid A freeze-dried powder is compared with the ischemia-reperfusion injury model group: cerebral infarction volume is than significantly reducing (P<0.01), and cerebral index and brain water content all obviously reduce (P<0.01 or P<0.05); Salvianolic acid A freeze-dried powder low dose group and nimodipine group be no difference of science of statistics relatively; Relatively, its Infarction volume and cerebral index and brain water content all significantly reduce (P<0.05 or P<0.01), and the trend lower than same dosage salvianolic acid A monomeric compound group is arranged for the middle and high dosage group of salvianolic acid A freeze-dried powder and nimodipine group; Show that the salvianolic acid A freeze-dried powder can reduce rats after cerebral ischemic reperfusion cerebral tissue infarction size, can alleviate the cerebral tissue edema degree after cerebral ischemia reperfusion injury, effect is better than salvianolic acid A monomeric compound and nimodipine.
Experimental example 25: the impact of salvianolic acid A freeze-dried powder on rats with cerebral ischemia cerebral tissue ischemia half blanking bar regional cerebral blood flow (rCBF)
1 test method
Adopt the standby rat brain of improvement line bolt legal system focal ischemia model: male SD rat, pentobarbital sodium intraperitoneal anesthesia.Expose and separate left carotid, external carotid artery, internal carotid artery and arteria pterygopalatina, ligation external carotid artery distal end, arteriole folder folder closes common carotid artery, the tie wings arteria palatina, cut a kerf in the nearly common carotid artery crotch of external carotid artery, head end is scribbled to the fishing line that smooth paraffin diameter is 0.3mm and through left side external carotid artery trunk otch, slowly to internal carotid artery, enter the propelling of cranium direction, take the common carotid artery crotch as labelling, while advancing 18~20mm to feel slight resistance, block middle cerebral artery and cause cerebral ischemia.Fishing line stays about 1cm in order to pouring into use, sterilization, skin suture outward again.Sham operated rats except plug wire not, the same model group of all the other operating process.
Model after success is divided into nimodipine group (10mg/kg), salvianolic acid A monomeric compound group (10mg/kg), the high, medium and low dosage group of salvianolic acid A freeze-dried powder (10mg/kg, 5mg/kg, 2.5mg/kg) at random.Each treated animal after model success immediately the tail vein give relative medicine, sham operated rats and model group give the normal saline of same volume.Adopt Laser Doppler Flowmetry to measure rCBF through cranium.The laser-Doppler probe that the use cyanoacrylate is 0.5mm by diameter is close to skull surface and is fixed, selecting respectively after bregma the other 2mm that opens in 1mm center line right side under stereotaxic instrument is that after ischemia half blanking bar rCBF monitoring point, bregma other to open 6mm be rCBF monitoring point, ischemia center on 2mm center line right side, record blood flow, continue to monitor 2h after ischemia.Record before administration and administration after blood flow.
2 result of the tests
After middle cerebral artery occlusion in rat, ischemia center cerebral blood flow drop to normal rCBF before modeling 10%~20% between, ischemia half blanking bar rCBF drop to rCBF before modeling 30%~40% between.10min after administration, the ischemia penumbra rCBF of each medicine group rat cerebral tissue than administration before all existing risings in various degree, 30min after administration, each medicine group cerebral tissue ischemia penumbra rCBF peaks.Concrete experimental data statistical analysis is in Table 39.
The impact (x ± s, n=10) of table 39 salvianolic acid A freeze-dried powder on rats with cerebral ischemia continuous ischemia phase cerebral tissue ischemia half blanking bar rCBF
Annotate: with sham operated rats (baseline value), compare * P<0.01; With comparison before administration, ★ P<0.01, ☆ p<0.05
3 interpretations of result
From table 39 data, after the operation modeling, model control group and each medicine group cerebral tissue half blanking bar rCBF compare with sham operated rats, have utmost point significant difference (p<0.01) to mean the modeling success.After administration, 10min begins, each medicine group than self administration before ischemia half blanking bar rCBF obvious rising is arranged, and with nimodipine and high, the middle dosage group of salvianolic acid A freeze-dried powder particularly significantly (p<0.01); To 30min after administration, each medicine group ischemia half blanking bar rCBF rises to the highest, and respectively organizes self rCBF baseline value before administration relatively, has raise 15%~30%; Though after this have a declining tendency, but last till ischemia 2h, each medicine group is compared before than model group and self administration, still has remarkable significant difference (p<0.01 or p<0.05); Each dosage group of salvianolic acid A freeze-dried powder is compared, and good dose-effect relationship is arranged; In the salvianolic acid A freeze-dried powder, the rCBF of dosage group day part is suitable with the nimodipine group, and the trend higher than same dosage salvianolic acid A monomeric compound is arranged.Hence one can see that, and the salvianolic acid A freeze-dried powder has the effect that increases rats with cerebral ischemia cerebral tissue ischemia half blanking bar rCBF, thereby is conducive to save the cerebral tissue that ischemia half blanking bar is at death's door, the effect of performance treatment cerebral ischemia.
Experimental example 26: the impact of salvianolic acid A freeze-dried powder on rats after cerebral ischemic reperfusion cerebral tissue ischemia half blanking bar rCBF
Respectively organize rat in experimental example 25 after continuous ischemia 2h observation ischemia half blanking bar rCBF, extract the bolt line, realize ischemia-reperfusion injury model.After model is set up, each organizes the tail intravenously administrable, and dosage is with experimental example 25.Still press the described method of experimental example 25 and measure the rear 3h cerebral tissue ischemia half blanking bar rCBF of filling again.Respectively organize rat and fill with again rear different time sections 10min, 30min, 60min, 90min, 120min, 180min cerebral tissue ischemia half blanking bar rCBF.Data are carried out statistical analysis.Concrete data are in Table 40.
The impact (x ± s, n=10) of table 40 salvianolic acid A freeze-dried powder on rats after cerebral ischemic reperfusion cerebral tissue ischemia half blanking bar rCBF
Annotate: compare * P<0.01 with sham operated rats; With filling is relatively front again, ☆ p<0.01; Compare ★ P<0.01 with model group
The experimental result demonstration, after rat continuous ischemia 2h recovers to fill with again, each organizes rat ischemia half blanking bar rCBF all increase in various degree.The model group rat rises to top level at 60,90 minutes ischemia half blanking bar rCBF, with filling is front than obvious statistical significance (P<0.01) is arranged again, but also only be about 50% of the front baseline value of ischemia, after this sharply descend again, fill with again in 3h, the rCBF value before ischemia baseline value 37%~50% between, in the meantime again the perfusion remain incomplete, still be low perfusion phenomena, cerebral tissue can continue impaired.After filling with, nimodipine, the high, medium and low dosage group of salvianolic acid A freeze-dried powder rat rCBF obviously increase again, and each time period rCBF has compared utmost point significant difference (P<0.01) with model group.1h after filling with again, salvianolic acid A freeze-dried powder high dose group rCBF return to approach former rCBF 75%, dosage group, nimodipine group return to and are about 69% of former rCBF in the salvianolic acid A freeze-dried powder, 10mg/kg salvianolic acid A monomeric compound group returns to 65% left and right of former rCBF, and salvianolic acid A freeze-dried powder low dose group returns to and is about 61% of former rCBF; Each dosage group of salvianolic acid A freeze-dried powder relatively, is dose dependent; And, to pouring in 3h, each medicine group rCBF maintains in metastable scope again.The experimental result prompting, the salvianolic acid A freeze-dried powder can obviously improve the cerebral blood flow of ischemia half blanking bar cerebral tissue after Ischemia and Reperfusion in vivo in Rats, recovering brain cell blood supplies, thereby save ischemia half blanking bar, further damage is even dead to prevent cerebral tissue, and effect is better than the salvianolic acid A monomeric compound, ischemic cerebrovascular is had to good therapeutical effect.
Experimental example 27: the impact of salvianolic acid A freeze-dried powder on the rats after cerebral ischemic reperfusion Energy Metabolism of Brain Tissue
Experimental example 26 each treated animals are after the cerebral blood flow of having measured again 3h after perfusion, and sacrificed by decapitation, get brain to freezing in liquid nitrogen; Get the cerebral tissue of 100mg corresponding site after one week, under freezing state, pulverize, remove albumen with perchloric acid homogenate, low-temperature centrifugation 10min, supernatant neutralizes with KOH, vortex oscillation, then low-temperature centrifugation 10min, get supernatant, high effective liquid chromatography for measuring cerebral tissue adenosine triphosphate (ATP), adenosine diphosphate (ADP) (ADP), AMP (AMP), lactic acid (LA), phosphagen (PC) content.
The impact (x ± s, μ mol/g, n=10) of table 41 salvianolic acid A freeze-dried powder on the rats after cerebral ischemic reperfusion Energy Metabolism of Brain Tissue
Annotate: compare * P<0.01 with sham operated rats; Compare * * P<0.01, ☆ P<0.05 with model group
ATP, ADP, AMP, LA, PC are the human body energy metabolite.By table 39 experimental data, can be found out, model group ATP, ADP, AMP, PC than sham operated rats significantly reduce, LA significantly raise (P<0.01), rat cerebral ischemia tissues following MCAO in rats energy metabolism serious hindrance is described, ATP exhausts fast, brain-capacity is supplied with significantly and is reduced, anaerobic metabolism product LA piles up serious, even after implementing to fill with, the energy metabolism disorder still exists again.And each administration group is compared with model group, cerebral tissue ATP content extremely significantly raise (P<0.01), LA significantly reduces, result shows can the raise content of cerebral tissue ATP, ADP, AMP, PC of salvianolic acid A freeze-dried powder, reduce cerebral tissue LA content, can significantly improve the energy metabolism of rat cerebral ischemia and ischemia-reperfusion.Prompting salvianolic acid A freeze-dried powder can be by improving the energy metabolism of Neurons Against Cerebral Ischemia tissue, increase the supply of cerebral tissue energy matter, strengthen the survival ability of brain cell, the brain cell that ischemia half blanking bar after the redemption cerebral ischemia is at death's door, further damage is even dead to prevent cerebral tissue, and action effect is obvious than salvianolic acid A monomeric compound and nimodipine, can perform well in treating ischemic cerebrovascular.
The impact of experimental example 28 salvianolic acid A freeze-dried powders on rats after cerebral ischemic reperfusion cerebral tissue neuronal apoptosis rate
Prepare rat pattern of ischemia reperfusion, grouping, administration with experimental example 23 methods.After rat cerebral ischemia 2h fills with 24h again, broken end is got brain, with 4% paraformaldehyde, fix, and section, paraffin embedding, prepare the thick crown section of thick 3 μ m; Adopt the transferase mediated dUTP breach end-labelling (TUNEL method) of last deoxyribonucleic eventually to detect the cerebral tissue neurocyte, strictly press the operation of test kit description, the DAB colour developing, under light microscopic, apoptotic nucleus is brown.Unduplicated 5 high powers (40 * 10) visual field is chosen in every section at random, and the input computer carries out image analysis, detects apoptotic cell number and the normal cell number of the TUNEL positive, calculates the neuronal apoptosis rate, results averaged.
The impact of table 42 salvianolic acid A freeze-dried powder on rats after cerebral ischemic reperfusion cerebral tissue neuronal apoptosis rate
Compare #P<0.001 with sham operated rats; Compare * * P<0.001, * P<0.01 with model group
Neuronal apoptosis is the principal mode of cerebral ischemia and transient ischemia/reperfusion damage delayed neuronal death, can determine the brain tissue impairment degree that ischemic cerebrovascular is final.The experimental result demonstration, after rat cerebral ischemia 2h fills with 24h again, neuronal apoptosis is serious; And after nimodipine, salvianolic acid A monomeric compound and the intervention of various dose salvianolic acid A freeze-dried powder, with model group, compare, in rat cerebral tissue, neuronal apoptosis significantly reduces (P<0.001 or P<0.01), and minimum with the apoptosis rate of high, the middle dosage group of salvianolic acid A freeze-dried powder; Show that the salvianolic acid A freeze-dried powder has the inhibition neuronal apoptosis, suppresses the effect that cerebral ischemia causes rat cerebral tissue's neuronal death, effect is better than salvianolic acid A monomeric compound and nimodipine.
The impact of experimental example 29 salvianolic acid A freeze-dried powders on rats after cerebral ischemic reperfusion cerebral tissue neurotrophic factor
Prepare rats after cerebral ischemic reperfusion model, grouping administration with experimental example 28 methods.Ischemia Reperfusion 24h is by aortic cannulation, normal saline flushing, after 4% paraformaldehyde perfusion, broken end is got brain, cerebral tissue is fixed, dehydration, paraffin embedding, section, thick approximately 5 μ m, Immunohistochemical Method detects neurotrophic factor nerve growth factor (NGF), Brain Derived Neurotrophic Factor (BDNF), neurotrophic factor-3 (NT-3) protein expression in rat cerebral tissue; Replace the negative contrast of primary antibodie with PBS; With endochylema, after birth, the aixs cylinder of cell be brown or brown yellow granule into immunity positive.Under light microscopic, observe, Cai Tu also uses the image analysis system analysis, measures its average gray value.Average gray is higher, means that the intensity of positive cell is more weak.
The impact of table 43 salvianolic acid A freeze-dried powder on rat cerebral tissue's neurotrophic factor protein expression (gray value)
The neurotrophic factor histone matter molecule essential with survival that be neure growth, play supporting function to the integrity of neure growth, growth and function.NGF, BDNF, NT-3 are the parts of neurotrophic factor family, can maintain neuronal survival and promote the neurocyte differentiation and induce axon growth; Energy neuroprotective unit, promotion neuron reparation and inhibition delayed neuronal death, thereby to anti-cerebral ischemia, protection cerebral ischemia.Experimental result shows, after Ischemia Reperfusion, rat cerebral tissue in, NGF, BDNF express and increase to some extent than sham operated rats, and after the prompting cerebral reperfusion injury, in cerebral tissue, express stress the protectiveness increase for NGF, BDNF; But in the Neurons Against Cerebral Ischemia tissue, NT-3 content obviously reduces.With model control group, compare, each dosage group of salvianolic acid A freeze-dried powder NGF, BDNF, NT-3 protein expression all obviously strengthen (P<0.05 or P<0.01), and the trend that is better than same dosage salvianolic acid A monomeric compound and nimodipine is arranged.Prompting salvianolic acid A freeze-dried powder can strengthen the expression of ischemic injuries cerebral tissue endogenous neurotrophic factor NGF, BDNF, NT-3, for neuronal survival provides condition, and reaches the effect of neuro-protective.
The impact of experimental example 30 salvianolic acid A freeze-dried powders on the rats after cerebral ischemic reperfusion inflammatory cytokine
Prepare rats after cerebral ischemic reperfusion model, grouping administration with experimental example 28 methods.Break end and get brain rapidly after Ischemia Reperfusion 24h, get ischemia side cerebral tissue and make 10% tissue homogenate, the centrifugal 10min of low temperature 2000r/min, get supernatant, use the content of each inflammatory cytokine of ELISA kit measurement: interleukin-1 ' beta ' (IL-1 β), interleukin-6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor (TNF-α), intercellular adhesion molecule-1 (ICAM-1).
The impact of table 44 salvianolic acid A freeze-dried powder on the rats after cerebral ischemic reperfusion inflammatory cytokine
Compare #P<0.001 with sham operated rats; Compare Δ P<0.01, * P<0.05 with model group.
The experimental result demonstration, after ischemia-reperfusion, in cerebral tissue, inflammatory cytokine IL-1 β, IL-6, IL-8, TNF-α, ICAM-1 content all extremely significantly increase (P<0.001); Each inflammatory cytokine content of rat cerebral tissue that gives each dosage group of salvianolic acid A freeze-dried powder obviously reduces than model group, and salvianolic acid A monomeric compound group and the nimodipine group with dosage is remarkable.Prompting salvianolic acid A freeze-dried powder can suppress the expression of ischemic injuries brain tissue inflammation cytokine, suppress the generation of brain tissue inflammation's reaction, suppress neuron and the cerebral tissue cascade damage of inflammatory reaction mediation, effect is better than salvianolic acid A monomeric compound and nimodipine.
Experimental example 31: the salvianolic acid A freeze-dried powder is to rats after cerebral ischemic reperfusion cerebral tissue Ca
2+, K
+, Mg
2+the impact of content
Get experimental example 24 and dry the cerebral tissue to constant weight, after weighing, proceed to conical flask, use analytical pure nitric acid and perchloric acid in (200 ± 10) ℃ digestion, add the deionized water dissolving residue, after proceeding to color comparison tube standardize solution, with atomic spectrophotometer, survey Ca in cerebral tissue
2+, K
+, Mg
2+content.Data are carried out statistical analysis.
Table 45 salvianolic acid A freeze-dried powder is to rats after cerebral ischemic reperfusion cerebral tissue Ca
2+, K
+, Mg
2+the impact of content (x ± s)
Annotate: compare * P<0.01 with sham operated rats; Compare * P<0.05, * * P<0.01 with model group
Ca in cell
2+overload is one of encephaloclastic important mechanism of mediation Secondary cases in During Ischemia, is the last common pathway that ischemia, anoxia produce irreversible neuronal damage.Ca
2+overload can be by exciting activator protein enzyme as the second message,second messenger, activate phospholipase, activate a series of enzyme reactions such as endonuclease produces infringement to cell, and cell death inducing, cause acute cell death and Delayed onset neuronal necrosis.K
+, Mg
2+be Ca
2+antagonist.K
+as the requisite cation of neurocyte polarized state, can suppress calcium ion in flow to and alleviate calcium overload; Mg
2+can activate plurality of enzymes system in body, participate in the multiple important metabolic activity of cell in cerebral tissue, conduction, ion transport, the synthetic all many-sides of energy metabolism that reach of albumen affect the nerves, the spasm of energy alleviating vascular smooth muscle, improve microcirculation, improve hypoxic-ischemic after brain injury, calcium overload in retardance after craniocerebral injury neurocyte.From experimental data, cerebral ischemia re-pouring model group and sham operated rats be cerebral tissue Ca relatively
2+content extremely significantly increases, K
+, Mg
2+content significantly reduces; With model group, compare, each dosage group of nimodipine group, salvianolic acid A monomeric compound group and salvianolic acid A freeze-dried powder can significantly reduce Ca in cerebral tissue
2+content, rising K
+, Mg
2+content, and the most remarkable with salvianolic acid A freeze-dried powder effect.Illustrate that the salvianolic acid A freeze-dried powder can suppress Ca
2+interior stream alleviates calcium overload, thereby can suppress Ca
2+the neuronal cell apoptosis that overload is induced.
Experimental example 32: the impact of salvianolic acid A freeze-dried powder on rats after cerebral ischemic reperfusion cerebral tissue neurotransmitter
1 experimental technique
1.1 grouping administration and model preparation
Male SD rat (250 ± 20) g, be divided at random 7 groups, every group 30: sham operated rats, cerebral ischemia re-pouring model control group, the high, medium and low dosage of salvianolic acid A freeze-dried powder (10mg/kg, 5mg/kg, 2.5mg/kg) group, salvianolic acid A monomeric compound group (10mg/kg), nimodipine matched group (10mg/kg).Adopt re-perfusion model (as described in experimental example 23) after the standby middle cerebral artery occlusion in rat 2h of line bolt legal system, sham operated rats except plug wire not, the same model group of all the other operating process.Each group 30min and each is administered once through tail vein injection when perfusion starts again before ischemia, sham operated rats and cerebral ischemia re-pouring model group give the normal saline of same volume.After filling with 2h again, each group is got 4 broken ends and is got brain and do histopathology section, and HE dyeing, observe histopathology and change.
1.2 the mensuration of rat cerebral tissue's monoamine neurotransmitters
Each organizes rat after ischemia 2h pours into 2h again, respectively get 8, broken end is got brain fast, separate cerebral cortex and striatum, weigh, add n-butyl alcohol homogenate, the centrifuging and taking supernatant is used fluorescent spectrophotometer assay 5-hydroxy tryptamine (5-HT), norepinephrine (NE), dopamine (DA) content after carrying.Data are carried out statistical analysis, the results are shown in Table 46.
1.3 the mensuration of rat cerebral tissue's content of amino acids neurotransmitter
Each organizes rat after ischemia 2h pours into 2h again; respectively get 8; broken end is got brain fast; broken end is got brain; sharp separation ischemia side cerebral cortex in ice bath; weigh; put in homogenizer; make homogenate with sulfosalicylic acid; centrifugal, get supernatant, dilution; after the OPA derivative reaction, detect the content of amino acid neurotransmitter glutamic acid (Glu), aspartic acid (Asp), glycine (Gly), γ-aminobutyric acid (GABA), taurine (Tau) in brain tissue homogenate's supernatant by high performance liquid chromatography.Mobile phase is a certain proportion of potassium phosphate buffer and methanol, tetrahydrofuran solution, and pH is about 6.6, flow velocity 1ml/min.Calculate excitatory toxicity index (EI): EI=[Glu] [Gly]/[GABA].Data are carried out statistical analysis, the results are shown in Table 47.
2 experimental results
2.1 histopathology observed result
Sham operated rats structure of neurons, form be normal, without the interstitial edema; Ischemia-reperfusion group neuronal cell volume dwindles, distortion, karyopycnosis, and nervous tissue is loose, and neuron and perivascular space increase, and the interstitial cerebral edema is obvious; Each administration group is compared with model group, and cerebral edema obviously alleviates, and the neuronal cell form is obviously improved, and neuron peripheral clearance is obviously dwindled; Especially the most remarkable with high, the middle dosage group of salvianolic acid A freeze-dried powder, its neuronal cell is more complete, the form normal.
2.2 the impact of salvianolic acid A freeze-dried powder on monoamine neurotransmitter in the rats after cerebral ischemic reperfusion cerebral tissue
With sham operated rats, compare, cerebral ischemia re-pouring group rat cerebral cortex and striatum NE, DA, 5-HT content all significantly reduce (P<0.01).Compare each administration group rat cerebral cortex, striatum NE, DA, 5-HT content obviously raise (P<0.01 or P<0.05) with the cerebral ischemia re-pouring model group.
The impact (x ± s, ng/mg, n=8) of table 46 salvianolic acid A freeze-dried powder on monoamine neurotransmitter in the rats after cerebral ischemic reperfusion cerebral tissue
Annotate: compare * P<0.01 with sham operated rats; Compare * P<0.05, * * P<0.01 with model group
2.3 the impact of salvianolic acid A freeze-dried powder on amino acid neurotransmitter in the rats after cerebral ischemic reperfusion cerebral tissue
With sham operated rats, compare, in cerebral ischemia re-pouring model group rat cerebral cortex, the content of Glu, Asp, Gly, GABA, Tau all has remarkable increase (P<0.01 or P<0.05); With model group, compare, in each administration group cerebral tissue, Glu, Asp, Gly all significantly reduce (P<0.01 or P<0.05), Tau content significantly raise (P<0.01 or P<0.05); Except the GABA content of salvianolic acid A freeze-dried powder low dose group and nimodipine group slightly raises than model group, difference does not have outside statistical significance, GABA content significantly raise (P<0.01) in other each administration group cerebral tissue.Cerebral ischemia re-pouring model group EI value has extremely significantly and increases (P<0.01) than sham operated rats, and the EI value of each administration group obviously reduces (P<0.01 or P<0.05) than model group, and high, the middle dosage group of salvianolic acid A freeze-dried powder is the most remarkable.
The impact (x ± s, n=8) of table 47 salvianolic acid A freeze-dried powder on amino acid neurotransmitter in the rats after cerebral ischemic reperfusion cerebral tissue
Annotate: compare * P<0.01, ※ P<0.05 with sham operated rats; Compare * P<0.05, * * P<0.013 conclusion with model group
Monoamine neurotransmitter disorder and toxicity of excitatory amino acid play an important role in ischemic brain injury, acute cerebral ischemia cell death, reperfusion injury and delayed neuronal death.During cerebral ischemia, monoamine neurotransmitters significantly raises in extracellular fluid, and reduces in brain essence.In cerebral tissue ischemia equivalent damage situation, monoamine neurotransmitter generation metabolism disorder in brain, NE, DA and 5-HT content obviously reduce, and cerebral ischemia is heavier, and cerebral tissue NE, DA, 5-HT content are just lower.Glu and Asp are the important excitatory neurotransmitters of brain, and GABA and Gly are the important inhibitory neurotransmitters of brain, and Tau, as a kind of neuromodulator, has protective effect in cerebral ischemia.During cerebral ischemia in brain amino acid neurotransmitters excited-to suppress unbalance be one of key factor of causing cerebral ischemia.This experimental result shows that the salvianolic acid A freeze-dried powder can obviously improve the cerebral cortex of cerebral ischemia-reperfusion injury in rats and the content of striatum monoamine transmitters, GABA, Tau content, the content that significantly reduces Glu in cerebral tissue, Asp, Gly and aminoacid exitotoxicity index in rising cerebral ischemia/reperfusion injury of rats cerebral tissue.And dosage increases, effect strengthens, and effect has advantage with dosage salvianolic acid A monomeric compound and nimodipine.The salvianolic acid A freeze-dried powder shown in conjunction with the histopathology pathological examination can obviously alleviate cerebral edema, improves the result of neuronal cell form, shows that the salvianolic acid A freeze-dried powder can suppress monoamine neurotransmitter and excessively discharge, and improves the monoamine neurotransmitter disorder; Suppress the accumulation of excitatory amino acid in cerebral ischemia re-pouring, stablize the balance of excitatory amino acid-inhibitory aminoacid mediator, alleviate toxicity of excitatory amino acid; Thereby suppress the neuronal cell apoptosis that monoamine neurotransmitter is disorderly and toxicity of excitatory amino acid is induced.
Experimental example 33: the impact of salvianolic acid A freeze-dried powder on LPO, SOD, GSH-Px in the rats after cerebral ischemic reperfusion cerebral tissue
10 remaining rats after each group detects under 32 of experimental examples, broken end is got brain, weigh, make brain tissue homogenate's liquid of 10% with 4 ℃ of normal saline, centrifugal, remove supernatant, measure the activity of lipid peroxide contents (LPO), superoxide dismutase (SOD) and glutathion peroxidase (GSH-Px).Result is carried out statistical analysis.
The impact (x ± s, n=10) of table 48 salvianolic acid A freeze-dried powder on LPO, SOD, GSH-Px in the rats after cerebral ischemic reperfusion cerebral tissue
Annotate: compare * P<0.01 with sham operated rats; Compare * P<0.05, * * P<0.01 with model group
In cerebral ischemia re-pouring model group rat cerebral tissue, LPO content significantly raises than sham operated rats, and SOD and GSH-Px activity significantly reduce (P<0.01) than sham operated rats.When Cerebral ischemia and reperfusion is described, the brain tissue oxygen free radical sharply increases, and the integrity of infringement membrane structure and function causes lipid peroxidation, produces a large amount of lipid peroxide; And the free radical scavenging enzymatic activity significantly lowers; Therefore the dynamic equilibrium heavy damage of free-radical generating and removing.Free radical toxicity chain reaction meeting accelerator nerve units apoptosis, increase the weight of cerebral ischemia.Experimental result shows, each dosage group of salvianolic acid A freeze-dried powder is compared with model group, and in rat cerebral tissue, LPO content significantly reduces, and lower than the salvianolic acid A monomeric compound group of same dosage; SOD and GSH-Px are active significantly to raise (P<0.01 or P<0.05), and the trend higher than same dosage salvianolic acid A monomeric compound group is arranged, and effect is obvious than the nimodipine group; Experimental result shows that the salvianolic acid A freeze-dried powder can increase the generation of the activity of peroxide scavenger enzyme in the ischemical reperfusion injury cerebral tissue, inhibition peroxide, thereby the damage to antioxidant radical to neuronal cell and cerebral tissue, its antioxidation has the trend of the salvianolic acid A monomeric compound that is better than same dosage.
Experimental example 34: the salvianolic acid A freeze-dried powder is protected RHRSP cerebral thrombosis Neurons Against Cerebral Ischemia vascular endothelial cell
Prepare RHRSP Cerebrovascular embolism model, grouping with experimental example 16 methods.The administration volume tail vein injection administration that each group is pressed immediately 0.3ml/100g after model preparation operation, after this every day the tail intravenously administrable once, continue to and draw materials.Sham operated rats, the postoperative tail vein injection saline of model control group; The postoperative tail vein injection salvianolic acid A respectively of the high, medium and low dosage group of salvianolic acid A freeze-dried powder freeze-dried powder 40mg/kg, 20mg/kg, 10mg/kg; Salvianolic acid A monomeric compound group injection salvianolic acid A monomeric compound 20mg/kg, nimodipine group injection nimodipine 20mg/kg.Each group is got rat respectively at the postoperative 6h of MCAO, 12h, 24h, 48h, 72h time point and is poured into 4% paraformaldehyde neutral buffered solution through heart, gets brain.Conventional fixing, the dehydration paraffin embedding of cerebral tissue, be cut into the thick crown section of 5um continuously.TUNEL method (the dUTP breach end-labelling of deoxyribose nucleotides terminal transferase mediation) detects vascular endothelial cell.Press the operation of TUNEL cell apoptosis detection kit (Wuhan doctor's moral biological reagent company) description, DAB colour developing, observed result under optical microscope.Nucleus the brown yellow granule the occurs positive apoptosis endotheliocyte of person.Each specimen random observation volume top and Striatum and Basal ganglia under * 400 times of mirrors have blood vessel but nonoverlapping 10 visuals field, calculate its TUNEL positive vessels endotheliocyte sum, i.e. apoptosis cell.Data are carried out the statistical analysis processing.
The impact (x ± s) of table 49 salvianolic acid A freeze-dried powder on RHRSP cerebral thrombosis Neurons Against Cerebral Ischemia apoptosis of vascular endothelial cell
Annotate: compare #P<0.01 with sham operated rats; Compare * P<0.01 with model group
Experimental result shows, the cerebrovascular endothelial cell apoptosis number of each time period of model group is significantly higher than sham operated rats (P<0.01), 6h after the cerebral tissue ischemia, and endothelial cell apoptosis is showed increased just, to ischemia, within 24 hours, reaches peak.With model group, compare, the apoptosis digital display work of each time period of each dosage group of salvianolic acid A freeze-dried powder reduces (P<0.01), and is less than salvianolic acid A monomeric compound and the nimodipine group of same dosage.Prompting salvianolic acid A freeze-dried powder can suppress cerebral ischemia hindbrain apoptosis of vascular endothelial cell, improve the cerebrovascular endothelial cell survival rate, thereby guarantee the normal of cerebrovascular endothelial cell function, maintain the complete of ischemic injuries hindbrain blood vessel structure and function and strengthen the ability to anti-cerebral ischemia damnification, the effect of performance treatment ischemic cerebrovascular.
Experimental example 35: the shadow noon of salvianolic acid A freeze-dried powder to anoxia and Hypoxia/Reoxygenation Injury Brain Microvascular Endothelial (BMVEC) survival rate
The SD rat of the about 100g of male body weight, after broken end, get brain after alcohol disinfecting, peel off pia mater encephali and macroscopic trunk, remove cerebral white matter and cerebellum, thereafter, shred cerebral tissue, homogenate, cross successively 90,180 mesh filter screens and filter, rinse and collect the blood capillary section on filter screen, add the 0.1%II collagenase, 37 ℃ of digestion 15min, the centrifugal 5min of 1500r/min, repeat 3 times, precipitation is inoculated in culture bottle and continues to cultivate after suspending with culture fluid, every 2d, changes liquid 1 time.Treat that cell grows up to the fusion state, identify through Morphological Identification and VIII factor SABC, be defined as Brain Microvascular Endothelial (BMVEC), purity is greater than 98%.The cultivation of being gone down to posterity.Get third generation BMVEC, make single cell suspension after digestion, be inoculated in 96 orifice plates.Experiment divides 8 groups: model group, 6 dosage groups of salvianolic acid A freeze-dried powder (final concentration is respectively 10,20,30,40,50,60 μ mol/L), salvianolic acid A monomeric compound group (final concentration 30 μ mol/L) and nimodipine group (final concentration is 30 μ mol/L).After the cell inoculation, second day, change culture fluid into PBS liquid, is positioned over (37 ℃, 95%N in the anoxia tank
2, 5%CO
2) effect 4h, cause BMVEC anoxia-induced apoptosis (simulated ischemia); Change again common culture fluid into and normally cultivate 12h, cause BMVEC Hypoxia/Reoxygenation Injury (simulated ischemia-fill with again).Each dosage group of nimodipine group, salvianolic acid A monomeric compound group and salvianolic acid A freeze-dried powder all adds respectively the medicine of respective concentration when 4h, anoxia and reoxygenation before modeling.Detect with mtt assay the survival rate of respectively organizing BMVEC respectively after anoxia-induced apoptosis 4h, anoxia 4h-reoxygenation 12h damage.
The impact (x ± s, n=6) of table 50 salvianolic acid A freeze-dried powder on the BMVEC survival rate of anoxia and Hypoxia/Reoxygenation Injury
Compare #P<0.05, * P<0.01 with model control group; With comparison before reoxygenation, ☆ P<0.01; With the nimodipine group, compare, Δ P<0.05,
Experimental result shows, after anoxia 4h damage, the BMVEC survival rate is only 25.45% left and right, cell injury occurred after anoxia is described; The survival rate of nimodipine group 30 μ mol/L and salvianolic acid A monomeric compound 30 μ mol/L and salvianolic acid A freeze-dried powder 10,20,30 μ mol/L processed group and the trend that model group relatively has rising, but significant difference do not shown; After salvianolic acid A freeze-dried powder 40,50,60 μ mol/L dosage group anoxia-induced apoptosis 4h, the BMVEC survival rate is significantly higher than model control group (P<0.05).After Hypoxia/Reoxygenation Injury, the BMVEC survival rate is only 13.22% left and right, with comparison before reoxygenation, significantly reduces (p<0.01), illustrates that hypoxia/reoxygenation has aggravated cell injury; After each drug effect, the BMVEC survival rate significantly raises (P<0.01), with salvianolic acid A freeze-dried powder 30,40,50,60 μ mol/L dosage group best results; And salvianolic acid A freeze-dried powder 20,30,40,50,60 μ mol/L dosage group survival rates are significantly higher than nimodipine 30 μ mol/L group (P<0.05, or P<0.01), salvianolic acid A freeze-dried powder 30 μ mol/L dosage groups are also higher than the cell survival rate of the salvianolic acid A monomeric compound group with dosage.Prompting salvianolic acid A freeze-dried powder can be protected microvascular endothelial cells oxygen and Hypoxia/Reoxygenation Injury; strengthen its hypoxia-bearing capability; improve the brain microvessel endothelial cells in vitro survival rate of anoxia-induced apoptosis and Hypoxia/Reoxygenation Injury, and be better than nimodipine and salvianolic acid A monomeric compound.
The impact of experimental example 36 salvianolic acid A freeze-dried powders on Hypoxia/Reoxygenation Injury Brain Microvascular Endothelial (BMVEC) apoptosis
Method by experimental example 35: third generation BMVEC is inoculated in 96 orifice plates, experiment divides 7 groups: Normal group, model group, the high, medium and low dosage group of salvianolic acid A freeze-dried powder ( final concentration 40,20,10 μ mol/L), salvianolic acid A monomeric compound group (final concentration 20 μ mol/L), nimodipine group (final concentration 40 μ mol/L).Modeling and medication are with experimental example 35.Normal group does not carry out the hypoxia/reoxygenation processing, by normal method, cultivates corresponding experimental period.Each porocyte of trypsinization, centrifugal collecting cell, adopt phosphatidyl in conjunction with albumen-Fluorescein isothiocyanate/propidium iodide (Annexin V-FITC/PI) dyeing, uses the cells were tested by flow cytometry cell in early days and the apoptosis rate in late period.
Table 51 salvianolic acid A freeze-dried powder causes the impact (x ± s, n=6) of BMVEC apoptosis on Hypoxia/Reoxygenation Injury
Compare #P<0.01 with Normal group; Compare * P<0.01, * * P<0.001 with model group; With the nimodipine group, compare, Δ P<0.01,
Apoptosis especially plays an important role at ischemia injury in the transient ischemia/reperfusion damage.The apoptosis of vascular endothelial cell can cause the destruction of vascular integrity, and the angiolysis damage is the basis of cerebrovascular; The apoptosis of brain microvessel endothelial cells in vitro can affect the integrity of blood brain barrier and the secretory function of vascular endothelial cell, and then increases the weight of ischemic brain injury.By experimental result, shown, Hypoxia/Reoxygenation Injury, can cause each phase apoptosis rate of BMVEC significantly to increase.With model group relatively, each medicine group all can significantly lower cell early, late period and total apoptosis rate (P<0.01); Be certain dose-effect relationship between each dosage group of salvianolic acid A freeze-dried powder.And salvianolic acid A freeze-dried powder 10 μ mol/L dosage groups are suitable with nimodipine 40 μ mol/L dosage group effects, with the salvianolic acid A freeze-dried powder of dosage, be better than the salvianolic acid A monomeric compound.Prompting salvianolic acid A freeze-dried powder has the effect of the BMVEC apoptosis that good anti-hypoxia-reoxygenation injury causes.
Experimental example 37 salvianolic acid A freeze-dried powders affect Hypoxia/Reoxygenation Injury Brain Microvascular Endothelial (BMVEC) secretory function
As described in experimental example 35, third generation BMVEC is inoculated in 96 orifice plates to preparation BMVEC hypoxia/reoxygenation model.Grouping and administration are with experimental example 36.The collecting cell supernatant, the ELISA method detects the impact of salvianolic acid A freeze-dried powder on BMVEC secretory tissue fiber proenzyme activator (t-PA), tissue plasminogen activator's inhibitor (PAI), nitric oxide (NO), Endothelin (ET).
Table 52 salvianolic acid A freeze-dried powder is on Hypoxia/Reoxygenation Injury (BMVEC) secretory function impact (x ± s, n=6)
After Hypoxia/Reoxygenation Injury, with normal group, compare, BMVEC secretion t-PA and NO obviously reduce, and ET raises, and t-PA/PAI and NO/ET ratio also significantly descend.The t-PA of each medicine group and NO secretory volume significantly raise (P<0.01 or P<0.001) than model group, and wherein the middle and high dosage group of salvianolic acid A freeze-dried powder rises to the Normal group level that approaches; Each administration group t-PA/PAI and NO/ET ratio ratio also significantly improve than model group.Prompting salvianolic acid A freeze-dried powder can improve the secretory function of brain microvessel endothelial cells in vitro after Hypoxia/Reoxygenation Injury, and action effect significantly is better than nimodipine, and the trend that is better than same dosage salvianolic acid A monomeric compound is arranged.
Experimental example 38 salvianolic acid A freeze-dried powders are to the interior Ca of Hypoxia/Reoxygenation Injury Brain Microvascular Endothelial (BMVEC)
2+the impact of concentration
As described in experimental example 35, third generation BMVEC is inoculated in 96 orifice plates to preparation BMVEC hypoxia/reoxygenation model.Grouping and administration are with experimental example 36.Each porocyte of trypsinization, after centrifugal collecting cell, add Fluo-3 (a kind of calcium fluorescent probe, final concentration is 5 μ mol/L), hatches 45min for 37 ℃, and PBS liquid rinses 3 times, uses the cells were tested by flow cytometry fluorescence intensity.Almost there is no fluorescence while existing with the free ligand form because of Fluo-3, and and Ca
2+strengthen in conjunction with rear fluorescence, can detect Cytoplasmic Ca according to fluorescence intensity change
2+concentration change.
Table 53 salvianolic acid A freeze-dried powder is to Ca in Hypoxia/Reoxygenation Injury BMVEC
2+the impact of concentration (x ± s, n=6)
Compare #P<0.01 with Normal group; Compare * P<0.01 with model group; With the nimodipine group, compare,
The experimental result demonstration, after Hypoxia/Reoxygenation Injury, Ca in BMVEC born of the same parents
2+concentration significantly increases (P<0.01).Compare each medicine group Ca with model group
2+concentration extremely significantly reduces, and the middle and high dosage group of salvianolic acid A freeze-dried powder intracellular calcium concentration is significantly lower than nimodipine 40 μ mol/L dosage groups (P<0.05), and is better than the salvianolic acid A monomeric compound of same dosage.Prompting salvianolic acid A freeze-dried powder has and suppresses preferably Hypoxia/Reoxygenation Injury and cause Ca in BMVEC born of the same parents
2+the effect of concentration.
Experimental example 39: the impact of salvianolic acid A freeze-dried powder on the rat artery thrombus formation time
Get the SD rat, male and female half and half, body weight is 250~300g, is divided at random matched group, salvianolic acid A monomeric compound group (2.5mg/kg), aspirin group (20mg/kg) and the high, medium and low dosage of salvianolic acid A freeze-dried powder (12.5,2.5,0.5mg/kg) group.Each organizes tail intravenously administrable 1 time every day (matched group gives the isometric(al) normal saline), continuously after 7d, 30min after the last administration, pentobarbital sodium (40mg/kg) anesthetized rat, dorsal position is fixed on the Mus plate, the cervical region median incision, separate the about 15mm of right carotid, the stimulating electrode and the temperature sensor probe that thrombus in vivo are formed to analyzer are placed on common carotid artery, stimulating electrode is positioned at proximal part, with 2mA galvanism blood vessel 7min, makes the tunica intima damage, record is because of the time of thrombosis blocking blood flow in arterial lumen, i.e. thrombus formation time (OT).Experimental data statistical result is in Table 54.
The impact of table 54 salvianolic acid A freeze-dried powder on the rat artery thrombus formation time
Annotate: compare * P<0.01 with the normal saline group
Experimental result shows, compares the thrombus formation time significant prolongation (P<0.01) of salvianolic acid A freeze-dried powder 12.5,2.5,0.5mg/kg dosage group with the normal saline matched group; Low dose group thrombus formation time and 20mg/kg aspirin group be (P>0.05) quite; Middle dosage group extends than the salvianolic acid A monomeric compound group thrombus formation time with dosage; Between high, medium and low dosage group, thrombus formation time has significant difference (P<0.05).Show that the salvianolic acid A freeze-dried powder can extend thrombus formation time, the formation of prevention of arterial thrombosis, pre-preventing thrombosis and the ischemic cerebrovascular that causes.
Experimental example 40: the salvianolic acid A freeze-dried powder is to thrombotic inhibitory action
The SD rat, male and female half and half, grouping, administration are with experimental example 39.30min pentobarbital sodium anesthesia after the last administration, dorsal position is fixed, and right common carotid artery and left external jugular vein are isolated in operation, with three sections polyethylene tubes, connect.Put into the long 5cm operation silk thread of having weighed in the polyethylene tube stage casing.Be full of polyethylene tube with heparin-saline solution (5u/mL).One end of pipe inserts left external jugular vein, and the other end is connected with right common carotid artery.Open bulldog clamp, blood returns to left jugular vein by the right carotid polyethylene tube of flowing through.Herba Clinopodii in after open blood flow 15min, take out rapidly silk thread, and filter paper sucks supernatant blood, weighs, and gross weight subtracts line and heavily obtains wet weight of thrombus; Then put in 60 ℃ of baking ovens freeze-day with constant temperature to constant weight, weigh after cooling, be the thrombosis dry weight.Experimental data is in Table 55.
The inhibitory action that table 55 salvianolic acid A freeze-dried powder forms rat suppository
Annotate: compare * P<0.01 with the normal saline group
Experimental data shows, with the normal saline group, compares, and salvianolic acid A freeze-dried powder 12.5,2.5,0.5mg/kg dosage group rat suppository wet, dry weight all significantly alleviates (P<0.01), between each dosage group, have dose-effect relationship preferably.And low dose group and 20mg/kg aspirin group effect be (P>0.05) quite.The salvianolic acid A freeze-dried powder of prompting in the present invention has the thrombotic effect of good inhibition, can or treat the ischemic cerebrovascular due to thrombosis for prevention, and than salvianolic acid A monomeric compound successful.
Experimental example 41: the impact of salvianolic acid A freeze-dried powder on the rat vein thromboembolism
Male SD rat, body weight (200 ± 20) g, divide into groups with experimental example 39, pentobarbital sodium (40mg/kg) anesthetized rat, along abdominal part medisection rat stomach wall, open abdominal cavity, separate postcava, and in left renal vein lower end level place ligation postcava, close abdominal cavity, closed abdominal cavity, after 1h, the tail vein injection administration; Reopen abdominal cavity after 3h, in 2cm place, ligation below, folder closes blood vessel, the vein of ligation simultaneously side shoot, and blood vessel is cut in stringer open, exhausts the tube chamber inner blood, removal of thromboses, filter paper sops up residual blood, takes immediately wet weight of thrombus; After putting afterwards the interior freeze-day with constant temperature of 60 ℃ of baking ovens, claim the thrombosis dry weight.Test data is in Table 56.
The impact of table 56 salvianolic acid A freeze-dried powder on the rat vein thromboembolism
Annotate: compare * P<0.01 with the normal saline group
Experimental data shows, with the normal saline group, compare, salvianolic acid A freeze-dried powder 12.5,2.5,0.5mg/kg dosage group rat vein thrombosis wet, dry weight significantly alleviates (P<0.01), and low dose group and 20mg/kg aspirin group effect be (P>0.05) quite; Middle dosage group is with the salvianolic acid A monomeric compound successful of dosage.Show that the salvianolic acid A freeze-dried powder has the effect that suppresses preferably venous thrombosis, can be used for the venous thromboembolism after the prophylaxis of acute ischemic cerebrovascular occurs.
Experimental example 42: the salvianolic acid A freeze-dried powder is to the thrombotic inhibitory action of rats in vitro
The SD rat, 250~300g, male and female half and half; Random minute physiology saline group, salvianolic acid A monomeric compound group (2.5mg/kg), aspirin group (20mg/kg) and the high, medium and low dosage of salvianolic acid A freeze-dried powder (12.5,2.5,0.5mg/kg) group, each is organized the every day tail vein injection and gives and relative medicine 1 time, continuous 7 days; 30min after the last administration, pentobarbital sodium anesthesia, open abdominal cavity along ventrimeson, the about 1.5mi of abdominal aortic blood injects the silication sebific duct, by the docking of silica gel tube two ends circlewise, the silica gel sheath seal of tube is fixed rapidly, puts 37 ℃ of constant temperature rotation 15min on extracorporeal thrombosis forming device, removal of thromboses, measure thrombosis length, claim its weight in wet base; Survey its dry weight after drying in 60 ℃ of calorstats.Experimental data is in Table 57.
Table 57 salvianolic acid A freeze-dried powder is to the thrombotic inhibitory action of rats in vitro (x ± s)
Annotate: compare * P<0.01 with the normal saline group
Experimental data shows, with the normal saline group, compare, salvianolic acid A freeze-dried powder 12.5,2.5, the thrombotic length of 0.5mg/kg dosage group rats in vitro significantly shorten (P<0.01), thrombosis is wet, dry weight significantly alleviates (P<0.01), and low dose group and 20mg/kg aspirin group effect be (P>0.05) quite; Experiment shows that the salvianolic acid A freeze-dried powder forms and has inhibitory action preferably external thrombus, and the trend that is better than same dosage salvianolic acid A monomeric compound is arranged.
Experimental example 43: the thrombolytic experimental study of salvianolic acid A freeze-dried powder to established thrombosis in body
SD male rat (250 ± 20) g, pentobarbital sodium intraperitoneal anesthesia rat, separate left common carotid artery with the unidirectional current continued stimulus rat artery of 2mA 7 minutes, with blood flowmeter continuous probe Flow of carotid artery.Reduce to 50% before stimulating with blood flow after stimulate finishing and be considered as thrombosis.Minutes 6 groups at random of animals, normal saline group, urokinase (2000U/kg) group, salvianolic acid A monomeric compound (5mg/kg) group and the high, medium and low dosage of salvianolic acid A freeze-dried powder (10,5,2.5mg/kg) group; Each group is 20min after forming thrombosis, all through the disposable injection relative medicine of femoral vein, and revascularization situation in 1h after the observation administration; If revascularization in this period, continue to observe vessel open state 1h.The Flow of carotid artery of every animal be take stimulates front blood flow as baseline, with >=50% or≤25% stimulate before the blood flow person be judged to be continue to lead to again or continue after thromboembolism again; After logical again in 1h, each treated animal blood flow is divided into >=and 50%, 25%~50% and≤25% baseline values.According to blood flow, the carotid artery vascular degree of opening is divided three kinds of states, is respectively and 1. continues thromboembolism without logical again; 2. logical and thromboembolism is staggered again occurs; 3. continuous openness after leading to again, nothing is thromboembolism again.Experimental result is in Table 58.
Thrombolytic effect (n=10) in table 58 salvianolic acid A lyophilized powder needle body
Annotate: 1. after recanalization rate=administration, logical number of animals/animal number appears in 1h again
2. after the number of animals/administration of thromboembolism again that the bolt rate=logical rear 1h occurs again again in 1h, logical number of animals appears again
3. compare * P<0.01 with the normal saline group; Compare #P<0.05 with the urokinase group
Result shows: the normal saline group all continues thromboembolism, and without logical phenomenon occurring again; The number of animals that each medicine group continues thromboembolism is few, compares with the normal saline group and utmost point significant difference is all arranged (P<0.01); Dosage in the salvianolic acid A freeze-dried powder (5mg/kg) group, its vessel open degree is similar to 5mg/kg salvianolic acid A monomeric compound group and 2000U/kg urokinase group, its recanalization rate is suitable, but its vessel open state has more stable trend than salvianolic acid A monomeric compound and urokinase group; The lasting recanalization rate of salvianolic acid A freeze-dried powder high dose (10mg/kg) group and recanalization rate are all higher than the urokinase group, and the bolt rate is starkly lower than urokinase group (P<0.05) again; Salvianolic acid A freeze-dried powder low dosage (2.5mg/kg) though the group recanalization rate lower than the urokinase group, bolt rate is suitable with the urokinase group again for it, and has lower than the urokinase trend of bolt rate again.The effect of thromboembolism again after the above results prompting salvianolic acid A freeze-dried powder has preferably thrombolytic and prevents thrombolytic, and effect is more stable.
Experimental example 44: the impact of salvianolic acid A freeze-dried powder on the cerebral thrombosis hemorheology of rat
Adopt the method for carotid artery injection self thrombosis to prepare Cerebrovascular embolism model: after the intraperitoneal anesthesia of SD rat pentobarbital sodium, the neck median incision, separate the total tremulous pulse of right side strength (CCA), internal carotid artery (ICA), external carotid artery (ECA), ligation ECA far-end and arteria pterygopalatina, arteriole folder folder closes CCA and ICA, cut an osculum at the ECA near-end, unclamp CCA arteriole folder, extract arterial blood 0.5ml, the sodium citrate anticoagulant, centrifugal, getting platelet poor plasma adds a small amount of erythrocyte and thrombinogen and calcium chloride to mix, prepare the thrombosis that diameter is about 0.35mm, shred, the about 2mm of one trifle, folder closes CCA, by ECA, embolus is injected to ICA, and ligation ECA, unclamp CCA and arteria pterygopalatina place vascular clamp, sews up the incision.Experiment minutes 7 groups: sham operated rats, model control group, salvianolic acid A freeze-dried powder high, medium and low (10,5,2.5mg/kg) group, salvianolic acid A monomeric compound group (5mg/kg), nimodipine group (10mg/kg).30min after successful surgery, each treated animal tail vein relative medicine, after this inject once continuous 7 days every day; Sham operated rats and model group are injected isopyknic normal saline.The second day (fasting 12h) that administration finishes, intraperitoneal anesthesia, abdominal aortic blood, anticoagulant heparin, carry out Determination of Blood Rheology.
The impact of table 59 salvianolic acid A freeze-dried powder on the cerebral thrombosis hemorheology of rat
The experimental result demonstration, after cerebral thrombosis, rat whole blood viscosity, plasma viscosity significantly increase, and packed cell volume is significantly rising (P<0.01) also; Relatively, its whole blood viscosity and plasma viscosity and packed cell volume all obviously reduce, and than nimodipine group more remarkable effect, and the trend that is better than same dosage salvianolic acid A monomeric compound are arranged for each dosage group of salvianolic acid A freeze-dried powder and model group; Prompting salvianolic acid A freeze-dried powder can be accelerated micro-blood flow velocity, and the reduction blood viscosity, improve hemorheology and effectively to resist the effect of cerebral thrombosis comparatively remarkable.
Claims (6)
1. the salvianolic acid A freeze-dried powder is for the preparation of the purposes of protection cerebrovascular endothelial cell medicine, and wherein, described salvianolic acid A freeze-dried powder comprises containing salvianolic acid A master part raw material, filler and antioxidant; Each composition of wherein said freeze-dried powder is pressed column weight amount proportioning and is made: containing salvianolic acid A master part raw material 20g~60g, filler 20g~60g, antioxidant is to make 0.02%~0.1% of total amount, wherein said containing in salvianolic acid A master part raw material: salvianolic acid A 94%~97%, alkannic acid 0.2%~1.5%, rosmarinic acid 0.2%~1.5%, salvianolic acid B 0.2%~1.5%, salvianolic acid C 0.4%~2.0%;
Described salvianolic acid A freeze-dried powder adopts the method that is prepared as follows to obtain:
Get red rooted salvia, be cut into decoction pieces or be ground into diameter 1mm~5mm granule, add 3~15 times of amounts, 45~95 ℃ of water temperature lixiviates are got at every turn, with 10~50 rev/mins of speed, stir simultaneously, or add 3~15 times of water gagings decoction extractions, and extract altogether 1~3 time, extract 1~4 hour at every turn; Extracting solution is evaporated to relative density 1.0~1.25 (60 ℃), adds ethanol to make to measure 50%~85% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, obtains Radix Salviae Miltiorrhizae extract; Perhaps
Get red rooted salvia, be cut into decoction pieces or be ground into diameter 1mm~5mm granule, add 3~15 times of amount 30%~60% alcohol reflux at every turn, extract 1~4 hour at every turn, extract altogether 1~3 time; Decompression recycling ethanol also is concentrated into without the alcohol flavor, obtains Radix Salviae Miltiorrhizae extract;
Above-mentioned Radix Salviae Miltiorrhizae extract was diluted with water to every 1ml containing salvianolic acid B 1~30mg, and adjusting PH with base to 3.5 for aqueous solution~6.5 add with salvianolic acid B molar percentage 0.1~3% zinc chloride as catalyst, 100~140 ℃ of temperature thermal conversions 1~6 hour;
Conversional solution adjust pH to 2.5~4.5, standing, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 1~10mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 35~1: 70 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 4~1: 30, use respectively 1~8 times of cylinder hydrops, 1~10 times of column volume 10%~40% ethanol elution, remove impurity, use again 2~10 times of column volume 20%~60% ethanol elutions, HPLC detects, 20%~60% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor,
Aqueous solution is concentrated into the solution of every 1ml containing the 1-10mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 5~1: 25 with the polyamide ratio, the resin column blade diameter length ratio is 1: 4~1: 25, use respectively 1~10 times of cylinder hydrops, 5~20 times of column volume 20%~60% alcoholic solution eluting remove impurity, use again 4~15 times of column volumes, 40%~90% alcoholic solution eluting, 40%~90% alcoholic solution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without alcohol flavor aqueous solution;
Aqueous solution is concentrated, acid adjustment pH to 2.0~4.0, the t-butyl methyl ether of doubly measuring with aqueous solution 1-8, minute 2~6 extractions, separate organic layer, the reclaim under reduced pressure t-butyl methyl ether, make the extract of every 1ml containing salvianolic acid A 1g~10g, add 1~3 times of amount silica gel, stir, volatilize;
Stirring sample silica gel, be added on 5~20 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 4~1: 25, take pentane-t-butyl methyl ether as eluant, gradient elution, use respectively 6~30 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 6~30 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 5~20 times of water gagings and dissolves, microwave vacuum drying, obtain described containing salvianolic acid A master part raw material
Get containing salvianolic acid A master part raw material 10g~80g and inject water 1500~2800ml and be stirred to dissolve, by adjusting PH with base value 4.0~5.0, add again described filler to make its dissolving, add again described antioxidant, be stirred to dissolve and mix, then add active carbon 0.5~2g stirring and adsorbing, active carbon is removed in filtration, inject the water fill and become bottle, send into freeze dryer and carry out again lyophilization
Wherein said lyophilization comprises the steps:
A, freezing: be cooled to-40 ℃~-45 ℃ with 20 ℃~30 ℃/h speed, be incubated freezing 10~16 hours;
B, distillation: be evacuated to below 0.3mbar, in 10~14 hours, the salvianolic acid A salvianolic acid A formulation temperature freezed risen to-23 ℃~-27 ℃, maintain-23 ℃~-27 ℃ vacuum dryings 6~8 hours;
C, drying: continue to heat up, with 0.5 ℃~1.0 ℃/min, evenly be warming up to 40 ℃~45 ℃, maintain 40 ℃~45 ℃ dryings after 2~5 hours, sample temperature is down to room temperature, add a cover, obtain the salvianolic acid A freeze-dried powder.
2. purposes according to claim 1, also comprise the purposes for the protection of Injury of Cerebral Microvascular Endothelial Cells.
3. purposes according to claim 1 and 2, wherein said filler loading is 20mg~40mg/2ml~3ml.
4. purposes according to claim 1 and 2, microwave vacuum drying temperature: 20-100 ℃ wherein, return difference temperature 1-5 ℃, more than vacuum-0.07Mpa, microwave power 1-100KW, dry 10-200 minute.
5. purposes according to claim 4, microwave vacuum drying temperature: 50-85 ℃ wherein, return difference temperature 2-4 ℃, more than vacuum-0.07Mpa, microwave power 10-80KW, dry 100-150 minute.
6. purposes according to claim 5, microwave vacuum drying temperature: 55-80 ℃ wherein, return difference temperature 2-3 ℃, more than vacuum-0.07Mpa, microwave power 25-60KW, dry 120-140 minute.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210487175.0A CN103142576B (en) | 2012-11-20 | 2012-11-20 | Salvianolic acid A freeze-dried powder is for the preparation of the purposes of protection cerebrovascular endothelial cell medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210487175.0A CN103142576B (en) | 2012-11-20 | 2012-11-20 | Salvianolic acid A freeze-dried powder is for the preparation of the purposes of protection cerebrovascular endothelial cell medicine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103142576A true CN103142576A (en) | 2013-06-12 |
CN103142576B CN103142576B (en) | 2016-01-06 |
Family
ID=48541091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210487175.0A Active CN103142576B (en) | 2012-11-20 | 2012-11-20 | Salvianolic acid A freeze-dried powder is for the preparation of the purposes of protection cerebrovascular endothelial cell medicine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103142576B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432110A (en) * | 2012-11-20 | 2013-12-11 | 吕武清 | Application of salvianolic acid A freeze-dried injection in preparing drug for rescuing ischemic penumbra |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100999470A (en) * | 2006-11-17 | 2007-07-18 | 北京本草天源药物研究院 | Salvia minium phenolic acid A and process of preparing preparation and use |
CN101548966A (en) * | 2008-04-03 | 2009-10-07 | 北京本草天源药物研究院 | Application of salvianolic acid A in salvia miltiorrhiza |
CN102212004A (en) * | 2010-04-06 | 2011-10-12 | 山东靶点药物研究有限公司 | Method for preparing salvianolic acid A by catalytically converting salvianolic acid B |
-
2012
- 2012-11-20 CN CN201210487175.0A patent/CN103142576B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100999470A (en) * | 2006-11-17 | 2007-07-18 | 北京本草天源药物研究院 | Salvia minium phenolic acid A and process of preparing preparation and use |
CN101548966A (en) * | 2008-04-03 | 2009-10-07 | 北京本草天源药物研究院 | Application of salvianolic acid A in salvia miltiorrhiza |
CN102212004A (en) * | 2010-04-06 | 2011-10-12 | 山东靶点药物研究有限公司 | Method for preparing salvianolic acid A by catalytically converting salvianolic acid B |
Non-Patent Citations (1)
Title |
---|
姜民等: "丹酚酸A对缺氧/复氧损伤条件下脑微血管内皮细胞ICAM-1表达的影响", 《天津中医药》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432110A (en) * | 2012-11-20 | 2013-12-11 | 吕武清 | Application of salvianolic acid A freeze-dried injection in preparing drug for rescuing ischemic penumbra |
Also Published As
Publication number | Publication date |
---|---|
CN103142576B (en) | 2016-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103083303A (en) | Application of salvianolic acid A composition in preparing medicines for improving neural function symptom after cerebral ischemia | |
CN103083297A (en) | Application of salvianolic acid A composition in preparing medicines for improving neural function symptom after cerebral ischemia | |
CN103083306A (en) | Application of salvianolic acid A composition in preparing medicines for inhibiting brain tissue neuron damage or death | |
CN103083304A (en) | Application of salvianolic acid A composition for preparing medicines for preventing and/or treating cerebral thrombosis | |
CN103083302A (en) | Application of salvianolic acid A composition in preparing medicines for protecting ischemic brain tissue damage | |
CN103083301A (en) | Application of salvianolic acid A composition for preparing medicines for preventing and/or treating cerebral thrombosis | |
CN103083298A (en) | Application of salvianolic acid A composition in preparing medicines for protecting ischemic brain tissue damage | |
CN103142573B (en) | Salvianolic acid A freeze-dried powder is for the preparation of the purposes improving the function of nervous system's symptom medicine after cerebral ischemia | |
CN103142575A (en) | Application of salvianolic acid A freeze-dried powder to preparation of drug for inhibiting neuronal damage or death of brain tissue | |
CN103006576B (en) | Salvianolic acid A lyophilized powder injection and application thereof in preparation of drugs | |
CN103083296A (en) | Application of salvianolic acid A composition in preparing medicines for protecting cerebrovascular endothelial cells | |
CN103142576B (en) | Salvianolic acid A freeze-dried powder is for the preparation of the purposes of protection cerebrovascular endothelial cell medicine | |
CN103083257B (en) | A kind of salvianolic acid A freeze-dried powder and prepare medicinal usage | |
CN103142574B (en) | A kind of salvianolic acid A freeze-dried powder and prepare medicinal usage | |
CN103006575B (en) | Application of salvianolic acid A lyophilized powder injection in preparation of drugs for improving neurological function symptoms after cerebral ischemia | |
CN103432110B (en) | Salvianolic acid A freeze-dried powder is for the preparation of the purposes saving cerebral ischemic penumbra medicine | |
CN103083256B (en) | Application of salvianolic acid A freeze-dried powder injection for preparing medicines for preventing and/or treating cerebral thrombosis | |
CN103083254B (en) | Salvianolic acid A freeze-dried powder is for the preparation of the purposes preventing and/or treating cerebral thrombosis medicine | |
CN103083258B (en) | Application of salvianolic acid A freeze-dried powder injection in preparing medicines for protecting cerebrovascular endothelial cells | |
CN103083255B (en) | Purpose of salvianolic acid A freeze-dried powder injection for preparing medicine for inhibiting brain tissue neuron damage or death | |
CN103006577B (en) | Application of salvianolic acid A lyophilized powder injection in preparation of drugs for preventing and/or treating cerebral thrombosis | |
CN103083259B (en) | Purpose of salvianolic acid A freeze-dried powder injection for preparing medicine for saving ischemic penumbra | |
CN103006581B (en) | Application of salvianolic acid A lyophilized powder injection in preparation of drugs for treating ischemic penumbra | |
CN103083294B (en) | Salvianolic acid A freeze-dried powder is for the preparation of the purposes of protection ischemic tissue of brain damage medicine | |
CN103142508B (en) | Salvianolic acid A freeze-dried powder is for the preparation of the purposes of protection ischemic tissue of brain damage medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151125 Address after: 341000 East Road, Shahe Industrial Park, Jiangxi, Ganzhou, No. 8 Applicant after: Jiangxi Qingfeng Pharmaceutical Co., Ltd. Address before: 330046 No. 529, culture and education road, Nanchang, Jiangxi Applicant before: Lv Wuqing |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |